FINANCIAL STATEMENTS – STATUTORY BASIS 
AND SUPPLEMENTARY INFORMATION
 
Transamerica Life Insurance Company
Years Ended December 31, 2025, 2024 and 2023
 
 
 
 
 
1

 
Transamerica Life Insurance Company
 
Financial Statements – Statutory Basis
and Supplementary Information
 
Years Ended December 31, 2025, 2024 and 2023
 
Contents
Report of Independent Auditors3
Balance Sheets – Statutory Basis2
Statements of Operations – Statutory Basis3
Statements of Changes in Capital and Surplus – Statutory Basis4
Statements of Cash Flow – Statutory Basis6
1. Organization and Nature of Business8
2. Basis of Presentation and Summary of Significant Accounting Policies9
3. Accounting Changes and Correction of Errors27
4. Fair Values of Financial Instruments29
5. Investments40
6. Policy and Contract Attributes74
7. Reinsurance94
8. Income Taxes97
9.Capital and Surplus106
10. Securities Lending107
11. Retirement and Compensation Plans109
12. Related Party Transactions110
13. Managing General Agents and Third-Party Administrators117
14. Commitments and Contingencies118
15. Sales, Transfers, and Servicing of Financial Assets and Extinguishments of Liabilities123
16. Subsequent Events125
Appendix A – Listing of Affiliated Companies126
Statutory-Basis Financial Statement Schedules128
Summary of Investments – Other Than Investments in Related Parties130
Supplementary Insurance Information131
 
 
2

 
 
Report of Independent Auditors
 
To the Board of Directors of
Transamerica Life Insurance Company 
 
Opinion
 
We have audited the statutory-basis financial statements of Transamerica Life Insurance Company (the Company), which comprise the balance sheets as of December 31, 2025 and 2024, and the related statements of operations, changes in capital and surplus and cash flows for the year then ended, and the related notes to the financial statements (collectively referred to as the “financial statements”).
 
Unmodified Opinion on Statutory Basis of Accounting
 
In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, on the basis of accounting described in Note 2.
 
Adverse Opinion on U.S. Generally Accepted Accounting Principles
 
In our opinion, because of the significance of the matter described in the Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles section of our report, the financial statements do not present fairly, in accordance with accounting principles generally accepted in the United States of America, the financial position of the Company at December 31, 2025 and 2024, or the results of its operations or its cash flows for the years then ended.
 
Basis for Opinion
 
We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
 
Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles
 
As described in Note 2 to the financial statements, the Company prepared these financial statements using accounting practices prescribed or permitted by the Iowa Insurance Division, which is a basis of accounting other than accounting principles generally accepted in the United States of America.
 
3

 

The effects on the financial statements of the variances between these statutory accounting practices described in Note 2 and accounting principles generally accepted in the United States of America, although not reasonably determinable, are presumed to be material and pervasive.
 
Report of Other Auditors on 2023 Financial Statements
 
The statutory-basis financial statements of the Company for the year ended December 31, 2023, were audited by another auditor who expressed an adverse opinion with respect to conformity with U.S. generally accepted accounting principles and an unmodified opinion with respect to conformity with accounting practices prescribed or permitted by the Iowa Insurance Division on those statements on April 11, 2024.
 
Responsibilities of Management for the Financial Statements
 
Management is responsible for the preparation and fair presentation of the financial statements in accordance with the accounting practices prescribed or permitted by the Iowa Insurance Division. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
 
In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date that the financial statements are issued.
 
Auditor’s Responsibilities for the Audit of the Financial Statements
 
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.
 
 
4

 
 
In performing an audit in accordance with GAAS, we:
 
We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.
 
/s/ Ernst & Young LLP
April 9, 2026
Philadelphia, PA
 
5

 
 

Report of Independent Auditors

 
To the Board of Directors of Transamerica Life Insurance Company
 
Opinions
 
We have audited the accompanying statutory basis financial statements of Transamerica Life Insurance Company (the “Company”), which comprise the statements of operations - statutory basis, of changes in capital and surplus - statutory basis, and of cash flow - statutory basis for the year ended December 31, 2023, including the related notes and supplementary insurance information for the year ended December 31, 2023, and reinsurance for the year ended December 31, 2023 listed in the accompanying index (collectively referred to as the “financial statements”). 
 
Unmodified Opinion on Statutory Basis of Accounting
 
In our opinion, the accompanying financial statements present fairly, in all material respects, the results of its operations and its cash flows for the year ended December 31, 2023, in accordance with the accounting practices prescribed or permitted by the Iowa Insurance Division described in Note 2.
 
Adverse Opinion on U.S. Generally Accepted Accounting Principles
 
In our opinion, because of the significance of the matter discussed in the “Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles” section of our report, the accompanying financial statements do not present fairly, in accordance with accounting principles generally accepted in the United States of America, the results of its operations or its cash flows for the year ended December 31, 2023.
 
Basis for Opinions
 
We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.
 
Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles
 
As described in Note 2 to the financial statements, the financial statements are prepared by the Company on the basis of the accounting practices prescribed or permitted by the Iowa Insurance Division, which is a basis of accounting other than accounting principles generally accepted in the United States of America.
 
The effects on the financial statements of the variances between the statutory basis of accounting described in Note 2 and accounting principles generally accepted in the United States of America, although not reasonably determinable, are presumed to be material.
 
Responsibilities of Management for the Financial Statements
 
Management is responsible for the preparation and fair presentation of the financial statements in accordance with the accounting practices prescribed or permitted by the Iowa Insurance Division. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
 
In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are available to be issued.
6

 
 
 
Auditors’ Responsibilities for the Audit of the Financial Statements
 
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.
 
In performing an audit in accordance with US GAAS, we:
 
        Exercise professional judgment and maintain professional skepticism throughout the audit.
        Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
        Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.  Accordingly, no such opinion is expressed.
        Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
        Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.
 
We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.
 
 
/s/PricewaterhouseCoopers LLP
Chicago, Illinois
April 11, 2024
 
 
1

 
Transamerica Life Insurance Company
 
Balance Sheets – Statutory Basis
(Dollars in Millions)
 
           
 
December 31
    
2025
    
2024
 
Admitted assets
         
Cash, cash equivalents and short-term investments
 $1,103   $1,939 
Bonds
  49,696    51,162 
Preferred stocks
  40    44 
Common stocks
  2,684    2,952 
Mortgage loans on real estate
  8,818    8,885 
Real estate
  37    39 
Policy loans
  2,376    2,239 
Securities lending reinvested collateral assets
  1,657    1,667 
Derivative assets
  247    399 
Receivable for derivative cash collateral
  531    466 
Other invested assets
  3,053    3,293 
Total cash and invested assets
  70,242    73,085 
           
Accrued investment income
  613    669 
Premiums deferred and uncollected
  63    70 
Net deferred income tax asset
  689    802 
Variable annuity reserve hedge offset deferral
  645    883 
Excess of loss reinsurance asset
      3,024 
Other assets
  1,999    1,464 
Separate account assets
  109,592    103,494 
Total admitted assets
 $183,843   $183,491 
           
Liabilities and capital and surplus
         
Aggregate reserves for policies and contracts
 $54,409   $58,055 
Policy and contract claim reserves
  919    1,048 
Liability for deposit-type contracts
  671    693 
Other policyholders’ funds
  49    47 
Transfers from separate accounts due or accrued
  (236   (254
Funds held under reinsurance treaties
  7,097    7,046 
Asset valuation reserve
  1,292    1,358 
Derivative liabilities
  934    1,481 
Payable for collateral under securities loaned and
other transactions
  1,735    1,764 
Borrowed money
  650    1,500 
Other liabilities
  1,450    1,334 
Separate account liabilities
  109,592    103,494 
Total liabilities
  178,562    177,566 
Total capital and surplus
  5,281    5,925 
Total liabilities and capital and surplus
 $183,843   $183,491 
See accompanying notes.
 
2

 
Transamerica Life Insurance Company
 
Statements of Operations – Statutory Basis
(Dollars in Millions)
 
                
 
Year Ended December 31
    
2025
    
2024
    
2023
 
Revenues
              
Premiums and other considerations
 $15,032   $18,767   $9,516 
Net investment income
  3,589    3,743    3,597 
Commissions and expense allowances on reinsurance
ceded
  (729   428    329 
Reserve adjustment on reinsurance ceded
  (183   (133   (139
Consideration received on reinsurance recapture and
novations
  104    243    140 
Fee revenue and other income
  1,785    1,805    2,119 
Total revenue
  19,598    24,853    15,562 
                
Benefits and expenses
              
Death benefits
  2,609    2,713    2,433 
Annuity benefits
  1,579    1,485    1,466 
Accident and health benefits
  1,170    1,104    1,046 
Surrender benefits
  18,364    18,845    14,692 
Other benefits
  288    282    257 
Net increase (decrease) in reserves
  (3,666   1,302    (5,482
Commissions
  1,550    1,442    1,343 
Taxes, licenses and fees
  177    176    163 
Funds withheld ceded investment income
  307    180    95 
Net transfers to (from) separate accounts
  (6,011   (6,163   (4,801
IMR adjustment due to reinsurance
  217        248 
General insurance expenses and other
  1,303    1,151    1,291 
Total benefits and expenses
  17,887    22,517    12,751 
Gain (loss) from operations before dividends
and federal income taxes
  1,711    2,336    2,811 
Dividends to policyholders
  7    8    8 
Gain (loss) from operations before federal income taxes
  1,704    2,328    2,803 
Federal income tax (benefit) expense
  (61   (37   75 
Net gain (loss) from operations
  1,765    2,365    2,728 
Net realized capital gains (losses), after tax and
amounts transferred to interest maintenance reserve
  (575   (1,439   (1,999
Net income (loss)
 $1,190   $926   $729 
 
See accompanying notes.
3

 
Transamerica Life Insurance Company
 
Statements of Changes in Capital and Surplus – Statutory Basis
(Dollars in Millions)
 
    
Common Stock
    
Paid-in Surplus
    
Special Surplus Funds
    
Unassigned Surplus
    
Total Capital and Surplus
 
Balance at January 1, 2023
 $7   $4,664   $380   $612   $5,663 
Net income (loss)
              729    729 
Change in net unrealized capital gains/losses,
    net of taxes
          136    1,148    1,284 
Change in net deferred income tax asset
              149    149 
Change in nonadmitted assets
              (417   (417
Change in asset valuation reserve
              (191   (191
Change in surplus as a result of reinsurance
              (435   (435
Dividends to stockholders
              (858   (858
Other changes - net
      8        (14   (6
Balance at December 31, 2023
 $7   $4,672   $516   $723   $5,918 
Merger of LIICA Re II and TPRe
          36    576    612 
Balance at January 1, 2024
 $7   $4,672   $552   $1,299   $6,530 
Net income (loss)
              926    926 
Change in net unrealized capital gains/losses,
    net of taxes
          524    (1,173   (649
Change in net deferred income tax asset
              8    8 
Change in nonadmitted assets
              (7   (7
Change in asset valuation reserve
              (46   (46
Change in surplus as a result of reinsurance
              (257   (257
Dividends to stockholders
              (415   (415
Other changes - net
      (11       (154   (165
Balance at December 31, 2024
 $7   $4,661   $1,076   $181   $5,925 
 
Continued on next page.
4

 
Transamerica Life Insurance Company
 
Statements of Changes in Capital and Surplus – Statutory Basis
(Dollars in Millions)
 
    
Common Stock
    
Paid-in Surplus
    
Special Surplus Funds
    
Unassigned Surplus
    
Total Capital and Surplus
 
Balance at December 31, 2024
 $7   $4,661   $1,076   $181   $5,925 
Net income (loss)
              1,190    1,190 
Change in net unrealized capital gains/losses,
    net of taxes
          (49   2    (47
Change in net deferred income tax asset
              (431   (431
Change in nonadmitted assets
              413    413 
Change in asset valuation reserve
              66    66 
Change in surplus as a result of reinsurance
              1,029    1,029 
Paid-in surplus adjustment
              824    824 
Return of contributed capital
      (399           (399
Dividends to stockholders
              (200   (200
Change in excess of loss reinsurance asset
              (3,025   (3,025
Other changes - net
      (13       (51   (64
Balance at December 31, 2025
 $7   $4,249   $1,027   $(2  $5,281 
 
See accompanying notes.
5

 
Transamerica Life Insurance Company
 
Statements of Cash Flow – Statutory Basis
(Dollars in Millions)
 
                
 
Year Ended December 31
    
2025
    
2024
    
2023
 
Operating activities
              
Premiums and annuity considerations
 $17,582   $18,865   $13,933 
Net investment income
  3,455    3,666    3,580 
Other income
  2,009    2,159    1,940 
Benefit and loss related payments
  (24,156   (24,428   (19,702
Net transfers from separate accounts
  5,853    6,094    4,842 
Commissions and operating expenses
  (3,183   (2,976   (2,787
Dividends paid to policyholders
  (5   (5   (5
Federal income taxes (paid) received
  (42   12    18 
Net cash provided by (used in) operating activities
 $1,513   $3,387   $1,819 
                
Investing activities
              
Proceeds from investments sold, matured or repaid
 $24,876   $6,828   $8,889 
Costs of investments acquired
  (26,448   (9,550   (8,332
Net change in policy loans
  (137   (131   (81
Net cash provided by (used in) investing activities
 $(1,709  $(2,853  $476 
                
Financing and miscellaneous activities
              
Capital and paid in surplus received (returned)
 $402   $(16  $6 
Dividends to stockholders
  (200   (415   (858
Net deposits (withdrawals) on deposit-type contracts
  (36   (32   (45
Net change in borrowed money
  (850   (236   (1,354
Net change in funds held under reinsurance treaties
  51    (433   43 
Net change in payable for collateral under securities lending and other transactions
  (28   (1,335   828 
Other cash (applied) provided
  21    482    (30
Net cash provided by (used in) financing and
miscellaneous activities
 $(640  $(1,985  $(1,410
                
Net increase (decrease) in cash, cash
equivalents and short-term investments
  (836   (1,451   885 
                
Cash, cash equivalents and short-term
investments:
              
Beginning of year
  1,939    3,390    2,420 
End of year
 $1,103   $1,939   $3,305 
See accompanying notes.
6

 
Transamerica Life Insurance Company
 
Statements of Cash Flow – Statutory Basis
(Dollars in Millions)
 
                
 
Year Ended December 31
Supplemental disclosures of cash flow information
  
2025
    
2024
    
2023
 
                
Non-cash activities during the year not included in the Statutory Statements of Cash Flows:
              
                
Receipt of bonds, other invested assets and interest  
related to affiliated reinsurance treaty
 $2,537   $   $792 
Increase of funds withheld related to affiliated
reinsurance agreement
          (4,394
 
See accompanying notes.
 
7

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
Years Ended December 31, 2025, 2024 and 2023
 
1.
Organization and Nature of Business
 
Transamerica Life Insurance Company (the Company) is a stock life insurance company domiciled in the State of Iowa, and is owned by Commonwealth General Corporation (CGC). CGC is an indirect, wholly-owned subsidiary of Aegon Ltd., a holding company organized under the laws of Bermuda.
 
On December 9, 2025, the Company merged with LIICA Re II Inc. (LIICA Re II) and Transamerica Pacific Reinsurance (TPRe), both affiliated captive insurance companies regulated in Vermont, with the Company as the surviving entity. As part of the merger, the Company assumed all assets and liabilities of both the captive companies, and the merger plans were approved by the Iowa Insurance Division (IID) and the Captive Insurance Division of the Vermont Department of Financial Regulation.
 
The merger was accounted for as a statutory merger according to requirements in SSAP No. 68, Business Combinations. As such, financial statements for the reporting periods ended December 31, 2025 and 2024 were combined and the recorded assets, liabilities and surplus of LIICA Re II and TPRe on a US statutory basis prior to the mergers were carried forward to the merged company without elimination of aspects of affiliate reinsurance activity and other related party transactions that do not impact total capital and surplus or net income between the merged entities. Additionally, the historical income tax positions were not recomputed on a merged entity basis. This treatment has no impact to income or capital and surplus of the Company. Amounts reported for the year ended December 31, 2023 were not combined as part of the merger, in accordance with the explicit permission of the IID. As a result of the merger, LIICA Re II and TPRe's common stock were deemed canceled by operation of law.
 
Summarized financial information for the Company, LIICA Re II and TPRe presented separately for periods prior to the merger is as follows:
 
                          
 
Year Ended December 31, 2024
    
Company
    
LIICA Re II
    
TPRe
    
Eliminations
    
Merged Totals
 
Total assets
 $179,107   $2,267   $2,612   $(495  $183,491 
Total liabilities
  173,182    2,007    2,377        177,566 
Capital and surplus
  5,925    260    235    (495   5,925 
Total revenue
  24,709    38    106        24,853 
Total benefits and expenses
  22,409    (18   126        22,517 
Net income (loss)
  912    48    (34       926 
 
8

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Nature of Business
 
The Company sells individual life insurance, including indexed universal life, whole life, term life, and final expense whole life. It also sells variable and registered index-linked annuities (RILA). In addition, the Company offers supplemental health insurance, group life insurance, group annuity contracts and stable value solutions. The Company is licensed in 49 states and the District of Columbia, Guam, Puerto Rico, and US Virgin Islands. Sales of the Company’s products are primarily through a network of independent agents and broker-dealers, affiliated agencies, and financial institutions.
 
 
2.
Basis of Presentation and Summary of Significant Accounting Policies
 
The accompanying financial statements have been prepared in conformity with accounting practices prescribed or permitted by the IID, which differ from accounting principles generally accepted in the United States of America (GAAP).
 
The IID recognizes only statutory accounting practices prescribed or permitted by the State of Iowa for determining and reporting the financial condition and results of operations of an insurance company, and for determining its solvency under the Iowa Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures Manual (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Iowa. The Commissioner of Insurance has the right to permit specific practices that deviate from prescribed practices.
 
The following is a summary of the accounting practices permitted and prescribed by the IID and reflected in the Company’s financial statements which differs from NAIC SAP:
 
The State of Iowa has adopted prescribed accounting practices that differ from the NAIC SAP related to the reported value of certain assets supporting the Company's guaranteed and RILA separate accounts. As prescribed by Iowa Administrative Code 508A.1.4, the Company is entitled to generally value these assets at amortized cost, whereas the assets would be required to be reported at fair value under Statement of Statutory Accounting Principles (SSAP) No. 56, Separate Accounts, of the NAIC SAP. There are no impacts to the Company’s income or surplus as a result of utilizing these prescribed practices.
 
Pursuant to Iowa Administrative Code 521A.5(1)c, the State of Iowa has allowed a permitted accounting practice that differs from the NAIC SAP related to the valuation of a foreign insurance subsidiary, controlled and affiliated (SCA) entity. With the explicit permission of the IID, the Company values Transamerica Life (Bermuda) Ltd. (TLB), a foreign SCA, in accordance with SSAP No. 97, Subsidiary, Controlled and Affiliated Entities, paragraph 8.b.i, as a U.S. insurance SCA entity at its underlying audited U.S. statutory equity. Absent this permitted practice, TLB would be valued in accordance with SSAP No. 97, paragraph 8.b.iv, as a foreign insurance SCA at its audited foreign statutory basis financial statements with certain adjustments.
 
9

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Iowa is shown below:
 
    
SSAP #
    
F/S Page
    
F/S Line
    
2025
    
2024
    
2023
 
                               
Net income (loss), State of Iowa basis
  
XXX
    
XXX
    
XXX
   $1,190   $926   $729 
State prescribed practices that are an
increase(decrease) from NAIC SAP:
                             
  None                             
State permitted practices that are an
increase(decrease) from NAIC SAP:
                             
  None                             
Net income (loss), NAIC SAP
  
XXX
    
XXX
    
XXX
   $1,190   $926   $729 
                               
Statutory surplus, state of Iowa basis
  
XXX
    
XXX
    
XXX
   $5,281   $5,925   $5,918 
State prescribed practices that are an increase(decrease) from NAIC SAP:
                             
  None                             
State permitted practices that are an
increase(decrease) from NAIC SAP:
                             
TLB valuation
  97    2    2.2    294    272    47 
Excess of loss reinsurance asset
  4    
Balance Sheet
    
Excess of loss reinsurance asset
        3,024     
Statutory surplus, NAIC SAP
  
XXX
    
XXX
    
XXX
   $4,987   $2,629   $5,871 
 
The IID issued a no objection letter for the Company to recognize previously held permitted practices issued by the Captive Insurance Division of the Vermont Department of Financial Regulation to LIICA Re II and TPRe. The permitted practices allowed the captives to include as an admitted asset the value of excess of loss (XOL) reinsurance assets. These historical permitted practices were included on a merged entity basis for December 31, 2024. The XOL reinsurance assets, totaling $3,024 at December 31, 2024, are for the benefit of the Company. The permitted practice terminated upon the merger of LIICA Re II and TPRe into the Company and has no impact at December 31, 2025.
 
Use of Estimates
 
The preparation of financial statements of insurance companies requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed herein.
10

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The effects of the following variances from GAAP on the accompanying statutory-basis financial statements have not been determined by the Company, but are presumed to be material. Significant accounting policies and variances from GAAP are as follows:
 
Investments
 
Investments in bonds, except those to which the Securities Valuation Office (SVO) of the NAIC has ascribed a NAIC designation of 6, are reported at amortized cost using the interest method. Bonds containing call provisions, except make-whole call provisions, are amortized to the call or maturity value/date which produces the lowest asset value, often referred to as yield-to-worst method. Bonds ascribed a NAIC designation of 6 are reported at the lower of amortized cost or fair value with unrealized gains and losses reported in changes in capital and surplus. Prepayment penalty or acceleration fees received in the event a bond is liquidated prior to its scheduled termination date are reported as investment income.
 
Hybrid securities, as defined by the NAIC, are securities designed with characteristics of both debt and equity and provide protection to the issuer's senior note holders. These securities meet the definition of a bond, in accordance with SSAP No. 26, Bonds, and therefore, are reported at amortized cost or fair value based upon their NAIC rating.
 
For GAAP, such fixed maturity investments would be designated at purchase as held-to-maturity, trading or available-for-sale. Held-to-maturity fixed investments would be reported at amortized cost, and the remaining fixed maturity investments would be reported at fair value with unrealized holding gains and losses reported in earnings for those designated as trading and as a separate component of other comprehensive income (OCI) for those designated as available-for-sale.
 
Single class and multi-class mortgage-backed/asset-backed securities are valued at amortized cost using the interest method, including anticipated prepayments, except for those with an initial NAIC designation of 6, which are valued at the lower of amortized cost or fair value. These securities are adjusted for the effects of changes in prepayment assumptions on the related accretion of discount or amortization of premium using either the retrospective or prospective methods. Prepayment assumptions are obtained from dealer surveys or internal estimates and are based on the current interest rate and economic environment. For statutory reporting, the retrospective adjustment method is used to value all such securities, except principal-only and interest-only securities, which are valued using the prospective method.
 
For GAAP, all securities purchased or retained that represent beneficial interests in securitized assets, other than high credit quality securities, are adjusted using the prospective method when there is a change in estimated future cash flows. If high credit quality securities are adjusted, the retrospective method is used.
11

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company closely monitors below investment grade holdings and investment grade issuers where the Company has concerns to determine if an other-than-temporary impairment (OTTI) has occurred. The Company also regularly monitors industry sectors. The Company considers relevant facts and circumstances in evaluating whether the impairment is other-than-temporary including: (1) the probability of the Company collecting all amounts due according to the contractual terms of the security in effect at the date of acquisition; (2) the Company’s decision to sell a security prior to its maturity at an amount below its carrying amount; and (3) the Company’s ability to hold a structured security for a period of time to allow for recovery of the value to its carrying amount. Additionally, financial condition, near term prospects of the issuer and nationally recognized credit rating changes are monitored. Non-structured securities in unrealized loss positions that are considered other-than-temporary are written down to fair value. The Company will record a charge to the Statements of Operations for the amount of the impairment.
 
For structured securities, cash flow trends and underlying levels of collateral are monitored. An OTTI is considered to have occurred if the fair value of the structured security is less than its amortized cost basis and the entity intends to sell the security or the entity does not have the intent and ability to hold the security for a period of time sufficient to recover the amortized cost basis. An OTTI is also considered to have occurred if the discounted estimated future cash flows are less than the amortized cost basis of the security and the security is in an unrealized loss position. Structured securities considered other-than-temporarily impaired are written down to discounted estimated cash flows if the impairment is the result of cash flow analysis. If the Company has an intent to sell or lack of ability to hold a structured security, it is written down to fair value. The Company will record a charge to the Statements of Operations for the amount of the impairments.
 
For GAAP, for debt securities classified as available-for-sale, management first assesses whether the Company has the intent to sell, or whether it is more likely than not it will be required to sell the security before the amortized cost basis is fully recovered. If either criterion is met, the amortized cost is written down to fair value through earnings as an impairment. If neither criterion is met, the securities are further evaluated to determine if the cause of the decline in fair value resulted from credit losses or other factors. When a credit loss is determined to exist and the present value of cash flows expected to be collected is less than the amortized cost of the security, an allowance for credit loss is recorded along with a charge to earnings, limited by the amount that the fair value is less than amortized cost. Any remaining unrealized loss after recording the allowance for credit loss is the non-credit amount and is recorded to other comprehensive income.
 
Investments in unaffiliated redeemable preferred stocks in good standing (those with NAIC designations 1 to 3) are reported at cost or amortized cost, depending on the characteristics of the securities. Investments in unaffiliated redeemable preferred stocks not in good standing (those with NAIC designations 4 to 6) are reported at the lower of cost, amortized cost, or fair value, depending on the characteristics of the securities. Investment in perpetual preferred stocks are reported at fair value, not to exceed any currently effective call price. Investment in mandatory convertible preferred stocks (regardless if the preferred stock is redeemable or perpetual) are reported at fair value, not to exceed any currently effective call price, in the periods prior to conversion. For preferred stocks reported at fair value, the related net unrealized capital gains and losses for all NAIC designations are reported in accordance with SSAP No. 7, Asset Valuation Reserve and Interest Maintenance Reserve.
12

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Common stocks of affiliated noninsurance subsidiaries are reported based on underlying audited GAAP equity. The net change in the subsidiaries’ equity is included in net unrealized capital gains or losses and are reported in changes in capital and surplus.
 
Common stocks of unaffiliated companies, which include shares of mutual funds, are reported at fair value and the related net unrealized capital gains or losses are reported in changes in capital and surplus.
 
The Company owns stock issued by the Federal Home Loan Bank (FHLB), which is only redeemable at par, and its fair value is presumed to be par, unless other-than-temporarily impaired.
 
If the Company determines that a decline in the fair value of a common stock or a preferred stock is other-than-temporary, the Company writes it down to fair value as the new cost basis and the amount of the write down is accounted for as a realized loss in the Statements of Operations. The Company considers the following factors in determining whether a decline in value is other-than-temporary: (a) the financial condition and prospects of the issuer; (b) whether or not the Company has made a decision to sell the investment; and (c) the length of time and extent to which the value has been below cost.
 
Mortgage loans are reported at unpaid principal balances, less an allowance for impairment. A mortgage loan is considered to be impaired when it is probable that the Company will be unable to collect all principal and interest amounts due according to the contractual terms of the mortgage agreement. When management determines the impairment is other-than-temporary, the mortgage loan is written down to realizable value and a realized loss is recognized. Prepayment penalty or acceleration fees received in the event a loan is liquidated prior to its scheduled termination date are reported as investment income.
 
Valuation allowances are established for mortgage loans, if necessary, based on the difference between the net value of the collateral, determined as the fair value of the collateral less estimated costs to obtain and sell, and the recorded investment in the mortgage loan. Under GAAP, an allowance for credit loss is recognized in earnings at time of purchase or origination based on an expected lifetime credit loss, which is an amount that represents the portion of the amortized cost basis of the mortgage loans that the Company does not expect to collect.
13

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The initial valuation allowance and subsequent changes in the allowance for mortgage loans are charged or credited directly to unassigned surplus as part of the change in asset valuation reserve (AVR), rather than being included as a component of earnings as would be required under GAAP.
 
Land is reported at cost. Real estate occupied by the Company is reported at depreciated cost net of encumbrances. Real estate held for the production of income is reported at depreciated cost net of encumbrances. Real estate the Company classifies as held for sale is measured at lower of carrying amount or fair value less encumbrances and estimated costs to sell. Depreciation is calculated on a straight-line basis over the estimated useful lives of the properties. The Company recognizes an impairment loss if the Company determines that the carrying amount of the real estate is not recoverable and exceeds its fair value. The Company deems that the carrying amount of the asset is not recoverable if the carrying amount exceeds the sum of undiscounted cash flows expected to result from the use and disposition. The impairment loss is measured as the amount by which the asset’s carrying value exceeds its fair value.
 
Investments in real estate are reported net of related obligations rather than on a gross basis as for GAAP. Real estate owned and occupied by the Company is included in investments rather than reported as an operating asset as under GAAP, and investment income and operating expenses for statutory reporting include rent for the Company’s occupancy of those properties. Changes between depreciated cost and admitted amounts are credited or charged directly to unassigned surplus rather than to income as would be required under GAAP.
 
The Company has interests in joint ventures and limited partnerships. The Company carries these investments based on its interest in the underlying audited GAAP equity of the investee.
 
For a decline in the fair value of an investment in a joint venture or limited partnership which is determined to be other-than-temporary, the Company writes it down to fair value as the new cost basis and the amount of the write down is accounted for as a realized loss in the Statements of Operations. The Company considers an impairment to have occurred if it is probable that the Company will be unable to recover the carrying amount of the investment or if there is evidence indicating inability of the investee to sustain earnings which would justify the carrying amount of the investment.
 
Investments in Low Income Housing Tax Credit (LIHTC) properties are valued at amortized cost. Tax credits are recognized in operations in the tax reporting year in which the tax credit is utilized by the Company. The carrying value is amortized over the life of the investment. Amortization is calculated as a ratio of the current year tax credits and tax benefits compared to the total expected tax credits and tax benefits over the life of the investment.
14

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Cash equivalents are short-term highly liquid investments with original maturities of three months or less (principally stated at amortized cost) or money market mutual funds which are reported at fair value.
 
Short-term investments include investments with remaining maturities of one year or less at the time of acquisition and are principally stated at amortized cost.
 
Other invested assets include surplus notes which are valued at either amortized cost (those that have an NAIC designation of 1 or 2) or the lesser of amortized cost or fair value (those that have an NAIC designation of 3 through 6).
 
Policy loans are reported at unpaid principal balances.
 
Realized capital gains and losses are determined using the specific identification method and are recorded net of related federal income taxes. Changes in admitted asset carrying amounts of bonds, mortgage loans, common and preferred stocks are credited or charged directly to unassigned surplus.
 
Interest income is recognized on an accrual basis. The Company does not accrue income on bonds in default, mortgage loans on real estate in default and/or foreclosure or which are delinquent more than twelve months, or real estate where rent is in arrears for more than three months. Income is also not accrued when collection is uncertain. Due and accrued amounts determined to be uncollectible are written off through the Statements of Operations.
 
Valuation Reserves
 
Under a formula prescribed by the NAIC, the Company defers the portion of realized capital gains and losses on sales of fixed income investments, primarily bonds and mortgage loans, attributable to changes in the general level of interest rates and amortizes those deferrals into net investment income over the remaining period to maturity of the bond or mortgage loan based on groupings of individual securities sold in five year bands. The net deferral is reported as the interest maintenance reserve (IMR) in the accompanying Balance Sheets. Realized capital gains and losses are reported in income net of federal income tax and transfers to the IMR. Under GAAP, realized capital gains and losses are reported in the Statements of Operations on a pre-tax basis in the period that the assets giving rise to the gains or losses are sold.
 
The AVR provides a valuation allowance for invested assets. The AVR is determined by an NAIC prescribed formula with changes reflected directly in unassigned surplus; AVR is not recognized for GAAP.
15

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Derivative Instruments
 
Overview: The Company may use various derivative instruments (options, caps, floors, swaps, foreign currency forwards, and futures) to manage risks related to its ongoing business operations. On the transaction date of the derivative instrument, the Company designates the derivative as either (A) hedging (fair value, foreign currency fair value, cash flow, foreign currency cash flow, forecasted transactions, or net investment in a foreign operation), (B) replication, (C) income generation, or (D) held for other investment/risk management activities. Replications, income generation and held for other investment/risk management activities do not qualify for hedge accounting under SSAP No. 86, Derivatives.
 
(A)
Derivative instruments used in hedging transactions that meet the criteria of an effective hedge are valued and reported in a manner that is consistent with the hedged asset or liability (amortized cost or fair value). Embedded derivatives are not accounted for separately from the host contract. Derivative instruments used in hedging transactions that do not meet or no longer meet the criteria of an effective hedge are accounted for at fair value, and the changes in the fair value are recorded in unassigned surplus as unrealized gains and losses. Under GAAP, the effective and ineffective portions of a single hedge are accounted for separately, and the change in fair value for cash flow hedges is credited or charged directly to a separate component of OCI rather than to income as required for fair value hedges, and an embedded derivative within a contract that is not clearly and closely related to the economic characteristics and the risk of the host contract is accounted for separately from the host contract and valued and reported at fair value.
 
(B)
Derivative instruments are also used in replication (synthetic asset) transactions (RSAT). A replication transaction is a derivative transaction entered into in conjunction with a cash instrument to reproduce the investment characteristics of an otherwise permissible investment. In these transactions, the derivative is accounted for in a manner consistent with the cash instrument and replicated asset. For GAAP, the derivative is reported at fair value, with the changes in fair value reported in income.
 
(C)
Derivative instruments used in income generation relationships are accounted for on a basis that is consistent with the associated covered asset or underlying interest to which the derivative relates (amortized cost or fair value).
 
(D)
Derivative instruments held for other investment/risk management activities are measured at fair value with value adjustments recorded in unassigned surplus.
 
16

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Derivative instruments are subject to market risk, which is the possibility that future changes in market prices may make the instruments less valuable. The Company uses derivatives as hedges, consequently, when the value of the hedged asset or liability changes, the value of the hedging derivative is expected to move in the opposite direction. Market risk is a consideration when changes in the value of the derivative and the hedged item do not completely offset (correlation or basis risk) which is mitigated by active measuring and monitoring.
 
The Company is exposed to credit-related losses in the event of non-performance by counterparties to derivative instruments, but it does not expect any counterparties to fail to meet their obligations given their high credit rating of 'BBB' or better. The credit exposure of interest rate swaps and currency swaps is represented by the fair value of contracts, aggregated at a counterparty level, with a positive fair value at the reporting date. The Company has entered into collateral agreements with certain counterparties wherein the counterparty is required to post assets on the Company's behalf. The posted amount is equal to the difference between the net positive fair value of the contracts and an agreed upon threshold that is based on the credit rating of the counterparty. Inversely, if the net fair value of all contracts with this counterparty is negative, then the Company is required to post assets.
 
Instruments:
 
Interest rate swaps may be used in the overall asset/liability management process to modify the interest rate characteristics of the underlying asset or liability. These interest rate swaps generally provide for the exchange of the difference between fixed and floating rate amounts based on an underlying notional amount. Typically, no cash is exchanged at the outset of the swap contract and a single net payment is exchanged each due date; however, if there are upfront costs this is treated as book value and amortized into income over the duration of the deal. Swaps that meet hedge accounting rules are carried in a manner consistent with the hedged item, generally at amortized cost, in the financial statements. If the swap is terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment. Swaps not meeting hedge accounting rules are carried at fair value with fair value adjustments recorded in unassigned surplus.
 
Cross currency swaps may be used to mitigate risks when the Company holds foreign denominated assets or liabilities; therefore, converting the asset or liability to a U.S. dollar denominated security. These cross currency swap agreements involve the exchange of two principal amounts in two different currencies at the prevailing currency rate at contract inception. During the life of the swap, the counterparties exchange fixed or floating rate interest payments in the swapped currencies. At maturity, the principal amounts are again swapped at a pre-determined rate of exchange. Each asset or liability is hedged individually where the terms of the swap must meet the terms of the hedged instrument. For swaps qualifying for hedge accounting, the premium or discount is amortized into income over the life of the contract and the foreign currency translation adjustment is recorded as unrealized gain/loss in capital and surplus. Swaps not meeting hedge accounting rules are carried at fair value with fair value adjustments recorded in capital and surplus. If a swap is terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the hedged instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment.
 
17

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Total return swaps may be used in the asset/liability management process to mitigate the delta risk created when the Company has issued minimum guarantee insurance contracts linked to an index. These total return swaps generally provide for the exchange of the difference between fixed leg (tied to the Standard and Poor’s 500 (S&P) or other global market financial index) and floating leg (tied to Secured Overnight Financing Rate (SOFR)) amounts based on an underlying notional amount (also tied to the underlying index). Typically, no cash is exchanged at the outset of the swap contract and a single net payment is exchanged each due date; however, if there are upfront costs this is treated as book value and amortized into income over the duration of the deal.  Swaps that meet hedge accounting rules are carried in a manner consistent with the hedged item, generally at amortized cost, in the financial statements. If the swap is terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment. Swaps not meeting hedge accounting rules are carried at fair value with fair value adjustments recorded in unassigned surplus.
 
Variance swaps may be used in the asset/liability management process to mitigate the gamma risk created when the Company has issued minimum guarantee insurance contracts linked to an index. These variance swaps are similar to volatility options where the underlying index provides for the market value movements. Variance swaps do not accrue interest. Typically, no cash is exchanged at the outset of initiating the variance swap, and a single receipt or payment occurs at the maturity or termination of the contract; however, if there are upfront costs this is treated as book value and amortized into income over the duration of the deal. The variance swaps that meet hedge accounting rules are carried in a manner consistent with the hedged item, generally at amortized cost, in the financial statements. If terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment. Swaps not meeting hedge accounting rules are carried at fair value with fair value adjustments recorded in unassigned surplus.
 
Bond forwards may be used to hedge the interest rate risk (rho) that future liability claims increase as rates decrease, leading to higher guarantee values. Bond return swaps are also used to hedge interest rate risk of the underlying liability by exchanging performance and interest of a treasury asset for a funding level plus spread. If terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment.
18

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Futures contracts may be used to hedge the liability risk associated with when the Company issues products providing the customer a return based on various global market indices. Futures are marked to market on a daily basis whereby a cash payment is made or received by the Company. These payments are recognized as realized gains or losses in the financial statements. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment.
 
The Company may issue products providing the customer a return based on the various global equity market indices. The Company uses options to hedge the liability option risk associated with these products. The costs to acquire options are treated as book value and amortized into income over the duration of the deal. If terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment. Options are marked to fair value in the Balance Sheets and fair value adjustments are recorded as unassigned surplus in the financial statements.
 
Caps may be used in the asset/liability management process to mitigate the interest rate risk created due to a rapidly rising interest rate environment. The caps are similar to options where the underlying interest rate index provides for the market value movements. The caps do not accrue interest until the interest rate environment exceeds the caps strike rate. Cash is exchanged at the onset, and a single receipt or payment occurs at the maturity or termination of the contract. The costs to acquire caps are treated as book value and amortized into income over the duration of the deal. Caps that meet hedge accounting rules are carried in a manner consistent with the hedged item, generally at amortized cost, on the financial statements. If terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment. Caps that do not meet hedge accounting rules are carried at fair value with fair value adjustments recorded in unassigned surplus.
 
The Company may use zero cost collars to hedge the interest rate risk associated with rising short term interest rates, whereby the exposure would otherwise adversely impact the Company’s capital generation. The collar position(s) help range bound the floating rate by combining a cap and floor position. If terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment.
19

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company may sell products with expected benefit payments extending beyond investment assets currently available in the market. Because assets will have to be purchased in the future to fund future liability cash flows, the Company is exposed to the risk of future investments made at lower yields than what is assumed at the time of pricing. Forward-starting interest rate swaps are utilized to lock-in the current forward rate. The accrual of income begins at the forward date, rather than at the inception date. These forward-starting swaps meet hedge accounting rules and are carried at cost in the financial statements. Gains and losses realized upon termination of the forward-starting swap are deferred and used to adjust the basis of the asset purchased in the hedged forecasted period. The basis adjustment is then amortized into income as a yield adjustment to the asset over its life.
 
The Company may issue fixed liabilities that have a guaranteed minimum crediting rate. The Company may use receiver swaptions, whereby the swaption is designed to generate cash flows to offset lower yields on assets during a low interest rate environment. The Company pays a single premium at the beginning of the contract that is subsequently amortized throughout the life of the swaption. These swaptions are marked to fair value in the Balance Sheets and the fair value adjustment is recorded in unassigned surplus. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment; however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment.
 
A replication transaction is a derivative transaction entered into in conjunction with a cash instrument to reproduce the investment characteristics of an otherwise permissible investment. The Company may replicate investment grade corporate bonds, sovereign debt, or commercial mortgage backed securities by combining a highly rated security as a cash component with a written credit default swap which, in effect, converts the high quality asset into an investment grade corporate asset, sovereign debt, or commercial mortgage backed security. The benefits of using the swap market to replicate credit include possible enhanced relative values as well as ease of executing larger transactions in a shortened time frame. Generally, a premium is received by the Company on a periodic basis and recognized in investment income. In the event the representative issuer defaults on its debt obligation referenced in the contract, a payment equal to the notional amount of the contract will be made by the Company and recognized as a capital loss. The Company complies with the specific rules established in AVR for replication transactions whereby the representative issuer defaults. If terminated prior to maturity, proceeds equal to the fair value of the contract are exchanged. These gains and losses may be included in IMR or AVR if the underlying instrument receives that treatment however, gains and losses related to the unamortized book value at termination are not permitted to receive IMR treatment.
 
20

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company may designate and account for fair value hedges when the effectiveness requirements of SSAP No. 86 are achieved. The following hedge type relationships are considered: (A) an interest rate swap that converts a fixed rate asset to a floating rate asset; (B) an interest rate swap that converts a fixed rate liability to a floating rate liability; (C) a cross currency interest rate swap that converts a foreign denominated fixed rate asset to a U.S. dollar floating rate asset; and (D) a cross currency interest rate swap that converts a foreign denominated fixed rate liability to a U.S. dollar floating rate liability.
 
The Company may designate and account for cash flow hedges when the effectiveness requirements of SSAP No. 86 are achieved. The following hedge-type relationships are considered: (A) an interest rate swap that converts a floating rate asset to a fixed rate asset; (B) an interest rate swap that converts a floating rate liability to a fixed rate liability; (C) a cross currency interest rate swap that converts a foreign denominated floating rate asset to a U.S. dollar fixed rate asset; (D) a cross currency interest rate swap that converts a foreign denominated floating rate liability to a U.S. dollar fixed rate liability; and (E) a forward starting interest rate swap to hedge the forecasted purchases of fixed rate assets.
 
Any deferred gain (loss) related to forecasted transaction cash flow hedging is recognized in income as the purchased asset affects income. If the forecasted transaction no longer qualifies for hedge accounting or if the forecasted transaction is no longer probable, the forward-starting swap will cease to be valued at amortized cost and will be marked to market through surplus. For the year ended December 31, 2025, none of the Company’s cash flow hedges have been discontinued, as it was probable that the original forecasted transactions would occur by the end of the originally specified time period documented at inception of the hedging relationship.
 
The Company may enter into derivative transactions that economically mitigate risk associated with interest rate, exchange rate, credit, and equity movements within the marketplace. Due to the natural economic benefits of the hedge in relation to the hedged item, the Company chooses not to seek hedge accounting in these instances. Examples of these types of derivative transactions and the associated risks are as follows: (A) futures that hedge equity risk on universal life liabilities; (B) futures, options, swaps, or forward contracts that hedge the equity or interest rate risk on minimum rate guarantee liabilities; (C) credit default swap purchases of protection that hedge the credit risk of specific bonds; (D) interest rate caps that hedge a rapidly rising interest rate environment and withdrawal activity in pension products; and (E) interest rate swaptions that hedge the risk of a low interest rate environment on in-force recurring premium products.
The Company may enter into replicated (synthetic asset) transactions used for purposes other than hedging by the following: (A) combining a written credit default swap with a highly rated cash instrument to synthetically create corporate debt; (B) combining a written credit default swap with a highly rated cash instrument to synthetically create sovereign debt; or (C) combining a written credit default swap with a highly rated cash instrument to synthetically create a portfolio of commercial mortgage backed securities.
 
Securities Lending Assets and Liabilities
 
The Company loans securities to third parties under agent-managed securities lending programs accounted for as secured borrowings. Cash collateral received which may be sold or repledged by the Company is reflected as a one-line entry on the Balance Sheets (Securities lending reinvested collateral assets) and a corresponding liability is established to record the obligation to return the cash collateral. Non-cash collateral received which may not be sold or repledged is not recorded on the Company’s Balance Sheets. Under GAAP, the reinvested collateral is included within invested assets and is not reported as a single line item.
21

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Other Assets and Other Liabilities
 
Other assets consist primarily of cash surrender value of company owned life insurance, receivable from parent, subsidiaries and affiliates, disallowed IMR and general insurance accounts receivable.
 
Other liabilities consist primarily of amounts withheld by the Company, accrued expenses, remittances, custody offset, and municipal repurchase agreements. Municipal repurchase agreements are investment contracts issued to municipalities that pay either a fixed or floating rate of interest on the guaranteed deposit balance. The floating interest rate is based on a market index. The related liabilities are equal to the policyholder deposit and accumulated interest. These municipal repurchase agreements require a minimum of 95% of the fair value of the securities transferred to be maintained as collateral.
 
Separate Accounts
 
The majority of separate accounts held by the Company, primarily for individual policyholders as well as for group pension plans, do not have any minimum guarantees, and the investment risks associated with fair value changes are borne by the policyholder. The assets in the accounts consist of underlying mutual fund shares, common stocks, long-term bonds and short-term investments.
 
Assets held in trust for purchases of variable life, variable universal life, variable annuity and certain non-indexed guaranteed annuity contracts (which guarantee certain returns as specified in the contracts) and the Company's corresponding obligation to the contract owners are shown separately in the Balance Sheets. The assets and liabilities in the separate accounts are carried on a fair value basis. Income and gains and losses with respect to these assets accrue to the benefit of the policyholders and, accordingly, the operations of the separate accounts are not included in the accompanying financial statements. The investment risks associated with fair value changes of the separate accounts are borne entirely by the policyholders except in cases where minimum guarantees exist.
 
The individual variable life insurance policies typically provide a guaranteed minimum death benefit.
 
Certain other modified guaranteed annuity separate accounts represent funds invested by the Company for the benefit of contract holders who are guaranteed certain returns as specified in the contracts. These modified guaranteed annuity separate account assets and liabilities are carried at amortized cost. Income and gains and losses with respect to the assets in the separate accounts supporting modified guaranteed annuity contracts are included in the Company’s Statements of Operations as a component of net transfers from separate accounts.
22

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Separate account asset performance different than the guaranteed requirements is either transferred to or received from the general account and reported in the Statements of Operations. These guarantees are included in the general account due to the nature of the guaranteed return.
 
Surplus funds transferred from the general account to the separate accounts, commonly referred to as seed money, and earnings accumulated on seed money are reported as surplus in the separate accounts until transferred or repatriated to the general account. The transfer of such funds between the separate account and the general account is reported as surplus contributed or withdrawn during the year.
 
Aggregate Reserves for Policies and Contracts
 
Life, annuity and accident and health benefit reserves are calculated by actuarial methods and are determined based on published tables using statutorily specified interest rates and valuation methods that will provide, in the aggregate, reserves that are greater than or equal to the minimum or guaranteed cash value, or the amount required by law. For direct business issued after October 1964, the Company waives deduction of deferred fractional premiums upon death of the insured and returns any portion of the final premium for periods beyond the month of death. For policies assumed during 1992 from former affiliates, Monumental General Insurance Company and Monumental Life Insurance Group, Inc., and for all business from company mergers occurring in 1998, the Company waives deduction of deferred fractional premium upon death of the insured and returns any portion of the final premium paid beyond the month of death. For fixed premium life insurance business resulting from company mergers occurring in 2004 and 2007, the Company waives deduction of deferred fractional premiums upon death of the insured and refunds portions of premiums unearned after the date of death. Where appropriate, the Company holds a non-deduction and/or refund reserve. The reserve for these benefits is computed using aggregate methods. The reserves are equal to the greater of the cash surrender value and the legally computed reserve.
 
For GAAP, policy reserves are calculated based on estimated expected experience or actual account balances.
 
Surrender values are not promised in excess of the legally computed reserves. For annual premium variable life insurance there is an extra premium charged to the policyholder before the premium is transferred to the Separate Accounts. An additional reserve for this policy is held in the General Account that is a multiple of the reserve that would otherwise be held. For interest sensitive whole life, the reserves held in the General Account are equal to the cash surrender value.
 
23

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
In accordance with SSAP No. 51, Life Contracts, and No. 54, Individual and Group Accident and Health Contracts, the Company reports the amount of insurance, if any, for which the gross premiums are less than the net premiums according to the valuation standards and any related premium deficiency reserve established. Anticipated investment income is not included as a factor in the health contract premium deficiency calculation.
 
Policy and Contract Claim Reserves
 
Claim reserves represent the estimated accrued liability for claims reported to the Company and claims incurred but not yet reported through the Balance Sheets date. These reserves are estimated using either individual case-basis valuations or statistical analysis techniques. These estimates are subject to the effects of trends in claim severity and frequency. The estimates are continually reviewed and adjusted as necessary as experience develops or new information becomes available.
 
Deposit-Type Contracts
 
Deposit-type contracts do not incorporate risk from the death or disability of policyholders. These types of contracts may include guaranteed investment contracts (GICs), funding agreements and other annuity contracts. Deposits and withdrawals on these contracts are recorded as a direct increase or decrease, respectively, to the liability balance and are not reported as premiums, benefits or changes in reserves in the Statements of Operations. Interest on these policies is reflected in other benefits.
 
Premiums and Annuity Considerations
 
Revenues for life and annuity policies with mortality or morbidity risk (including annuities with purchase rate guarantees) consist of the entire premium received. Benefits incurred represent surrenders and death benefits paid and the change in policy reserves. Under GAAP, for universal life policies, premiums received in excess of policy charges would not be recognized as premium revenue and benefits would represent interest credited to the account values and the excess of benefits paid over the policy account value. Under GAAP, for all annuity policies without significant mortality risk, premiums received and benefits paid would be recorded directly to the reserve liability using deposit accounting.
 
Policyholder Dividends
 
Policyholder dividends are recognized when declared rather than over the term of the related policies as would be required under GAAP.
 
24

 
Reinsurance
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Coinsurance premiums, commissions, expense reimbursements and reserves related to reinsured business are accounted for on bases consistent with those used in accounting for the original policies and the terms of the reinsurance contracts. Gains associated with reinsurance of in force blocks of business are included in unassigned surplus and amortized into income as earnings emerge on the reinsured block of business. Premiums ceded and recoverable losses have been reported as a reduction of premium income and benefits, respectively. Policy liabilities and accruals are reported in the accompanying financial statements net of reinsurance ceded.
 
Any reinsurance amounts deemed to be uncollectible have been written off through a charge to operations. In addition, a liability for reinsurance balances would be established for unsecured policy reserves ceded to reinsurers not authorized to assume such business. Changes to the liability are credited or charged directly to unassigned surplus. Under GAAP, an allowance for amounts deemed uncollectible would be established through a charge to earnings.
 
Losses associated with an indemnity reinsurance transaction are reported within income when incurred rather than being deferred and amortized over the remaining life of the underlying reinsured contracts as would be required under GAAP.
 
Policy and contract liabilities ceded to reinsurers have been reported as reductions of the related reserves rather than as assets as would be required under GAAP.
 
Commissions allowed by reinsurers on business ceded are reported as income when incurred rather than being deferred and amortized with deferred policy acquisition costs as required under GAAP.
 
Under GAAP, for certain reinsurance agreements whereby assets are retained by the ceding insurer (such as funds withheld or modified coinsurance) and a return is paid based on the performance of underlying investments, the assets and liabilities for these reinsurance arrangements must be adjusted to reflect the fair value of the invested assets. The NAIC SAP does not contain a similar requirement.
 
25

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Deferred Income Taxes
 
The Company computes deferred income taxes in accordance with SSAP No. 101, Income Taxes. Unlike GAAP, SSAP No. 101 does not consider state income taxes in the measurement of deferred taxes. SSAP No. 101 also requires additional testing to measure gross deferred tax assets. The additional testing limits gross deferred tax asset admission to 1) the amount of federal income taxes paid in prior years recoverable through hypothetical loss carrybacks of existing temporary differences expected to reverse during a timeframe corresponding with the Internal Revenue Service tax loss carryback provisions, not to exceed three years, plus 2) the amount of remaining gross deferred tax assets expected to be realized within three years limited to an amount that is no greater than 15% of current period's adjusted statutory capital and surplus, plus 3) the amount of remaining gross deferred tax assets that can be offset against existing gross deferred tax liabilities after considering character (i.e. ordinary versus capital) and reversal patterns. The Company’s reported deferred tax asset or liability is the sum of gross deferred tax assets admitted through this three-part test plus the sum of all deferred tax liabilities.
 
Policy Acquisition Costs
 
The costs of acquiring and renewing business are expensed when incurred. Under GAAP, incremental costs directly related to the successful acquisition of insurance and investment contracts are deferred.
 
Value of Business Acquired
 
Under GAAP, value of business acquired (VOBA) is an intangible asset resulting from a business combination that represents the excess of book value over the estimated fair value of acquired insurance, annuity, and investment-type contracts in-force at the acquisition date. The estimated fair value of the acquired liabilities is based on projections, by each block of business, of future contracts and contract changes, premiums, mortality and morbidity, separate account performance, surrenders, operation expenses, investment returns, nonperformance risk adjustment and other factors. VOBA is not recognized under the NAIC SAP.
 
Subsidiaries and Affiliated Companies
 
Investments in SCA are stated in accordance with the Purposes and Procedures Manual of the NAIC SVO, as well as SSAP No. 97.
 
The accounts and operations of the Company’s subsidiaries are not consolidated with the accounts and operations of the Company as would be required under GAAP. Dividends or distributions received from an investee are recognized in investment income when declared to the extent that they are not in excess of the undistributed accumulated earnings attributable to an investee. Changes in investments in SCA’s are recorded as a change to the carrying value of the investment with a corresponding amount recorded directly to unrealized gain/loss (capital and surplus).
 
26

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Nonadmitted Assets
 
Certain assets designated as "nonadmitted", primarily net deferred tax assets, reinsurance receivables, agent's balances and other assets not specifically identified as an admitted asset within the NAIC SAP, are excluded from the accompanying Balance Sheets and are charged directly to unassigned surplus. Under GAAP, such assets are included in the Balance Sheets to the extent that they are not impaired.
 
Statements of Cash Flow
 
Cash, cash equivalents and short-term investments in the Statements of Cash Flow represent cash balances and investments with initial maturities of one year or less and money market mutual funds. Under GAAP, the corresponding caption of cash and cash equivalents includes cash balances and investments with initial maturities of three months or less.
 
3.
Accounting Changes and Correction of Errors
 
The Company's policy is to disclose recently adopted accounting pronouncements that have been classified by the NAIC as a new statutory accounting principle (SAP) concept change, as well as items classified by the NAIC as SAP clarification changes that have been adopted and have had a material impact on the financial position or results of operations of the Company.
 
Recent Accounting Pronouncements
 
Effective January 1, 2025, the NAIC implemented substantive revisions to SSAP No. 26, Bonds and SSAP No. 43, Asset-Backed Securities, incorporating concepts from the principles-based bond definition (PBBD) project regarding the criteria for reporting long-term bonds. In accordance with the NAIC’s transition guidance specific to the project, this update does not constitute a change in accounting principle. The updated guidance has led to modifications in how tables within footnotes 4, 5 and 15 are presented, which may differ from the presentation used in previous reporting periods.
 
27

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Effective January 1, 2025, the NAIC adopted revisions to SSAP No. 21, Other Admitted Assets, to reflect accounting and reporting guidance for investments that do not meet the requirements of PBBD, and for residual tranches or interests/loss positions.
 
The aggregate book adjusted carrying value for securities reclassified from Schedule D to Schedule BA was $5. The measurement basis for the transferred securities did not change. There was no impact to the Company’s net income or capital and surplus.
 
On January 10, 2024, the Statutory Accounting Principles Working Group (SAPWG) adopted INT 23-04, Scottish Re Life Reinsurance Liquidation Questions, effective for reporting periods on or after December 31, 2023. INT 23-04 provides clarity that the Scottish Re liquidation should be accounted for as a commutation or recapture and reported as such, including all relevant disclosures. An impairment analysis shall be conducted and any remaining receivables in dispute or not secured by a trust shall be non-admitted. Refer to Note 7 for further detail.
 
On August 13, 2023, the SAPWG adopted INT 23-01, Net Negative (Disallowed) Interest Maintenance Reserve, effective immediately. INT 23-01 provides optional, limited-time guidance, which allows the admittance of net negative (disallowed) IMR if certain conditions are met, up to 10% of adjusted general account capital and surplus. Refer to Note 5 for further detail.
Correction of Errors
 
There were additional errors identified in prior year financial statements that have been corrected in the years presented in the financial statements in accordance with SSAP No. 3, Accounting Changes and Corrections of Errors. These errors do not have a material impact on the financial statements, individually or in aggregate, and therefore have not been separately disclosed.
 
Reclassifications
 
Certain amounts in prior year financial statement balances and footnote disclosures have been reclassified to conform to the current year presentation.
28

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
4.
Fair Values of Financial Instruments
 
The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
 
Determination of Fair Value
 
The fair values of financial instruments are determined by management after taking into consideration several sources of data. When available, the Company uses quoted market prices in active markets to determine the fair value of its investments. The Company’s valuation policy utilizes a pricing hierarchy which dictates that publicly available prices are initially sought from indices and third-party pricing services. In the event that pricing is not available from these sources, those securities are submitted to brokers to obtain quotes. Lastly, securities are priced using internal cash flow modeling techniques. These valuation methodologies commonly use reported trades, bids, offers, issuer spreads, benchmark yields, estimated prepayment speeds, and/or estimated cash flows.
 
To understand the valuation methodologies used by third-party pricing services, the Company reviews and monitors their applicable methodology documents. Any changes to their methodologies are noted and reviewed for reasonableness. In addition, the Company performs in-depth reviews of prices received from third-party pricing services on a sample basis. The objective for such reviews is to demonstrate the Company can corroborate detailed information such as assumptions, inputs and methodologies used in pricing individual securities against documented pricing methodologies. Only third-party pricing services and brokers with a substantial presence in the market and with appropriate experience and expertise are used.
 
Each month, the Company performs an analysis of the information obtained from indices, third-party services, and brokers to ensure the information is reasonable and produces a reasonable estimate of fair value. The Company considers both qualitative and quantitative factors as part of this analysis, including but not limited to, recent transactional activity for similar securities, review of pricing statistics and trends, and consideration of recent relevant market events. Other controls and procedures over pricing received from indices, third-party pricing services, or brokers include validation checks such as exception reports which highlight significant price changes, stale prices or un-priced securities.
 
29

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Fair Value Hierarchy
 
The Company's financial assets and liabilities carried at fair value are classified, for disclosure purposes, based on a hierarchy defined by SSAP No. 100, Fair Value. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1), and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset’s or a liability’s classification is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The levels of the fair value hierarchy are as follows:
 
Level 1 -   Unadjusted quoted prices for identical assets or liabilities in active markets accessible at the measurement date.
 
Level 2 -
Quoted prices in markets that are not active or inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:
 
a)
Quoted prices for similar assets or liabilities in active markets
b)
Quoted prices for identical or similar assets or liabilities in non-active markets
c)
Inputs other than quoted market prices that are observable
d)
Inputs that are derived principally from or corroborated by observable market data through correlation or other means
 
Level 3 - 
Prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. They reflect the Company’s own assumptions about the assumptions a market participant would use in pricing the asset or liability.
 
The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:
 
Cash Equivalents and Short-Term Investments: The carrying amounts reported in the accompanying Balance Sheets for these financial instruments is either reported at fair value or amortized cost (which approximates fair value). Cash is not included in the below tables.
 
Short-Term Notes Receivable from Affiliates: The carrying amounts reported in the accompanying Balance Sheets for these financial instruments approximate their fair value.
 
Bonds and Stocks: The NAIC allows insurance companies to report the fair value determined by the SVO or to determine the fair value by using a permitted valuation method. The fair values of bonds and stocks are reported or determined using the following pricing sources: indices, third-party pricing services, brokers, external fund managers and internal models.
 
30

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Fair values for fixed maturity securities (including redeemable preferred stock) actively traded are determined from third-party pricing services, which are determined as discussed above in the description of Level 1 and Level 2 values within the fair value hierarchy. For fixed maturity securities (including redeemable preferred stock) not actively traded, fair values are estimated using values obtained from third-party pricing services, or are based on non-binding broker quotes or internal models. In the case of private placements, fair values are estimated by discounting the expected future cash flows using current market rates applicable to the coupon rate, credit and maturity of the investments.
 
Mortgage Loans on Real Estate: The fair values for mortgage loans on real estate are estimated utilizing discounted cash flow analyses, using interest rates reflective of current market conditions and the risk characteristics of the loans.
 
Real Estate: Real estate held for sale is typically valued utilizing independent external appraisers in conjunction with reviews by qualified internal appraisers. Valuations are primarily based on active market prices, adjusted for any difference in the nature, location or condition of the specific property. If such information is not available, other valuation methods are applied, considering the value that the property’s net earning power will support, the value indicated by recent sales of comparable properties and the current cost of reproducing or replacing the property.
 
Other Invested Assets: The fair values for other invested assets, which include investments in surplus notes issued by other insurance companies and fixed or variable rate investments with underlying characteristics of bonds, are determined primarily by using indices, third-party pricing services and internal models.
 
Derivative Financial Instruments: The fair value of futures and forwards are based upon the latest quoted market price and spot rates at the Balance Sheets date. The estimated fair values of equity and interest rate options (calls, puts, caps) are based upon the latest quoted market price at the Balance Sheets date. The estimated fair values of swaps, including equity, interest rate and currency swaps, are based on pricing models or formulas using current assumptions. The estimated fair values of credit default swaps are based upon active market data, including interest rate quotes, credit spreads, and recovery rates, which are then used to calculate probabilities of default for the fair value calculation. The Company accounts for derivatives that receive and pass hedge accounting in the same manner as the underlying hedged instrument. If that instrument is held at amortized cost, then the derivative is also held at amortized cost.
 
Policy Loans: The book value of policy loans is considered to approximate the fair value of the loan, which is stated at unpaid principal balance.
 
31

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Securities Lending Reinvested Collateral: The cash collateral from securities lending is reinvested in various short-term and long-term debt instruments. The fair values of these investments are determined using the methods described above under Cash Equivalents and Short-Term Investments and Bonds and Stocks.
 
Separate Account Assets and Annuity Liabilities: The fair value of separate account assets are based on quoted market prices when available. When not available, they are primarily valued either using third-party pricing services or are valued in the same manner as the general account assets as further described in this note. However, some separate account assets are valued using non-binding broker quotes, which cannot be corroborated by other market observable data, or internal modeling which utilizes input that are not market observable. The fair value of separate account annuity liabilities is based on the account value for separate accounts business without guarantees. For separate accounts with guarantees, fair value is based on discounted cash flows.
 
Investment Contract Liabilities: Fair value for the Company's liabilities under investment contracts, which include deferred annuities and GICs, are estimated using discounted cash flow calculations. For those liabilities that are short in duration, carrying amount approximates fair value. For investment contracts with no defined maturity, fair value is estimated to be the present surrender value.
 
Deposit-Type Contracts: The carrying amounts of deposit-type contracts reported in the accompanying Balance Sheets approximate their fair values. These are included in the investment contract liabilities.
 
Fair values for the Company's insurance contracts other than investment-type contracts (including separate account universal life liabilities) are not required to be disclosed. However, the fair values of liabilities under all insurance contracts are taken into consideration in the Company's overall management of interest rate risk, such that the Company's exposure to changing interest rates is minimized through the matching of investment maturities with amounts due under insurance contracts.
 
The Company accounts for its investments in affiliated common stock in accordance with SSAP No. 97, as such, they are not included in the following disclosures.
 
32

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following tables set forth a comparison of the estimated fair values and carrying amounts of the Company’s financial instruments, including those not measured at fair value in the Balance Sheets, as of December 31, 2025 and 2024, respectively:
 
33

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                          
 
December 31, 2025
    
Aggregate Fair Value
    
Admitted Value
    
(Level 1)
    
(Level 2)
    
(Level 3)
 
Admitted assets
                        
Cash equivalents and short-term investments, other than affiliates
 $1,081   $1,081   $1,011   $70   $ 
Bonds
                        
Asset-backed securities
  8,486    8,486    229    7,683    574 
Issuer credit obligations
  37,782    41,210    3,775    33,950    57 
Preferred stocks, other than affiliates
  40    40        39    1 
Common stocks, other than affiliates
  73    73    7    5    61 
Mortgage loans on real estate
  8,030    8,818            8,030 
Other invested assets
  213    235        200    13 
Derivative assets:
                        
Options
  75    75        75     
Interest rate swaps
  80    80        80     
Currency swaps
  66    26        66     
Credit default swaps
  34    18        34     
Equity swaps
  43    43        43     
Interest rate futures
  2    2    2         
Equity futures
  3    3    3         
Derivative assets total
  303    247    5    298     
Policy loans
  2,376    2,376        2,376     
Securities lending reinvested collateral
  1,458    1,458    1,343    115     
Separate account assets
  108,416    108,398    99,066    8,165    1,185 
                          
Liabilities
                        
Investment contract liabilities
 $11,269   $11,436   $   $195   $11,074 
Derivative liabilities:
                        
Options
  19    19        19     
Interest rate swaps
  1,121    721        1,121     
Currency swaps
  9    42        9     
Credit default swaps
      5             
Equity swaps
  102    102        102     
Interest rate futures
  1    1    1         
Equity futures
  44    44    44         
Derivative liabilities total
  1,296    934    45    1,251     
Payable for securities lending
  1,657    1,657        1,657     
Payable for derivative cash collateral
  78    78        78     
Separate account liabilities
  96,928    97,017    2    96,917    9 
 
34

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                          
 
December 31, 2024
    
Aggregate Fair Value
    
Admitted Value
    
(Level 1)
    
(Level 2)
    
(Level 3)
 
Admitted assets
                        
Cash equivalents and short-term investments, other than affiliates
 $1,465   $1,465   $1,462   $3   $ 
Short-term notes receivable from affiliates
  450    450        450     
Bonds
  45,903    51,162    4,334    40,738    831 
Preferred stocks, other than affiliates
  44    44        44     
Common stocks, other than affiliates
  90    90    4        86 
Mortgage loans on real estate
  7,752    8,885            7,752 
Other invested assets
  298    337        283    15 
Derivative assets:
                        
Options
  63    63        63     
Interest rate swaps
  105    105        105     
Currency swaps
  110    70        110     
Credit default swaps
  62    38        62     
Equity swaps
  119    119        119     
Interest rate futures
  2    2    2         
Equity futures
  2    2    2         
Derivative assets total
  463    399    4    459     
Policy loans
  2,239    2,239        2,239     
Securities lending reinvested collateral
  1,537    1,537    1,537         
Separate account assets
  102,011    102,098    95,458    5,955    598 
                          
Liabilities
                        
Investment contract liabilities
 $10,097   $9,763   $   $204   $9,893 
Derivative liabilities:
                        
Options
  5    5        5     
Interest rate swaps
  1,849    1,417        1,849     
Currency swaps
  1    2        1     
Credit default swaps
  (2   5        (2    
Equity swaps
  37    37        37     
Interest rate futures
  1    1    1         
Equity futures
  14    14    14         
Derivative liabilities total
  1,905    1,481    15    1,890     
Payable for securities lending
  1,667    1,667        1,667     
Payable for derivative cash collateral
  96    96        96     
Separate account liabilities
  91,620    91,698    2    91,609    9 
35

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following tables provide information about the Company's financial assets and liabilities measured at fair value as of December 31, 2025 and 2024:
 
                     
 
2025
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                   
Bonds
                   
Asset-backed securities
 $   $14   $1   $15 
Issuer credit obligations
      9    6    15 
Total bonds
      23    7    30 
Preferred stock
                   
Industrial and miscellaneous
      40        40 
Total preferred stock
      40        40 
Common stock
                   
Industrial and miscellaneous
  7    5    61    73 
Total common stock
  7    5    61    73 
Cash equivalents and short-term investments
                   
Industrial and miscellaneous
      3        3 
Money market mutual funds
  896            896 
Total cash equivalents and short-term investments
  896    3        899 
Derivative assets
  4    188        192 
Separate account assets
  98,701    4,118        102,819 
Total assets
 $99,608   $4,377   $68   $104,053 
Liabilities:
                   
Derivative liabilities
 $45   $303   $   $348 
Separate account liabilities
  2            2 
Total liabilities
 $47   $303   $   $350 
 
36

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                     
 
2024
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                   
Bonds
                   
Government
 $   $2   $   $2 
Industrial and miscellaneous
      26    2    28 
Total bonds
      28    2    30 
Preferred stock
                   
Industrial and miscellaneous
      44        44 
Total preferred stock
      44        44 
Common stock
                   
Industrial and miscellaneous
  4        86    90 
Total common stock
  4        86    90 
Cash equivalents and short-term investments
                   
Money market mutual funds
  1,176            1,176 
Total cash equivalents and short-term investments
  1,176            1,176 
Other long term
      5        5 
Derivative assets
  4    281        285 
Separate account assets
  95,290    4,021        99,311 
Total assets
 $96,474   $4,379   $88   $100,941 
Liabilities:
                   
Derivative liabilities
 $15   $799   $   $814 
Separate account liabilities
  2            2 
Total liabilities
 $17   $799   $   $816 
 
Bonds classified as Level 2 are valued using inputs from third party pricing services or broker quotes. Bonds classified as Level 3 are primarily those valued using non-binding broker quotes, which cannot be corroborated by other market observable data, or internal modeling which utilize significant inputs that are not market observable.
 
Preferred stock classified as Level 2 are valued using inputs from third party pricing services or broker quotes.
 
Common stock classified as Level 2 are valued using inputs from third party pricing services or broker quotes.
 
Common stock classified as Level 3 are comprised primarily of shares in the FHLB of Des Moines, which are valued at par as a proxy for fair value as a result of restrictions that allow redemptions only by FHLB.
 
Money market mutual funds and other cash or cash equivalents classified as Level 2 are valued using inputs from third party pricing services.
 
37

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Derivatives classified as Level 2 represent over-the-counter contracts valued using pricing models based on the net present value of estimated future cash flows, directly observed prices from exchange-traded derivatives, other over-the-counter trades, or external pricing services.
 
Separate account assets and liabilities are valued and classified in the same way as general account assets and liabilities (described above).
 
The following tables summarize the changes in assets classified as Level 3 for 2025 and 2024:
 
    
Beginning Balance at January 1, 2025
    
Transfers in (Level 3)
    
Transfers out (Level 3)
    
Total Gains (Losses) Included in Net income (a)
    
Total Gains (Losses) Included in Surplus (b)
 
Bonds
                        
Asset-backed securities
 $1   $   $   $(1  $1 
Issuer credit obligations
  1    13    1        (9
Preferred stock
                  (1
Common stock
  86            (3   7 
Total
 $88   $13   $1   $(4  $(2
 
    
Purchases
    
Issuances
    
Sales
    
Settlements
    
Ending Balance at December 31, 2025
 
Bonds
                        
Asset-backed securities
 $   $   $   $   $1 
Issuer credit obligations
  3                7 
Preferred stock
  1                 
Common stock
  16        45        61 
Total
 $20   $   $45   $   $69 
 
(a)
Recorded as a component of Net Realized Capital Gains (Losses) on Investments in the Statements of Operations
(b)
Recorded as a component of Change in Net Unrealized Capital Gains (Losses) in the Statements of Changes in Capital and Surplus
 
    
Beginning Balance at January 1, 2024
    
Transfers in (Level 3)
    
Transfers out (Level 3)
    
Total Gains (Losses) Included in Net income (a)
    
Total Gains (Losses) Included in Surplus (b)
 
Bonds
                        
Other
 $1   $20   $1   $(1  $(17
Common stock
  100            1    (4
Total
 $101   $20   $1   $   $(21
 
38

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
    
Purchases
    
Issuances
    
Sales
    
Settlements
    
Ending Balance at December 31, 2024
 
Bonds
                        
Other
 $   $   $   $   $2 
Common stock
  16        27        86 
Total
 $16   $   $27   $   $88 
 
(a)
Recorded as a component of Net Realized Capital Gains (Losses) on Investments in the Statements of Operations
(b)
Recorded as a component of Change in Net Unrealized Capital Gains (Losses) in the Statements of Changes in Capital and Surplus
 
Transfers between fair value hierarchy levels are recognized at the beginning of the reporting period.
 
Nonrecurring Fair Value Measurements
 
As indicated in Note 2, real estate held for sale is measured at the lower of carrying amount or fair value less encumbrances and estimated costs to sell. At December 31, 2025 and 2024, the Company held no properties classified as held-for-sale.
39

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
5.
Investments
 
Bonds and Stocks
 
The carrying amounts and estimated fair value of investments in bonds and stocks are as follows:
 
    
Book Adjusted Carrying Value
    
Gross Unrealized Gains
    
Gross Unrealized Losses
    
Estimated Fair Value
 
December 31, 2025
                   
ICOs:
                   
U.S. Government obligations (exempt from RBC)
 $4,440   $3   $1,074   $3,369 
Other U.S. Government obligations (not exempt from RBC)
  299        63    236 
Non-U.S. sovereign jurisdiction securities
  791    20    75    736 
Municipal bonds - general obligations (direct & guaranteed)
  231    3    25    209 
Municipal bonds - special revenue
  1,792    3    289    1,506 
Corporate bonds
  32,336    733    2,513    30,556 
Single entity backed obligation
  1,246    5    146    1,105 
Bank loans - acquired
  64        10    54 
Mortgage loans that qualify as SVO identified credit tenant loan - unaffiliated
  11    1        12 
Total ICOs
 $41,210   $768   $4,195   $37,783 
                     
ABS:
                   
Financial asset-backed securities - self liquidating:
                   
Agency RMBS - not/partially guaranteed (not exempt from RBC)
 $63   $   $8   $55 
Non-agency CLOs/CBOs/CDOs - unaffiliated
  414    2    2    414 
Non-agency CMBS - unaffiliated
  1,837    20    80    1,777 
Non-agency RMBS - unaffiliated
  476    55    8    523 
Other financial ABS - unaffiliated
  2,781    103    87    2,797 
Financial ABS - not self-liquidating:
                   
Equity backed securities - unaffiliated
  36            36 
Non-financial ABS - full analysis:
                   
Lease backed transactions - unaffiliated
  738    11    3    746 
Other non-financial ABS - unaffiliated
  262    5        267 
Non-financial ABS - practical expedient:
                   
Lease backed transactions - unaffiliated
  1,300    15    15    1,300 
Other non-financial ABS - unaffiliated
  579    6    15    570 
Total ABS
 $8,486   $217   $218   $8,485 
Common stock
 $58   $15   $   $73 
Preferred stock
 $40   $   $   $40 
   $49,794   $1,000   $4,413   $46,381 
40

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
    
Book Adjusted Carrying Value
    
Gross Unrealized Gains
    
Gross Unrealized Losses
    
Estimated Fair Value
 
December 31, 2024
                   
Bonds:
                   
United States Government and agencies
 $5,182   $   $1,284   $3,898 
State, municipal and other government
  3,131    9    536    2,604 
Hybrid securities
  249    8    9    248 
Industrial and miscellaneous
  34,923    478    3,621    31,780 
Mortgage and other asset-backed securities
  7,677    162    466    7,373 
Total unaffiliated bonds
  51,162    657    5,916    45,903 
Unaffiliated preferred stocks
  44            44 
   $51,206   $657   $5,916   $45,947 
 
    
Cost
    
Gross Unrealized Gains
    
Gross Unrealized Losses
    
Estimated Fair Value
 
Unaffiliated common stocks
 $88   $2   $   $90 
 
The carrying amount and estimated fair value of items held as bonds and short-term investments at December 31, 2025, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because certain borrowers have the right to call or prepay obligations with or without call or prepayment penalties.
 
           
 
December 31, 2025
December 31:
  
Carrying Value
    
Fair Value
 
Due in one year or less
 $1,968   $1,972 
Due after one year through five years
  7,305    7,454 
Due after five years through ten years
  10,587    10,458 
Due after ten years through twenty years
  12,717    11,342 
Due after twenty years
  8,837    6,759 
Subtotal
  41,414    37,985 
Mortgage and other asset-backed securities
  8,466    8,468 
Total
 $49,880   $46,453 
41

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The estimated fair value of bonds, preferred stocks and common stocks with gross unrealized losses at December 31, 2025 and 2024 is as follows:
 
                     
 
2025
 
Equal to or Greater than 12 Months
Less than 12 Months
    
Estimated Fair Value
    
Gross Unrealized Losses
    
Estimated Fair Value
    
Gross Unrealized Losses
 
ICOs:
                   
U.S. Government obligations (exempt from RBC)
 $1,669   $624   $1,521   $451 
Other U.S. Government obligations (not exempt from RBC)
  231    63         
Non-U.S. sovereign jurisdiction securities
  376    73    52    1 
Municipal bonds - general obligations (direct & guaranteed)
  118    25    17     
Municipal bonds - special revenue
  1,238    287    111    2 
Corporate bonds
  13,137    2,399    2,284    115 
Single entity backed obligation
  850    144    82    1 
Bank loans - acquired
  5        32    10 
Mortgage loans that qualify as SVO identified credit tenant loan - unaffiliated
               
Total ICOs
 $17,624   $3,615   $4,099   $580 
                     
ABS:
                   
Financial asset-backed securities - self liquidating:
                   
Agency RMBS - not/partially guaranteed (not exempt from RBC)
 $52   $8   $1   $ 
Non-agency CLOs/CBOs/CDOs - unaffiliated
  32    1    207    1 
Non-agency CMBS - unaffiliated
  1,087    79    92     
Non-agency RMBS - unaffiliated
  88    7    35    2 
Other financial ABS - unaffiliated
  802    83    471    3 
Financial ABS - not self-liquidating:
                   
Equity backed securities - unaffiliated
  1             
Non-financial ABS - full analysis:
                   
Lease backed transactions - unaffiliated
  81    2    52    1 
Other non-financial ABS - unaffiliated
          53     
Non-financial ABS - practical expedient:
                   
Lease backed transactions - unaffiliated
  201    15    170     
Other non-financial ABS - unaffiliated
  177    16    107     
Total ABS
 $2,521   $211   $1,188   $7 
Common stock
 $   $   $48   $ 
Preferred stock
 $11   $   $29   $ 
   $20,156   $3,826   $5,364   $587 
42

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                     
 
2024
 
Equal to or Greater than 12 Months
Less than 12 Months
    
Estimated Fair Value
    
Gross Unrealized Losses
    
Estimated Fair Value
    
Gross Unrealized Losses
 
United States Government and agencies
 $1,518   $649   $2,307   $635 
State, municipal and other government
  1,848    512    557    24 
Hybrid securities
  75    8    49    1 
Industrial and miscellaneous
  14,344    3,316    7,937    305 
Mortgage and other asset-backed securities
  3,445    438    1,393    28 
Total bonds
 $21,230   $4,923   $12,243   $993 
Common stocks-unaffiliated
 $   $   $1   $ 
   $21,230   $4,923   $12,244   $993 
 
During 2025, 2024 and 2023, respectively, there were $67, $7 and $13, of asset-backed or structured securities with a recognized OTTI due to intent to sell or lack of intent and ability to hold for a period of time to recover the amortized cost basis.
 
For asset-backed and structured securities with a recognized OTTI due to the Company’s cash flow analysis, in which the security is written down to estimated future cash flows discounted at the security’s effective yield, in 2025, 2024 and 2023, the Company recognized OTTI of $28, $0 and $25, respectively.
43

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following asset-backed and structured securities were held at December 31, 2025, for which an OTTI was recognized during the current reporting period:
 
CUSIP
  
Amortized Cost Before Current Period OTTI
    
Present Value of Projected Cash Flows
    
Recognized OTTI
    
Amortized Cost After OTTI
    
Fair Value at Time of OTTI
 
Date of Financial Statement Where Reported
 61,762TAH9  $3   $2   $1   $2   $2 
3/31/2025
BAE3K7RU3-TA
                   
3/31/2025
 86,362AAA6   1        1         
3/31/2025
 44,421MAA8   13    11    2    11    11 
3/31/2025
 36,260JAD9   4    3    1    3    3 
3/31/2025
 23,345LAA7   21    18    3    18    18 
3/31/2025
 36,269KAA3   4    4        4    4 
3/31/2025
 26,207AAF0   2    2        2    2 
3/31/2025
 83,164HP46                    
3/31/2025
 83,164HKQ2                    
3/31/2025
 46,651AA2   4    3    1    3    3 
3/31/2025
 61,691YAJ0   5    4    1    4    4 
3/31/2025
 5,490TAA0   2    2        2    2 
3/31/2025
 12,654YAA7   2    2        2    2 
3/31/2025
 14,576AAB8   1    1        1    1 
3/31/2025
 86,190BAB0   2    2        2    2 
3/31/2025
 10,901AAA4   2    2        2    2 
3/31/2025
 12,510HAC4   1    1        1    1 
3/31/2025
 86,190BAD6   1    1        1    1 
3/31/2025
 83,162CTG8   1    1        1    1 
3/31/2025
 46,616VAA8   1    1        1    1 
3/31/2025
 67,190AAB2   2    2        2    2 
3/31/2025
BAE2LRK94-TA
                   
6/30/2025
BAE1PAJF7-TA
                   
6/30/2025
BAE2XVVY5-TA
                   
6/30/2025
 12,640WAG5   1    1        1    1 
6/30/2025
 61,762TAH9   1        1         
9/30/2025
 12,640WAG5                    
9/30/2025
 98,162JAG1   26        26        9 
9/30/2025
             $37             
 
44

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The unrealized losses of asset-backed and structured securities where fair value is less than cost or amortized cost for which an OTTI has not been recognized in earnings as of December 31, 2025 and 2024 is as follows:
 
                     
 
2025
2024
    
Losses 12 Months or More
    
Losses Less Than 12 Months
    
Losses 12 Months or More
    
Losses Less Than 12 Months
 
Year ended December 31:
                   
The aggregate amount of unrealized losses
 $219   $7   $449   $28 
The aggregate related fair value of securities with unrealized losses
  2,521    1,089    3,460    1,485 
 
At December 31, 2025 and 2024, respectively, for bonds and preferred stocks that have been in a continuous loss position for greater than or equal to twelve months, the Company held 2,445 and 2,911 securities with a carrying amount of $23,982 and $26,152, and an unrealized loss of $3,826 and $4,923. Of this portfolio, at December 31, 2025 and 2024, 97.8% and 96.9% were investment grade with associated unrealized losses of $3,731 and $4,767, respectively.
 
At December 31, 2025 and 2024, respectively, for bonds and preferred stocks that have been in a continuous loss position for less than twelve months, the Company held 596 and 1,543 securities with a carrying amount of $5,903 and $13,236, and an unrealized loss of $587 and $993. Of this portfolio, at December 31, 2025 and 2024, 97.1% and 97.3% were investment grade with associated unrealized losses of $569 and $977, respectively.
 
At December 31, 2025 and 2024, there were no common stocks that have been in a continuous loss position for greater than or equal to twelve months.
 
At December 31, 2025 and 2024, for common stocks that have been in a continuous loss position for less than twelve months, the Company held 11 and 5 securities, respectively, with a cost of $48 and $1 and an insignificant unrealized loss.
 
45

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following table provides the number of 5GI securities, aggregate book adjusted carrying value and aggregate fair value by investment type:
 
    
Number of 5GI Securities
    
Book / Adjusted Carrying Value
    
Fair Value
 
December 31, 2025
              
Issuer credit obligations, amortized cost
  3   $11   $11 
Total
  3   $11   $11 
                
December 31, 2024
              
Bond, amortized cost
  9   $42   $24 
Total
  9   $42   $24 
 
The Company did not have any offsetting assets and liabilities at December 31, 2025 and 2024.
 
During 2025 and 2024, respectively, the Company sold, redeemed or otherwise disposed of 50 and 69 securities as a result of a callable feature which generated investment income of $9 and $16 as a result of a prepayment penalty and/or acceleration fee.
 
Proceeds from sales and other disposals of bonds and preferred stock and related gross realized capital gains and losses are reflected in the following table. The amounts exclude maturities and include transfers associated with reinsurance agreements, if applicable.
 
                
 
Year Ended December 31
    
2025
    
2024
    
2023
 
                
Proceeds
 $10,370   $4,303   $7,301 
                
Gross realized gains
 $130   $85   $184 
Gross realized losses
  (482   (143   (747
Net realized capital gains (losses)
 $(352  $(58  $(563
 
The Company had gross realized losses, which relate to losses recognized on other-than-temporary declines in the fair value of bonds and preferred stocks, for the years ended December 31, 2025, 2024 and 2023 of $88, $42 and $106, respectively.
 
At December 31, 2025 and 2024, the Company had recorded investments in restructured securities of $28 and $2.
 
46

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Concentrations of Credit Risk
 
Credit risk represents the risk that a counterparty will fail to perform on its contractual obligations. The Company’s investment portfolio includes exposures that may be subject to concentrations of credit risk by industry sector and asset class. Such concentrations arise when multiple issuers share similar economic characteristics or are exposed to common industry‑specific, regulatory or macroeconomic factors that could affect their ability to meet contractual obligations.
 
The Company’s significant concentrations of credit risk are primarily related to corporate fixed‑income investments and structured securities diversified across a range of industries and asset classes.
 
Communications (Stable)
 
The Company maintains material exposure to issuers within the communications sector, including cable, media and telecommunications companies. Credit risk within this sector is influenced by competitive pressures, technological change, capital intensity and regulatory considerations that may impact issuer cash flows and overall credit quality.
 
Consumer Cyclical (Stable)
 
The Company holds investments in consumer cyclical industries, including retailers, restaurants, gaming entities and lodging and leisure companies. Credit risk within this sector is sensitive to changes in discretionary consumer spending, employment conditions, inflationary pressures and broader economic cycles that may affect revenues and profitability.
 
Consumer Noncyclical (Mostly Stable)
 
The Company’s consumer noncyclical exposure includes issuers in the food and beverage, consumer products, supermarkets, tobacco, healthcare and pharmaceutical industries. Credit risk in these sectors is influenced by factors such as pricing power, input cost volatility, regulatory environments, healthcare policy developments, and the relative stability of consumer demand.
 
Government and Government‑Related Securities (Stable)
 
The Company also invests in government and government‑related securities, including U.S. Treasury securities, municipal obligations, supranational entities and non‑U.S. sovereign issuers. Credit risk for these investments is largely associated with changes in fiscal conditions, interest rates and geopolitical developments.
 
47

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Real Estate Investment Trusts (Stable)
 
The Company holds investments in real estate investment trusts diversified across property types. Credit risk within this sector is influenced by real estate market fundamentals, occupancy levels, rental rate trends, operating cost pressures and access to capital markets.
 
Structured Securities (Stable)
 
Beyond corporate fixed‑income securities, the Company holds structured securities, including asset‑backed securities and commercial mortgage‑backed securities. Credit risk related to these investments is primarily influenced by the performance of the underlying collateral, the level of structural credit enhancement and prevailing macroeconomic conditions.
 
Technology (Stable)
 
The Company’s technology exposure includes issuers engaged in hardware manufacturing, software development and semiconductor production. Credit risk within this sector is affected by rapid technological advancement, capital investment requirements, product demand cycles and, in certain cases, global supply chain dynamics.
 
Transportation (Stable)
 
Transportation‑related exposure includes airlines, automotive manufacturers, railroads and transportation service providers. Credit risk within this sector is affected by fuel and operating costs, labor dynamics, trade and tariff policies, supply chain disruptions and overall economic activity.
 
Utilities and Infrastructure-Related (Stable)
 
The Company also maintains exposure to regulated and infrastructure‑oriented issuers, including electric utilities and other utility‑related entities. Credit risk in this sector is influenced by capital expenditure requirements, regulatory frameworks, weather‑related events and sensitivity to interest rate movements.
 
The Company evaluated the near-term prospects of the issuers in relation to the severity and duration of unrealized losses in each of the above sectors and does not consider those investments to be other-than-temporarily impaired as of December 31, 2025.
 
48

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Mortgage Loans
 
The credit quality of mortgage loans by type of property for the years ended December 31, 2025 and 2024 were as follows:
 
December 31, 2025
              
  
Farm
    
Commercial
    
Total
 
AAA - AA
 $   $4,506   $4,506 
A
  26    3,906    3,932 
BBB
  6    269    275 
B
      105    105 
   $32   $8,786   $8,818 
 
December 31, 2024
              
  
Farm
    
Commercial
    
Total
 
AAA - AA
 $   $4,553   $4,553 
A
  30    3,643    3,673 
BBB
  3    591    594 
BB
      1    1 
B
      79    79 
   $33   $8,867   $8,900 
 
The above tables exclude residential mortgage loans.
 
The credit quality for commercial and farm mortgage loans was determined based on an internal credit rating model which assigns a letter rating to each mortgage loan in the portfolio as an indicator of the credit quality of the mortgage loan. The internal credit rating model was designed based on rating agency methodology, then modified for credit risk associated with the Company's mortgage lending process, taking into account such factors as projected future cash flows, net operating income and collateral value. The model produces a credit rating score and an associated letter rating which is intended to align with S&P ratings as closely as possible. Information supporting the credit risk rating process is updated at least annually.
 
During 2025, the Company issued mortgage loans with a maximum interest rate of 6.57% and a minimum interest rate of 5.07% for commercial loans. The maximum percentage of any one admitted loan to the value of the security (exclusive of insured or guaranteed or purchase money mortgages) originated or acquired during the year ending December 31, 2025 at the time of origination was 64%. During 2024, the Company issued mortgage loans with a maximum interest rate of 7.26% and a minimum interest rate of 5.66% for commercial loans. The maximum percentage of any one admitted loan to the value of the security (exclusive of insured or guaranteed or purchase money mortgages) originated or acquired during the year ending December 31, 2024 at the time of origination was 68%.
 
49

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
During 2025 and 2024, the Company issued agricultural loans with both a maximum and minimum interest rate of 0% and 6.55%, respectively.
 
During 2025 and 2024, the Company did not reduce the interest rate on any outstanding mortgage loans.
 
The age analysis of mortgage loans and identification in which the Company is a participant or co-lender in a mortgage loan agreement is as follows for December 31, 2025 and 2024:
 
         
Commercial
      
  
Farm
    
All Other
    
Total
 
December 31, 2025
              
Recorded Investment (All)
              
Current
 $29   $8,786   $8,815 
180+ Days Past Due
  3        3 
                
Accruing interest 180+
              
days past due
              
Recorded investment
  3        3 
                
Participant or Co-lender in Mortgage Loan Agreement
              
Recorded Investment
 $28   $763   $791 
 
50

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
         
Commercial
      
  
Farm
    
All Other
    
Total
 
December 31, 2024
              
Recorded Investment (All)
              
Current
 $29   $8,848   $8,877 
30-59 Days Past Due
  4        4 
60-89 Days Past Due
      12    12 
180+ Days Past Due
      7    7 
                
Accruing interest 180+
              
days past due
              
Recorded investment
      7    7 
                
Participant or Co-lender in Mortgage Loan Agreement
              
Recorded Investment
 $29   $795   $824 
 
At December 31, 2025 and 2024, the Company held $3 and $7, respectively, of mortgage loans that were non-income producing for the previous 180 days. There was an insignificant amount of accrued interest related to these mortgage loans at December 31, 2025 and 2024. The Company has a mortgage or deed of trust on the property thereby creating a lien which gives it the right to take possession of the property (among other things) if the borrower fails to perform according to the terms of the loan documents. The Company requires all mortgaged properties to carry fire insurance equal to the value of the underlying property. At December 31, 2025 and 2024, there were no taxes, assessments and other amounts advanced and not included in the mortgage loan total.
 
At December 31, 2025 and 2024, the Company held 0 and 2 impaired loans with or without a related allowance for credit losses. There were no impaired mortgage loans held without an allowance for credit losses as of December 31, 2025 and 2024, respectively, that were subject to participant or co-lender mortgage loan agreement for which the Company is restricted from unilaterally foreclosing on the mortgage loans. There were no average recorded investments in impaired loans during 2025 and 2024.
 
The Company had an allowance for credit losses on mortgage loans of $0, $15 and $0 at December 31, 2025, 2024, and 2023.
 
As of December 31, 2025 and 2024, the Company had no mortgage loans derecognized as a result of foreclosure.
 
51

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company accrues interest income on impaired loans to the extent deemed collectible (delinquent less than 91 days) and the loan continues to perform under its original or restructured contractual terms. Interest income on nonperforming loans generally is recognized on a cash basis. For the years ended December 31, 2025, 2024 and 2023, the Company has recognized no interest income on impaired loans or on a cash basis.
 
At December 31, 2025 and 2024, the Company held a mortgage loan loss reserve in the AVR of $103 and $97, respectively.
 
The Company’s mortgage loan portfolio is diversified by geographic region and specific collateral property type as follows:
 
 
                             
Geographic Distribution
 
Property Type Distribution
 
December 31
   
December 31
 
2025
2024
   
2025
2024
                             
Pacific
  27 %   29 %  
Apartment
  52 %   52 %
South Atlantic
  21     21    
Industrial
  24     22  
Middle Atlantic
  13     12    
Office
  13     14  
E. North Central
  11     11    
Retail
  11     12  
Mountain
  10     8                  
W. South Central
  8     9                  
W. North Central
  5     5                  
New England
  3     3                  
E. South Central
  2     2                  
 
At December 31, 2025 and 2024, the Company had no mortgage loans with a total net admitted asset value that had been restructured in accordance with SSAP No. 36, Troubled Debt Restructuring. There were no realized losses during the years ended December 31, 2025, 2024 and 2023 related to such restructurings. At December 31, 2025 and 2024, there were no commitments to lend additional funds to debtors owing receivables.
 
52

 
Real Estate
 
The fair value of property is determined based on an appraisal from a third-party appraiser, along with information obtained from discussions with internal asset managers and a listing broker regarding recent comparable sales data and other relevant property information. There were no impairment losses taken on real estate in 2025, 2024 and 2023 to write the book value down to the current fair value.
 
As of December 31, 2025 and 2024, there are no properties classified as held for sale. During 2025, there were no properties classified as held for sale disposed, resulting in no net realized gains. During 2024, four properties classified as held for sale were disposed, resulting in an insignificant net realized gain. Any associated gains and losses from these held for sale disposals were included in net realized capital gains (losses) within the Statements of Operations.
 
The Company disposed of other properties during 2025, 2024 and 2023 resulting in an insignificant amount of net realized gains. These gains and losses were included in net realized capital gains (losses) within the Statements of Operations.
 
The carrying value of the Company's real estate assets at December 31, 2025 and 2024 was as follows:
 
    
2025
    
2024
 
Home office properties
 $37   $39 
   $37   $39 
 
Accumulated depreciation on real estate at December 31, 2025 and 2024, was $35 and $33, respectively.
 
Other Invested Assets
 
The Company recorded impairments of $20, $4 and $0 throughout years 2025, 2024 and 2023, respectively. These impairments were primarily related to private equity funds. The impairments were taken because the decline in fair value of the funds were deemed to be other than temporary and a recovery in value from the remaining underlying investments in the funds were not anticipated. These write-downs are included in net realized capital gains (losses) within the Statements of Operations.
 
53

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Tax Credits
 
The Company invests in projects designed to generate federal and state tax credits and other tax benefits through ownership interests in tax credit structures, including partnerships and limited liability entities. These investments primarily relate to affordable housing and historic rehabilitation. The Company’s objective in making these investments is to realize value through the receipt and utilization of tax credits and related tax benefits rather than through operating income or appreciation of the underlying assets.
 
Tax credits generated by these investments may be transferable or certificated in certain jurisdictions or non‑transferable and usable only against the Company’s income tax liabilities. The investments are accounted for in accordance with SSAP No. 93 and SSAP No. 94, as applicable.
 
Tax credits generated from these investments are recognized as assets in accordance with SSAP No. 94 and are recorded at amounts expected to be realized through utilization or, where applicable, transfer or sale. The recognition of tax credits impacts the Company’s statutory financial position through the recording of admitted or nonadmitted tax credit assets.
 
Utilization of tax credits reduces income tax expense and current tax payable, favorably affecting statutory results of operations. Unused tax credits remain recorded as assets and are evaluated for admissibility and recoverability based on expected future taxable income, statutory limitations, and credit expiration provisions. Tax credits not expected to be realized are reduced through nonadmission or impairment, which negatively impacts statutory surplus and results of operations in the period recognized. Tax credit benefits recognized in 2025 and 2024 was $31 and $17, respectively, and other tax benefits recognized was $3 and $3. The balance of the investment recognized as of December 31, 2025 and 2024 is $53 and $58, respectively.
 
During the year ended December 31, 2025 and 2024, the Company recognized ($13) and ($14), respectively, of investment amortization related to investments generating tax credits and other tax benefits. This amortization was recognized as a component of net investment income.
 
The Company recognized an insignificant amount of non-income tax related activity associated with these investments as a component of net investment income during 2025 and 2024.
 
There were no other returns allocated to these investments recognized outside of income tax expense.
 
The following schedule reflects the aggregate amount of tax credits expected to be generated in each of the subsequent five years and thereafter, disaggregated between transferable/certificated and non‑transferable tax credits:
 
54

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Year
  
Transferable/
Certificated
    
Nontransferable
    
Total
 
2026
 $   $12   $12 
2027
      11    11 
2028
      10    10 
2029
      6    6 
2030
      5    5 
2031 and After
      4    4 
   $   $48   $48 
 
55

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company has commitments related to investments in tax credit structures, including obligations to make additional capital contributions upon the occurrence of specified events. The table below presents these commitments and the periods in which such amounts are expected to be funded:
 
Year
  
Tax Credit
 
2026
 $1 
2027
  2 
2028
   
2029
   
2030
   
2031 and After
   
   $3 
 
The Company is not subject to regulatory review for any underlying projects as of December 31, 2025 and 2024.
 
The Company did not recognize impairment losses on tax credit investments as of December 31, 2025 and 2024.
 
The following tables provide the carrying value of tax credits, disaggregated by transferable/certificated and non-transferable, gross of any related tax liabilities by jurisdiction and in total as of December 31, 2025 and 2024:
 
             
   
December 31, 2025
Description of State Transferable and Non-Transferable Tax Credits
Jurisdiction
  
Carrying Value
    
Unused Amount*
 
Low-Income Housing Tax Credits
MA
 $   $5 
Economic Redevelopment and Growth Tax Credits
NJ
      11 
Low-Income Housing Tax Credits
CA
  13    30 
Low-Income Housing Tax Credits
United States
  46    49 
Total
XXX
 $59   $95 
 
             
   
December 31, 2024
Description of State Transferable and Non-Transferable Tax Credits
Jurisdiction
  
Carrying Value
    
Unused Amount
 
Economic Redevelopment and Growth Tax Credits
NJ
 $1   $16 
Low-Income Housing Tax Credits
CA
      15 
Low-Income Housing Tax Credits
United States
  58    59 
Total
XXX
 $59   $90 
56

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company did not have any non-transferable state tax credits.
 
The following tables provide total unused tax credits by jurisdiction, disaggregated by transferable/certificated and non-transferable as of December 31, 2025 and 2024:
 
                  
December 31, 2025
 
Jurisdiction
  
Transferable/Certificated
    
Nontransferable
    
Total
 
State:
                
Massachusetts
MA
 $5   $   $5 
New Jersey
NJ
  11        11 
California
CA
  30        30 
Federal
XXX
      49    49 
Total
XXX
 $46   $49   $95 
 
                  
December 31, 2024
 
Jurisdiction
  
Transferable/Certificated
    
Nontransferable
    
Total
 
State:
                
New Jersey
NJ
 $16   $   $16 
California
CA
  15        15 
Federal
XXX
      59    59 
Total
XXX
 $31   $59   $90 
 
The Company estimated the utilization of the remaining state transferable tax credits by projecting a future tax liability based on projected premium, tax rates and tax credits, and comparing the projected future tax liability to the availability of remaining state transferable tax credits. The Company had no impairment losses related to state transferable tax credits.
 
The following tables identify tax credits by transferable/certificated and non-transferable classifications and identify the admitted and nonadmitted portions of each classification as of December 31, 2025 and 2024:
 
           
December 31, 2025
    
Total Admitted
    
Total Nonadmitted
 
State:
         
Transferable
 $13   $ 
Non-transferable
       
           
Federal:
         
Transferable
 $   $ 
Non-transferable
  46     
57

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
           
December 31, 2024
    
Total Admitted
    
Total Nonadmitted
 
State:
         
Transferable
 $1   $ 
Non-transferable
       
           
Federal:
         
Transferable
 $   $ 
Non-transferable
  58     
 
Derivatives
 
Amounts disclosed in this Derivatives section do not include derivatives utilized in the hedging of variable annuity guarantees in accordance with SSAP No. 108, Derivatives Hedging Variable Annuity Guarantees. Please see the subsequent section “Derivatives Hedging Variable Annuity Guarantees” for results associated with those derivatives.
 
The Company has entered into collateral agreements with certain counterparties wherein the counterparty is required to post assets (cash or securities) on the Company's behalf in an amount equal to the difference between the net positive fair value of the contracts and an agreed upon threshold based on the credit rating of the counterparty. If the net fair value of all contracts with this counterparty is negative, then the Company is required to post similar assets (cash or securities). Fair value of derivative contracts, aggregated at a counterparty level at December 31, 2025 and 2024 was as follows:
 
    
2025
    
2024
 
Fair value - positive
 $337   $484 
Fair value - negative
  (1,330   (1,926
 
At December 31, 2025, 2024 and 2023, the Company has recorded unrealized gains (losses) of ($78), $132 and ($433), respectively, for the component of derivative instruments utilized for hedging purposes that did not qualify for hedge accounting. This has been recorded directly to unassigned surplus as an unrealized gain (loss). The Company did not recognize any unrealized gains or losses during 2025, 2024 and 2023 that represented the component of derivative instruments gain or loss that was excluded from the assessment of hedge effectiveness.
 
The maximum term over which the Company is hedging its exposure to the variability of future cash flows is approximately 18 years for forecasted hedge transactions. At December 31, 2025 and 2024, none of the Company’s cash flow hedges have been discontinued as it was probable that the original forecasted transactions would occur by the end of the originally specified time period documented at inception of the hedging relationship. As of December 31, 2025 and 2024, the Company has no accumulated deferred gains related to the termination of swaps that were hedging forecasted transactions. It is expected that these gains will be used as basis adjustments on future asset purchases expected to transpire throughout 2026.
 
58

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Summary of realized gains (losses) by derivative type for the years ended December 31, 2025, 2024 and 2023:
 
    
2025
    
2024
    
2023
 
Options:
              
Calls
 $(110  $5   $13 
Puts
  (4   1    (1
Total options
 $(114  $6   $12 
Swaps:
              
Interest rate
 $   $(6  $ 
Credit
  3         
Foreign exchange
  8         
Total return
  (788   (1,570   (1,092
Total swaps
 $(777  $(1,576  $(1,092
Futures - net positions
  753    442    41 
Total realized gains (losses)
 $(138  $(1,128  $(1,039
 
The average estimated fair value of derivatives held for other than hedging purposes is presented in the following table for the years ended December 31, 2025 and 2024:
 
                     
 
Asset(1)
Liability(1)
    
2025
    
2024
    
2025
    
2024
 
Derivative component of RSATs
                   
Credit default swaps
 $47   $63   $(4  $(5
Interest rate swaps
  10    8         
(1) Asset and liability classification is based on the positive (asset) or negative
(liability) book/adjusted carrying value (BACV) of each derivative.
 
59

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The estimated fair value of derivatives held for other than hedging purposes is presented in the following table for the years ended December 31, 2025 and 2024:
 
                     
 
Asset(1)
Liability(1)
    
2025
    
2024
    
2025
    
2024
 
Derivative component of RSATs
                   
Credit default swaps
 $34   $59   $3   $4 
Interest rate swaps
  11    9         
Total
 $45   $68   $3   $4 
(1) Asset and liability classification is based on the positive (asset) or negative
(liability) BACV of each derivative.
 
The Company did not have net realized gains (losses) on derivatives held for other than hedging purposes for the years ended December 31, 2025, 2024 and 2023.
 
As stated in Note 2, the Company replicates investment grade corporate bonds, sovereign debt, and commercial mortgage backed securities by writing credit default swaps. As a writer of credit swaps, the Company actively monitors the underlying asset, being careful to note any events (default or similar credit event) that would require the Company to perform on the credit swap. If such events would take place, a payment equal to the notional amount of the contract, less any potential recoveries as determined by the underlying agreement, will be made by the Company to the counterparty to the swap.
 
60

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following tables present the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at December 31, 2025 and 2024:
 
                     
      
2025
Rating Agency Designation of Referenced Credit Obligations (1)
  
NAIC Designation
    
Estimated Fair Value of Credit Default Swaps
    
Maximum Amount of Future Payments under Credit Default Swaps
    
Weighted Average Years to Maturity (2)
 
AAA/AA/A
  1                
Single name credit default swaps(3)
      $8   $591    2.0 
Credit default swaps referencing indices
           32    39.4 
Subtotal
       8    623    3.9 
BBB
  2                
Single name credit default swaps(3)
       20    598    2.1 
Credit default swaps referencing indices
       10    629    2.1 
Subtotal
       30    1,227    2.1 
Total
      $38   $1,850    2.7 
 
(1)
The rating agency designations are based on availability and the blending of the applicable ratings among Moody's Investors Service, S&P, and Fitch Ratings. If no rating is available from a rating agency, then an internally derived rating is used.
(2)
The weighted average years to maturity of the credit default swaps is calculated based on weighted average notional amounts.
(3)
Includes corporate, foreign government and state entities.
 
61

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                     
      
2024
Rating Agency Designation of Referenced Credit Obligations
  
NAIC Designation
    
Estimated Fair Value of Credit Default Swaps
    
Maximum Amount of Future Payments under Credit Default Swaps
    
Weighted Average Years to Maturity(2)
 
AAA/AA/A
  1                
Single name credit default swaps(3)
      $12   $978    2.2 
Credit default swaps referencing indices
           32    40.4 
Subtotal
       12    1,010    3.4 
BBB
  2                
Single name credit default swaps (3)
       35    1,461    1.9 
Credit default swaps referencing indices
       16    992    2.6 
Subtotal
       51    2,453    2.2 
BB
  3                
Single name credit default swaps (3)
           85    0.9 
Subtotal
           85    0.9 
Total
      $63   $3,548    2.5 
(1)
The rating agency designations are based on availability and the blending of the applicable ratings among Moody's Investors Service, S&P, and Fitch Ratings. If no rating is available from a rating agency, then an internally derived rating is used.
(2)
The weighted average years to maturity of the credit default swaps is calculated based on weighted average notional amounts.
(3)
Includes corporate, foreign government and state entities.
 
The Company may enter into credit default swaps to purchase credit protection on certain of the referenced credit obligations in the table above. At December 31, 2025 and 2024, there were not any potential future recoveries available to offset the $1,850 and $3,548, respectively, from the table above.
62

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
At December 31, 2025 and 2024, the Company’s outstanding derivative instruments, shown in notional or contract amounts and fair value, are summarized as follows:
 
                     
 
Contract or Notional Amount*
Fair Value
    
2025
    
2024
    
2025
    
2024
 
Derivative assets:
                   
Credit default swaps
 $1,530   $3,343   $34   $62 
Currency swaps
  520    905    66    110 
Equity futures
          3    2 
Equity swaps
  2,801    3,770    43    120 
Interest rate swaps
  1,594    1,367    24    29 
Options
  317    314    75    63 
Derivative liabilities:
                   
Credit default swaps
  609    715        (2
Currency swaps
  826    135    9    1 
Equity futures
          44    13 
Equity swaps
  4,233    2,494    102    37 
Interest rate swaps
  7,754    6,719    986    1,101 
Options
  (1,079   (597   19    5 
 
*Futures are presented in contract format. Swaps and options are presented in notional format.
 
Derivatives Hedging Variable Annuity Guarantees
 
The hedged obligation consists of guaranteed benefits on variable annuity contracts and resembles a long dated put option where claim payment is made whenever account value is less than a guaranteed amount, adjusted for applicable fees. Changes in interest rates impact the present value of future product cash flows (discount rate) as well as the value of investments comprising the account value to be assessed against the guarantee. Under this VM-21 compliant clearly defined hedging strategy, interest rate risk may be hedged by a duration matched portfolio of interest sensitive derivatives such as treasury bond forwards, treasury futures, interest rate swaps, interest rate swaptions or treasury future options. With approval of the IID, the guaranteed benefits included are variable annuity contracts with Guaranteed Minimum Death Benefit and Guaranteed Minimum Income Benefit riders, excluding contracts assumed via reinsurance. Total return on the designated portfolio of derivatives remains highly effective in covering the interest rate risk of the hedged obligation. Hedge effectiveness is measured in accordance with the requirements outlined under SSAP No. 108 and entails assessment of the total return on the designated portfolio of derivatives against changes in the fair value of the hedged obligation due to interest rate movements on a cumulative basis.
 
63

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Scheduled amortization for SSAP No. 108 derivatives as of December 31, 2025 is as follows:
 
Amortization Year
  
Deferred Assets
    
Deferred Liabilities
 
2026
 $(137  $51 
2027
  (137   51 
2028
  (137   51 
2029
  (137   51 
2030
  (137   51 
2031
  (137   51 
2032
  (117   51 
2033
  (89   46 
2034
  (55   32 
2035
  (3   5 
Total
 $(1,086  $440 
 
The following table is a reconciliation of the total deferred balance (net of tax) of SSAP No. 108 derivatives:
 
    
Total Deferred Balance
 
1.  Balance at January 1, 2024
 $445 
2.  Amortization
  63 
3.  Deferred Recognition
  (501
4.  Balance at December 31, 2024 [1-(2+3)]
 $883 
5.  Amortization
  88 
6.  Deferred Recognition
  149 
7.  Balance at December 31, 2025 [4-(5+6)]
 $646 
 
The following tables provide information regarding SSAP No. 108 hedging instruments:
 
    
2025
    
2024
 
Amortized cost
 $   $(3
Fair value
  (78   (672
 
64

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
December 31, 2025
                   
    
Net Investment Income
    
Realized Gain (Loss)
    
Unrealized Gain (Loss)
    
Total*
 
Derivative performance
 $(9  $(467  $591   $115 
                     
SSAP No. 108 Adjustments
                   
Portion of the derivative performance attributed to natural offset
  7    83    (16   74 
Deferred
  2    384    (575   (189
*Totals shown are pre-tax
                   
 
December 31, 2024
                   
    
Net Investment Income
    
Realized Gain (Loss)
    
Unrealized Gain (Loss)
    
Total*
 
Derivative performance
 $(1  $409   $(1,524  $(1,116
                     
SSAP No. 108 Adjustments
                   
Portion of the derivative performance attributed to natural offset
  15    (148   615    482 
Deferred
  (14   (261   909    634 
*Totals shown are pre-tax
                   
 
           
 
Year Ended December 31
    
2025
    
2024
 
Prior year fair value of hedged item
 $1,663   $630 
Current year fair value of hedged item
  1,538    1,663 
Change in fair value attributable to interest rates
 $(125  $1,033 
Portion of the fair value change attributed to the hedged risk
 $(124  $1,032 
 
65

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Restricted Assets
 
The following tables show the pledged or restricted assets as of December 31, 2025 and 2024, respectively:
 
                          
 
Gross (Admitted & Nonadmitted) Restricted
 
2025
         
G/A Supporting
                
         
Separate
    
Total S/A
    
S/A Assets
      
    
Total General
    
Account (S/A)
    
Restricted
    
Supporting
      
Restricted Asset Category
  
Account (G/A)
    
Activity
    
Assets
    
G/A Activity
    
Total
 
Collateral held under security lending agreements
 $1,657   $   $   $   $1,657 
Subject to repurchase agreements
  296                296 
FHLB capital stock
  39                39 
On deposit with states
  57                57 
Pledged as collateral to FHLB (including assets backing funding agreements)
  3,909                3,909 
Pledged as collateral not captured in other categories
  2,585                2,585 
Other restricted assets
  5,918                5,918 
Collateral assets received and on balance sheet
  78                78 
Assets held under modco reinsurance agreements
  132                132 
Assets held under funds withheld reinsurance agreements
  4,877                4,877 
Total restricted assets
 $19,548   $   $   $   $19,548 
 
66

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
  Gross (Admitted & Nonadmitted) Restricted Percentage
                        Gross      
                        (Admitted &    Admitted 
                        Nonadmitted)    Restricted to 
    Total From         Total    Total    Restricted    Total 
    Prior Year    Increase/    Nonadmitted    Admitted    to Total    Admitted 
Restricted Asset Category   (2024)    (Decrease)    Restricted    Restricted    Assets    Assets 
Collateral held under security lending agreements  $1,667   $(10  $ —    $1,657    0.89%   0.90%
Subject to repurchase agreements   306    (10   —     296    0.16%   0.16%
FHLB capital stock   77    (38   —     39    0.02%   0.02%
On deposit with states   57    —     —     57    0.03%   0.03%
Pledged as collateral to FHLB (including assets backing funding agreements)   3,956    (47   —     3,909    2.11%   2.13%
Pledged as collateral not captured in other categories   3,085    (500   —     2,585    1.39%   1.41%
Other restricted assets   7,920    (2,002   —     5,918    3.19%   3.22%
Collateral assets received and on balance sheet   —     78    —     78    0.04%   0.04%
Assets held under modco reinsurance agreements   —     132    —     132    0.07%   0.07%
Assets held under funds withheld reinsurance agreements   —     4,877    —     4,877    2.63%   2.65%
Total restricted assets  $17,068   $2,480   $ —    $19,548    10.53%   10.63%
 
The amounts reported as other restricted assets in the table above represent assets held in trust related to reinsurance.
 
67

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following tables show the pledged or restricted assets in other categories as of December 31, 2025 and 2024, respectively:
 
                          
 
Gross (Admitted & Nonadmitted) Restricted
 
2025
              
Total S/A
    
S/A Assets
      
         
G/A Supporting
    
Restricted
    
Supporting G/A
      
Description of Assets
  
Total G/A
    
S/A Activity (a)
    
Assets
    
Activity (b)
    
Total
 
Derivatives
 $2,495   $   $   $   $2,495 
Secured funding agreements
  58                58 
AMBAC
  32                32 
Total
 $2,585   $   $   $   $2,585 
Amount of total pledged under derivative contracts
  2,495                   2,495 
Total excluding derivative collateral (total minus amount of total pledged under derivative contracts)
 $90   $   $   $   $90 
 
  Gross (Admitted & Nonadmitted) Restricted Percentage
                   Gross      
                   (Admitted &    Admitted 
                   Nonadmitted)    Restricted to 
    Total From Prior         Total    Restricted    Total 
    Year    Increase/    Admitted    to Total    Admitted 
Description of Assets   (2024)    (Decrease)    Restricted    Assets    Assets 
Derivatives  $3,052   $(557  $2,495    1.35%   1.36%
Secured funding agreements   1    57    58    0.03%   0.03%
AMBAC   32    —     32    0.02%   0.02%
Total  $3,085   $(500  $2,585    1.40%   1.41%
Amount of total pledged under derivative contracts   —     2,495    2,495    1.35%   1.36%
Total excluding derivative collateral (total minus amount of total pledged under derivative contracts)  $3,085   $(2,995  $90    0.05%   0.05%
 
 
68

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following tables show the collateral received and reflected as assets within the financial statements as of December 31, 2025 and 2024:
 
                          
 
2025
    
BACV
    
BACV
    
BACV
    
Fair Value
    
Fair Value
 
Collateral Assets
  
Collateral
    
Modco
    
FWH
    
Collateral
    
Modco
 
General Account
                        
Cash
 $78   $52   $67   $78   $52 
Securities lending collateral assets
  1,657            1,657     
Other
      81    4,809        78 
Total collateral assets
 $1,735   $133   $4,876   $1,735   $130 
 
  2025
         % of BACV to           
         Total Assets    % of BACV to    BACV 
    Fair Value    (Admitted and    Total Admitted    FWH Including 
Collateral Assets   FWH    Nonadmitted)    Assets    Modco 
General Account                    
Cash  $67    0.26%   0.27%  $119 
Securities lending collateral assets   —     2.19%   2.23%   —  
Other   4,544    6.45%   6.59%   4,890 
Total collateral assets  $4,611    8.90%   9.09%  $5,009 
 
         
    Amount    % of Liability to Total Liabilities 
Recognized obligation to return collateral asset  $1,763    2.53%
 
  2024
Collateral Assets   Carrying Value    Fair Value    % of CV to Total Assets (Admitted and Nonadmitted)    % of CV to Total Admitted Assets 
Cash  $94   $94    0.12%   0.12%
Securities lending collateral assets   1,667    1,667    2.16    2.2 
Other   2    2    —     —  
Total collateral assets  $1,763   $1,763    2.28%   2.32%
 
    Amount    % of Liability to Total Liabilities 
Recognized obligation to return collateral asset  $1,763    2.53%
69

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Net Investment Income
 
Detail of net investment income is presented below:
 
                
 
Year Ended December 31
    
2025
    
2024
    
2023
 
Income:
              
Bonds
 $2,404   $2,235   $2,170 
Preferred stocks
  3    4    5 
Common stocks
  271    481    392 
Mortgage loans on real estate
  385    384    383 
Real estate
  9    9    9 
Policy loans
  114    112    110 
Cash, cash equivalents and short-term investments
  56    113    95 
Derivatives
  392    421    403 
Other invested assets
  144    177    200 
Gross investment income
  3,778    3,936    3,767 
Less: investment expenses
  177    180    198 
Net investment income before amortization of IMR
  3,601    3,756    3,569 
Amortization of IMR
  (12   (13   28 
Net investment income
 $3,589   $3,743   $3,597 
 
At December 31, 2025 and 2024, the Company excluded investment income due and accrued of $2 and $5, respectively. There was $2 and $0 excluded for mortgage loans or real estate for 2025 and 2024.
 
The gross, nonadmitted and admitted amounts for interest income due and accrued are presented in the following table:
 
           
 
Year Ended December 31
    
2025
    
2024
 
Gross
 $615   $674 
Nonadmitted
 $2   $5 
Admitted
 $613   $669 
 
At December 31, 2025 and 2024, the Company had cumulative amounts for paid-in-kind interest of $25 and $1, respectively, included in the principle balance.
 
70

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Realized Capital Gains (Losses)
 
Net realized capital gains (losses) on investments, including OTTI, are summarized below:
 
                
 
Realized
 
Year Ended December 31
    
2025
    
2024
    
2023
 
                
Bonds
 $(440  $(101  $(669
Preferred stocks
  1    1     
Common stocks
  2    2    (8
Mortgage loans on real estate
  (19   (21   (1
Cash, cash equivalents and short-term investments
          (1
Derivatives
  (566   (1,471   (2,043
Variable annuity reserve hedge offset
          (44
Other invested assets
  17    46    27 
Net realized capital gains (losses), before taxes
  (1,005   (1,544   (2,739
Federal income tax effect
  4        106 
Transfer from (to) IMR
  426    105    634 
Net realized capital gains (losses) on investments
 $(575  $(1,439  $(1,999
 
71

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Unrealized Capital Gains (Losses)
 
The changes in net unrealized capital gains and losses on investments, including the changes in net unrealized foreign capital gains and losses were as follows:
 
                
 
Change in Unrealized
 
Year Ended December 31
    
2025
    
2024
    
2023
 
                
Bonds
 $(30  $42   $10 
Preferred stocks
  (1       1 
Common stocks
  13    (6   1 
Affiliated entities
  (157   (260   443 
Mortgage loans on real estate
  15    (15    
Cash equivalents and short-term investments
  (2        
Derivatives
  223    268    600 
Other invested assets
  (107   (104   327 
Change in unrealized capital gains (losses), before taxes
  (46   (75   1,382 
Taxes on unrealized capital gains (losses)
  (1   13    (98
Change in unrealized capital gains (losses), net of tax*
 $(47  $(62  $1,284 
 
*2024 variance to Statement of Changes in Capital and Surplus related to an immaterial prior period correction included within the "Other changes - net" line.
 
72

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Admitted Disallowed IMR
 
The Company has admitted net negative (disallowed) IMR in accordance with the following criteria:
 
A.
Fixed income investments generating IMR losses comply with the reporting entity’s documented investment or liability management policies.
B.
IMR losses for fixed income related derivatives are all in accordance with prudent and documented risk management procedures, in accordance with a reporting entity’s derivative use plans and reflect symmetry with historical treatment in which unrealized derivative gains were reversed to IMR and amortized in lieu of being recognized as realized gains upon derivative termination.
C.
Any deviation to (a) was either because of a temporary and transitory timing issue or related to a specific event, such as a reinsurance transaction, that mechanically made the cause of IMR losses not reflective of reinvestment activities.
D.
Asset sales that were generating admitted negative IMR were not compelled by liquidity pressures (e.g., to fund significant cash outflows including, but not limited to excess withdrawals and collateral calls).
 
The aggregate net negative (disallowed) IMR allocation is presented in the following table for the years ended December 31, 2025 and 2024:
 
    
Total
    
General Account
    
Insulated Separate Account
    
Non-Insulated Separate Account
 
2025
 $347   $347   $   $ 
2024
  149    149         
 
The allocation of the admitted negative (disallowed) IMR is presented in the following table for the years ended December 31, 2025 and 2024:
 
    
Total
    
General Account
    
Insulated Separate Account
    
Non-Insulated Separate Account
 
2025
 $347   $347   $   $ 
2024
  133    133         
 
73

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The calculation of adjusted capital and surplus with consideration of the negative (disallowed) IMR is presented in the following table for the years ended December 31, 2025 and 2024:
 
    
2025
    
2024
 
Prior period, as of September 30, the most recent statement filed with the IID, general account capital and surplus
 $5,647   $5,912 
From prior period SAP financials:
         
Net positive goodwill (admitted)
       
EDP equipment & operating system software (admitted)
       
Net DTAs (admitted)
  741    800 
Net negative (disallowed) IMR (admitted)
  238    114 
Adjusted capital and surplus
 $4,668   $4,998 
 
The admitted net negative (disallowed) IMR represents 7.43% and 2.66% of adjusted capital and surplus for 2025 and 2024.
 
The Company did not have gains/losses associated with derivatives sold allocated to IMR during 2025 and 2024.
 
6.
Policy and Contract Attributes
 
Insurance Liabilities
 
Policy reserves, deposit-type contracts and policy claims at December 31, 2025 and 2024 were as follows:
 
           
 
Year Ended December 31
    
2025
    
2024
 
           
Life insurance reserves
 $30,386   $35,987 
Annuity reserves and supplementary contracts with life contingencies
  16,839    14,816 
Accident and health reserves (including long term care)
  7,184    7,252 
Total policy reserves
 $54,409   $58,055 
           
Deposit-type contracts
  671    693 
Policy claims
  919    1,048 
Total policy reserves, deposit-type contracts and claim liabilities
 $55,999   $59,796 
 
74

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Life Insurance Reserves
 
The aggregate policy reserves for life insurance policies are based upon the 1941, 1958, 1980, 2001 and 2017 Commissioner's Standard Ordinary Mortality Tables, the 1912, 1941 and 1961 Standard Industrial Mortality Tables, the 1960 Commissioner's Standard Group Mortality Table, the American Men, Actuaries and American Experience Mortality Tables. The reserves are calculated using interest rates ranging from 0.75 to 6.50 percent and are computed principally on the Net Level Premium Valuation and the Commissioner's Reserve Valuation Method. Reserves for universal life policies are based on account balances adjusted for the Commissioner's Reserve Valuation Method or Actuarial Guideline XXXVIII. Term insurance issued after July 1, 2017 and Indexed Universal life Insurance issued after January 1, 2020 follow Valuation Manual section 20 (VM-20) reserve requirements.
 
Tabular interest, tabular less actual reserves released and tabular cost have been determined by formula.
 
The Company waives deduction of deferred fractional premiums upon death of the insured and returns any portion of the final premium for periods beyond the date of death.
 
Additional premiums are charged or additional mortality charges are assessed for policies issued on substandard lives according to underwriting classification. Generally, reserves are determined by computing the regular reserve for the plan at the true age and holding, in addition, the unearned portion of the extra premium charge for the year. Effective July 1, 2017, for substandard term insurance policies, per VM-20 requirements, the substandard rating is applied to the reserve mortality. For certain flexible premium and fixed premium universal life insurance products, reserves are calculated utilizing the Commissioner's Reserve Valuation Method for universal life policies and recognizing any substandard ratings.
 
As of December 31, 2025 and 2024, the Company had insurance in force aggregating $26,514 and $31,676, respectively, in which the gross premiums are less than the net premiums required by the valuation standards established by the IID. The Company established policy reserves of $1,272 and $2,055 to cover these deficiencies as of December 31, 2025 and 2024, respectively.
 
Participating life insurance policies were issued by the Company in prior years which entitle policyholders to a share in the earnings of the participating policies, provided that a dividend distribution, which is determined annually based on mortality and persistency experience of the participating policies, is authorized by the Company. Participating insurance constituted less than 0.05% of ordinary life insurance in force at December 31, 2025 and 2024.
 
75

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Annuity Reserves and Supplementary Contracts Involving Life Contingencies
 
Deferred annuity reserves are calculated according to the Commissioner’s Annuity Reserve Valuation Method including excess interest reserves to cover situations where the future interest guarantees plus the decrease in surrender charges are in excess of the maximum valuation rates of interest.
 
Reserves for immediate annuities and supplementary contracts with and without life contingencies are equal to the present value of future payments assuming interest rates ranging from 1.25 to 11.75 percent and mortality rates, where appropriate, from a variety of tables.
 
Annuity reserves also include GICs and funding agreements classified as life-type contracts as defined in SSAP No. 50, Classifications of Insurance or Managed Care Contracts. These liabilities have annuitization options at guaranteed rates and consist of floating interest rate and fixed interest rate contracts. The contract reserves are carried at the greater of the account balance or the value as determined for an annuity with cash settlement option, on a change in fund basis, according to the Commissioner’s Annuity Reserve Valuation Method.
 
For variable annuities with guaranteed living benefits and variable annuities with minimum guaranteed death benefits the Company complies with VM-21. VM-21 specifies statutory reserve requirements for variable annuity contracts with benefit guarantees (VACARVM) and without benefit guarantees and related products. The VM-21 reserve calculation covers all variable annuity products. Examples of covered guaranteed benefits include guaranteed minimum accumulation benefits, return of premium death benefits, guaranteed minimum income benefits, guaranteed minimum withdrawal benefits and guaranteed payout annuity floors. The aggregate reserve for contracts falling within the scope of VM-21 is equal to the stochastic reserves plus the additional standard projection amount. The Company establishes a voluntary reserve in addition to the reserve required under VM-21 to help manage volatility associated with unhedged base contract cashflows. The VA voluntary reserve totaled $125 and $0 as of December 31, 2025 and 2024, respectively.
 
Both the stochastic reserves and the standard projection are determined as the conditional tail expectation (CTE)-70 of the scenario reserves. To determine the CTE-70 values, the Company used 1,000 of the pre-packaged scenarios developed by the American Academy of Actuaries (AAA) and Society of Actuaries. The stochastic reserves uses prudent estimate assumptions based on Company experience, while the standard projection uses the assumptions prescribed in VM-21 for determining the additional standard projection amount.
 
Accident and Health Liabilities
 
Accident and health policy reserves are equal to the greater of the gross unearned premiums or any required mid-terminal reserves plus net unearned premiums and the present value of amounts not yet due on both reported and unreported claims.
76

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
At December 31, 2025 and 2024, the Company had no premium deficiency reserve related to accident and health policies.
 
The Company’s primary method utilized to estimate premium adjustments for contracts subject to redetermination is to review experience periodically and to adjust premiums for differences between the experience anticipated at the time of redetermination and that underlying the original premiums. The Company has not limited its degree of discretion contractually; however, in some states it has agreed not to raise premiums in order to recoup past losses. The Company forgoes premium changes on existing policies at its option if the administrative cost and other business issues associated with the change outweigh the direct financial impact of the change. Also, the Company has extra-contractually guaranteed the current premium scale for certain policies.
 
For indeterminate premium products, a full schedule of current and anticipated premium rates is developed at the point of issue. Premium rate adjustments are considered when anticipated future experience foretells deviations from the original profit standards. The source of deviation (mortality, persistency, expense, etc.) is an important consideration in the re-rating decision as well as the potential effect of a rate change on the future experience of the existing block of business.
 
The Company does not write any accident and health business that is subject to the Affordable Care Act risk sharing provisions.
 
Liabilities for losses and loss/claim adjustment expenses for accident and health contracts are estimated using statistical claim development models to develop best estimates of liabilities for medical expense business and using tabular reserves employing mortality/morbidity tables and discount rates meeting minimum regulatory requirements for other business. Unpaid claims include amounts for losses and related adjustment expenses and are estimates of the ultimate net costs of all losses, reported and unreported. These estimates are subject to the impact of future changes in claim severity, frequency and other factors.
 
77

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Activity in the liability for unpaid claims and related processing costs net of reinsurance is summarized as follows:
 
    
Unpaid Claims Liability Beginning of Year
    
Claims
Incurred
    
Claims
Paid
    
Unpaid Claims Liability End of Year
 
Year ended December 31, 2025
                   
2025
 $   $1,249   $508   $741 
2024 and prior
  2,176    (92   687    1,397 
    2,176   $1,157   $1,195    2,138 
Active life reserve
 $5,476             $5,414 
Total accident and health reserves
 $7,652             $7,552 
                     
    
Unpaid Claims Liability Beginning of Year
    
Claims
Incurred
    
Claims
Paid
    
Unpaid Claims Liability End of Year
 
Year ended December 31, 2024
                   
2024
 $   $1,233   $470   $763 
2023 and prior
  2,000    54    641    1,413 
    2,000   $1,287   $1,111    2,176 
Active life reserve
 $5,508             $5,476 
Total accident and health reserves
 $7,508             $7,652 
 
The change in the Company's unpaid claims reserve was ($92) and $54 for the years ended December 31, 2025 and 2024, respectively, for health claims that were incurred prior to those Balance Sheets date. The change in 2025 was due to the closed block Supplemental Health portions running off and reducing reserves. The change in 2024 was due to worse than expected experience primarily due to higher medical claims.
 
78

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Activity in the liability for unpaid claims adjustment expense is summarized as follows:
 
    
Liability Beginning of Year
    
Incurred
    
Paid
    
Liability End of Year
 
Year ended December 31, 2025
                   
2025
 $   $36   $19   $17 
2024 and prior
  44    (10   1    33 
   $44   $26   $20   $50 
                     
Year ended December 31, 2024
                   
2024
 $   $38   $22   $16 
2023 and prior
  42    (12   2    28 
   $42   $26   $24   $44 
 
There was no significant change in the claim adjustment expense provision for insured events of prior years during 2025.
 
Premium and Annuity Considerations Deferred and Uncollected
 
Reserves on the Company's traditional life insurance products are computed using mean and interpolated or mid-terminal reserving methodologies. The mean methodologies result in the establishment of assets for the amount of the net valuation premiums that are anticipated to be received between the policy's paid-through date to the policy's next anniversary date. The interpolated methodologies do not require the establishment of such assets, however, it is required to hold unearned premium liabilities. At December 31, 2025 and 2024, the gross premiums and net of loading amounts related to these assets (which are reported as premiums deferred and uncollected), are as follows:
 
                     
 
2025
2024
    
Gross
    
Net of Loading
    
Gross
    
Net of Loading
 
Life and annuity:
                   
Ordinary first-year business
 $2   $   $1   $ 
Ordinary renewal business
  12    11    24    19 
Group life direct business
  1    1    10    6 
   $15   $12   $35   $25 
 
79

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Deposit-type Contracts
 
Tabular interest on funds not involving life contingencies has been determined primarily by formula.
 
The Company issues certain funding agreements with well-defined class-based annuity purchase rates defining either specific or maximum purchase rate guarantees. However, these funding agreements are not issued to or for the benefit of an identifiable individual or group of individuals. These contracts are classified as deposit-type contracts in accordance with SSAP No. 50.
 
Included in the liability for deposit-type contracts at December 31, 2025 and 2024 are approximately $12 and $10, respectively, of funding agreements issued to special purpose entities in conjunction with non-recourse medium-term note programs. Under these programs, the proceeds from each note series issuance are used to purchase a funding agreement from an affiliated Company which secures that particular series of notes. The funding agreement is reinsured to the Company. In general, the payment terms of the note series match the payment terms of the funding agreement that secures that series. Claims for the principal and interest for these funding agreements are afforded equal priority as other policyholders. As of December 31, 2025 and 2024, there were no contractual maturities.
 
80

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Withdrawal Characteristics of Annuity Reserves and Deposit Funds
 
A portion of the Company's policy reserves and other policyholders' funds (including separate account liabilities) relates to liabilities established on a variety of the Company's annuity, deposit fund and life products. There may be certain restrictions placed upon the amount of funds that can be withdrawn without penalty. The amount of reserves on annuity and deposit fund products, by withdrawal characteristics, is summarized as follows:
 
                           
 
December 31
 
2025
Individual Annuities:
  
General Account
    
Separate Account with Guarantees
    
Separate Account Non-Guaranteed
    
Total
 
Percent
Subject to discretionary withdrawal
                         
with adjustment:
                         
With fair value adjustment
 $212   $5,093   $   $5,305    7 %
At book value less surrender charge
                         
of 5% or more
  902            902    1  
At fair value
  5        58,930    58,935    82  
Total with adjustment or at fair value
  1,119    5,093    58,930    65,142    90  
At book value without adjustment
                         
(minimal or no charge or adjustment)
  5,504            5,504    8  
Not subject to discretionary withdrawal
                         
provision
  1,089        632    1,721    2  
Total individual annuity reserves
  7,712    5,093    59,562    72,367    100 %
Less reinsurance ceded
  4,593            4,593       
Net individual annuities reserves
 $3,119   $5,093   $59,562   $67,774       
Amount included in book value
                         
less surrender charge above that
                         
will move to book value without
                         
adjustment in the year after the
                         
statement date
 $196   $   $   $196       
 
81

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                           
 
December 31
 
2025
Group Annuities:
  
General Account
    
Separate Account with Guarantees
    
Separate Account Non-Guaranteed
    
Total
 
Percent
Subject to discretionary withdrawal
                         
with adjustment:
                         
With fair value adjustment
 $5,615   $8   $   $5,623    11 %
At book value less surrender charge
                         
of 5% or more
  15            15     —    
At fair value
          32,153    32,153    63  
Total with adjustment or at fair value
  5,630    8    32,153    37,791    74  
At book value without adjustment
                         
(minimal or no charge or adjustment)
  2,146            2,146    4  
Not subject to discretionary withdrawal
                         
provision
  11,070        74    11,144    22  
Total group annuities reserves
  18,846    8    32,227    51,081    100 %
Less reinsurance ceded
  5,251            5,251       
Net group annuities reserves
 $13,595   $8   $32,227   $45,830       
 
                           
 
December 31
 
2025
Deposit-type contracts (no life contingencies):
  
General Account
    
Separate Account with Guarantees
    
Separate Account Non-Guaranteed
    
Total
 
Percent
Subject to discretionary withdrawal
                         
with adjustment:
                         
With fair value adjustment
 $   $   $   $    0 %
Total with adjustment or at fair value
                  0  
At book value without adjustment
                         
(minimal or no charge or adjustment)
  198            198    25  
Not subject to discretionary withdrawal
                         
provision
  477    99    20    596    75  
Total deposit-type contracts
  675    99    20    794    100 %
Less reinsurance ceded
  4            4       
Net deposit-type contracts
 $671   $99   $20   $790       
 
82

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Reconciliation to the Annual Statement:
  
Amount
 
Life & Accident & Health Annual Statement:
    
Exhibit 5, Annuities section, total (net)
 $15,737 
Exhibit 5, Supp contracts with life contingencies section, total (net)
  977 
Exhibit 7, Deposit-type contracts, net balance at the end of the
    
                 current year after reinsurance
  671 
Subtotal
  17,385 
Separate Accounts Annual Statement:
    
Exhibit 3, Annuities section, total
  96,227 
Exhibit 3, Supp contracts with life contingencies section, total
  663 
Other contract deposit funds
  119 
Subtotal
  97,009 
Combined total
 $114,394 
 
                           
 
December 31
 
2024
Individual Annuities:
  
General Account
    
Separate Account with Guarantees
    
Separate Account Non-Guaranteed
    
Total
 
Percent
Subject to discretionary withdrawal
                         
with adjustment:
                         
With fair value adjustment
 $286   $2,208   $   $2,494    4 %
At book value less surrender charge
                         
of 5% or more
  880            880    1  
At fair value
  6        58,835    58,841    84  
Total with adjustment or at fair value
  1,172    2,208    58,835    62,215    89  
At book value without adjustment
                         
(minimal or no charge or adjustment)
  6,024            6,024    9  
Not subject to discretionary withdrawal
                         
provision
  1,043        569    1,612    2  
Total individual annuity reserves
  8,239    2,208    59,404    69,851    100 %
Less reinsurance ceded
  5,303            5,303       
Net individual annuity reserves
 $2,936   $2,208   $59,404   $64,548       
Amount included in book value
                         
less surrender charge above that
                         
will move to book value without
                         
adjustment in the year after the
                         
statement date
 $160   $   $   $160       
 
83

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                           
 
December 31
 
2024
Group Annuities:
  
General Account
    
Separate Account with Guarantees
    
Separate Account Non-Guaranteed
    
Total
 
Percent
Subject to discretionary withdrawal
                         
with adjustment:
                         
With fair value adjustment
 $4,842   $10   $   $4,852    12 %
At book value less surrender charge
                         
of 5% or more
  17            17     —    
At fair value
          29,901    29,901    70  
Total with adjustment or at fair value
  4,859    10    29,901    34,770    82  
At book value without adjustment
                         
(minimal or no charge or adjustment)
  2,299            2,299    5  
Not subject to discretionary withdrawal
                         
provision
  5,516        68    5,584    13  
Total group annuity reserves
  12,674    10    29,969    42,653    100 %
Less reinsurance ceded
  794            794       
Net group annuity reserves
 $11,880   $10   $29,969   $41,859       
 
                           
 
December 31
 
2024
Deposit-type contracts (no life contingencies):
  
General Account
    
Separate Account with Guarantees
    
Separate Account Non-Guaranteed
    
Total
 
Percent
Subject to discretionary withdrawal
                         
with adjustment:
                         
With fair value adjustment
 $   $   $   $    0 %
Total with adjustment or at fair value
                  0  
At book value without adjustment
                         
(minimal or no charge or adjustment)
  207            207    26  
Not subject to discretionary withdrawal
                         
provision
  492    87    18    597    74  
Total deposit-type contracts
  699    87    18    804    100 %
Less reinsurance ceded
  6            6       
Net deposit-type contracts
 $693   $87   $18   $798       
 
84

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Reconciliation to the Annual Statement:
  
Amount
 
Life & Accident & Health Annual Statement:
    
Exhibit 5, Annuities section, total (net)
 $13,876 
Exhibit 5, Supp contracts with life contingencies section, total (net)
  940 
Exhibit 7, Deposit-type contracts, net balance at the end of the
    
current year after reinsurance
  693 
Subtotal
  15,509 
Separate Accounts Annual Statement:
    
Exhibit 3, Annuities section, total
  90,994 
Exhibit 3, Supp contracts with life contingencies section, total
  597 
Other contract deposit funds
  105 
Subtotal
  91,696 
Combined total
 $107,205 
 
The amount of reserves on life products, by withdrawal characteristics, is summarized as follows:
 
                
 
December 31
 
2025
 
General Account
    
Account Value
    
Cash Value
    
Reserve
 
Subject to discretionary withdrawal,
              
surrender values, or policy loans:
              
Term policies with cash value
 $   $314   $434 
Universal life
  12,317    12,120    12,536 
Universal life with secondary guarantees
  5,610    5,190    13,523 
Indexed universal life with secondary
              
guarantees
  10,848    7,833    9,006 
Other permanent cash value life
              
insurance
  2    4,816    7,169 
Variable universal life
  954    953    1,039 
Not subject to discretionary withdrawal
              
or no cash values
              
Term policies without cash value
          7,988 
Accidental death benefits
          44 
Disability - active lives
          37 
Disability - disabled lives
          162 
Miscellaneous reserves
          1,381 
Total (gross)
  29,731    31,226    53,319 
Reinsurance ceded
  6,967    6,809    22,933 
Total (net)
 $22,764   $24,417   $30,386 
 
85

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                
 
December 31
 
2025
 
Separate Account - Guaranteed
    
Account Value
    
Cash Value
    
Reserve
 
Subject to discretionary withdrawal,
              
surrender values, or policy loans:
              
Variable universal life
 $699   $699   $699 
Total (net)
 $699   $699   $699 
 
                
 
December 31
 
2025
 
Separate Account - Nonguaranteed
    
Account Value
    
Cash Value
    
Reserve
 
Subject to discretionary withdrawal,
              
surrender values, or policy loans:
              
Variable universal life
 $11,024   $11,023   $11,023 
Total (net)
 $11,024   $11,023   $11,023 
 
86

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Reconciliation to the Annual Statement:
  
Amount
 
Life & Accident & Health Annual Statement:
    
Exhibit 5, Life insurance section, total (net)
 $29,686 
Exhibit 5, Accidental death benefits section total (net)
  26 
Exhibit 5, Disability - active lives section, total (net)
  19 
Exhibit 5, Disability - disabled lives section, total (net)
  141 
Exhibit 5, Miscellaneous reserves section, total (net)
  514 
Subtotal
  30,386 
Separate Accounts Annual Statement:
    
Exhibit 3, Life insurance section, total
  11,722 
Subtotal
  11,722 
Combined total
 $42,108 
 
                
 
December 31
 
2024
 
General Account
    
Account Value
    
Cash Value
    
Reserve
 
Subject to discretionary withdrawal,
              
surrender values, or policy loans:
              
Term policies with cash value
 $   $296   $430 
Universal life
  12,610    12,060    14,295 
Universal life with secondary guarantees
  5,479    5,360    16,322 
Indexed universal life with secondary
              
guarantees
  9,239    6,513    7,572 
Other permanent cash value life
              
insurance
  2    4,797    7,142 
Variable universal life
  709    708    1,025 
Not subject to discretionary withdrawal
              
or no cash values
              
Term policies without cash value
          8,007 
Accidental death benefits
          46 
Disability - active lives
          36 
Disability - disabled lives
          159 
Miscellaneous reserves
          2,155 
Total (gross)
  28,039    29,734    57,189 
Reinsurance ceded
  5,048    4,909    21,202 
Total (net)
 $22,991   $24,825   $35,987 
 
87

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                
 
December 31
 
2024
 
Separate Account - Guaranteed
    
Account Value
    
Cash Value
    
Reserve
 
Subject to discretionary withdrawal,
              
surrender values, or policy loans:
              
Variable universal life
 $690   $690   $690 
Total (net)
 $690   $690   $690 
 
88

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                
 
December 31
 
2024
 
Separate Account - Nonguaranteed
    
Account Value
    
Cash Value
    
Reserve
 
Subject to discretionary withdrawal,
              
surrender values, or policy loans:
              
Variable universal life
 $8,906   $8,904   $10,198 
Total (net)
 $8,906   $8,904   $10,198 
 
Reconciliation to the Annual Statement:
  
Amount
 
Life & Accident & Health Annual Statement:
    
Exhibit 5, Life insurance section, total (net)
 $34,633 
Exhibit 5, Accidental death benefits section total (net)
  25 
Exhibit 5, Disability - active lives section, total (net)
  17 
Exhibit 5, Disability - disabled lives section, total (net)
  136 
Exhibit 5, Miscellaneous reserves section, total (net)
  1,176 
Subtotal
  35,987 
Separate Accounts Annual Statement:
    
Exhibit 3, Life insurance section, total
  10,888 
Subtotal
  10,888 
Combined total
 $46,875 
 
89

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Separate Accounts
 
Information regarding the separate accounts of the Company as of and for the years ended December 31, 2025, 2024 and 2023 is as follows:
 
         
Nonindexed
    
Nonindexed
           
         
Guarantee
    
Guarantee
    
Nonguaranteed
      
    
Guaranteed
    
Less Than or
    
Greater
    
Separate
      
    
Indexed
    
Equal to 4%
    
Than 4%
    
Accounts
    
Total
 
Premiums, deposits and other
                        
considerations for the year
                        
ended December 31, 2025
 $   $   $10   $6,601   $6,611 
                          
Reserves for separate accounts
                        
as of December 31, 2025 with
                        
assets at:
                        
Fair value
 $   $111   $   $102,832   $102,943 
Amortized cost
  5,089    699            5,788 
Total as of December 31, 2025
 $5,089   $810   $   $102,832   $108,731 
                          
Reserves for separate accounts by
                        
withdrawal characteristics as of
                        
December 31, 2025:
                        
With fair value adjustment
 $5,089   $12   $   $   $5,101 
At fair value
              102,106    102,106 
At book value without fair
                        
value adjustment and with
                        
current surrender charge of
                        
less than 5%
      699            699 
Subtotal
  5,089    711        102,106    107,906 
Not subject to discretionary
                        
withdrawal
      99        726    825 
Total separate account reserve
                        
liabilities at December 31, 2025
 $5,089   $810   $   $102,832   $108,731 
 
90

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
         
Nonindexed
    
Nonindexed
           
         
Guarantee
    
Guarantee
    
Nonguaranteed
      
    
Guaranteed
    
Less Than or
    
Greater
    
Separate
      
    
Indexed
    
Equal to 4%
    
Than 4%
    
Accounts
    
Total
 
Premiums, deposits and other
                        
considerations for the year
                        
ended December 31, 2024
 $   $   $10   $7,999   $8,009 
                          
Reserves for separate accounts
                        
as of December 31, 2024 with
                        
assets at:
                        
Fair value
 $   $100   $   $99,374   $99,474 
Amortized cost
  2,419    690            3,109 
Total as of December 31, 2024
 $2,419   $790   $   $99,374   $102,583 
                          
Reserves for separate accounts by
                        
withdrawal characteristics as of
                        
December 31, 2024:
                        
With fair value adjustment
 $2,419   $14   $   $   $2,433 
At fair value
              98,719    98,719 
At book value without fair
                        
value adjustment and with
                        
current surrender charge of
                        
less than 5%
      690            690 
Subtotal
  2,419    704        98,719    101,842 
Not subject to discretionary
                        
withdrawal
      86        655    741 
Total separate account reserve
                        
liabilities at December 31, 2024
 $2,419   $790   $   $99,374   $102,583 
 
91

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
         
Nonindexed
    
Nonindexed
           
         
Guarantee
    
Guarantee
    
Nonguaranteed
      
    
Guaranteed
    
Less Than or
    
Greater
    
Separate
      
    
Indexed
    
Equal to 4%
    
Than 4%
    
Accounts
    
Total
 
Premiums, deposits and other
                        
considerations for the year
                        
ended December 31, 2023
 $   $   $10   $6,075   $6,085 
                          
Reserves for separate accounts
                        
as of December 31, 2023 with
                        
assets at:
                        
Fair value
 $710   $85   $   $96,283   $97,078 
Amortized cost
      684            684 
Total as of December 31, 2023
 $710   $769   $   $96,283   $97,762 
                          
Reserves for separate accounts by
                        
withdrawal characteristics as of
                        
December 31, 2023:
                        
With fair value adjustment
 $710   $18   $   $   $728 
At fair value
              95,712    95,712 
At book value without fair
                        
value adjustment and with
                        
current surrender charge of
                        
less than 5%
      684            684 
Subtotal
  710    702        95,712    97,124 
Not subject to discretionary
                        
withdrawal
      68        571    639 
Total separate account reserve
                        
liabilities at December 31, 2023
 $710   $770   $   $96,283   $97,763 
 
92

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
A reconciliation of the amounts transferred to and from the Company’s separate accounts is presented below:
 
                
 
Year Ended December 31
    
2025
    
2024
    
2023
 
Transfer as reported in the Summary of
              
Operations of the separate accounts
              
statement:
              
Transfers to separate accounts
 $6,697   $8,100   $6,167 
Transfers from separate accounts
  (12,679   (14,225   (10,944
Net transfers from separate accounts
  (5,982   (6,125   (4,777
Miscellaneous reconciling adjustments
  (29   (38   (24
Net transfers as reported in the Summary
              
of Operations of the life, accident and health
              
annual statement
 $(6,011  $(6,163  $(4,801
 
The legal insulation of separate account assets prevents such assets from being generally available to satisfy claims resulting from the general account. At December 31, 2025 and 2024, the Company’s separate account statement included legally insulated assets of $104,492 and $101,121, respectively. The assets legally insulated from general account claims at December 31, 2025 and 2024 are attributed to the following products:
 
    
2025
    
2024
 
Group annuities
 $30,371   $28,064 
Variable annuities
  61,792    61,483 
Fixed universal life
  735    727 
Variable universal life
  4,792    9,365 
Variable life
  6,739    1,367 
Modified separate accounts
  60    114 
Registered market value annuity product - SPL
  3    1 
Total separate account assets
 $104,492   $101,121 
 
At December 31, 2025 and 2024, the Company held separate account assets not legally insulated from the general account in the amount of $5,100 and $2,373, respectively.
 
Some separate account liabilities are guaranteed by the general account. In accordance with the guarantees provided, if the investment proceeds are insufficient to cover the rate of return guaranteed for the product, the policyholder proceeds will be remitted by the general account. To  compensate the general account for the risk taken, the separate account paid risk charges of $521, $551, $570, $584 and $579, to the general account in 2025, 2024, 2023, 2022 and 2021, respectively. During the years ended December 31, 2025, 2024, 2023, 2022 and 2021, the general account of the Company had paid $49, $41, $63, $56 and $45, respectively, toward separate account guarantees.
 
93

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
At December 31, 2025 and 2024, the Company reported guaranteed separate account assets at amortized cost in the amount of $5,577 and $2,784, respectively, based upon the prescribed practice granted by the State of Iowa as described in Note 2. These assets had a fair value of $5,593 and $2,699 at December 31, 2025 and 2024, respectively, which would have resulted in an unrealized gain/(loss) of $16 and ($86), respectively, had these assets been reported at fair value.
 
The Company does not participate in securities lending transactions within the separate account.
 
7.
Reinsurance
 
Certain premiums and benefits are assumed from and ceded to other insurance companies under various reinsurance agreements. The Company coinsures up to 100% of select policies or reinsures portions of the risk on certain insurance policies which exceed its established limits, thereby providing a greater diversification of risk and minimizing exposure on larger risks. The Company remains contingently liable with respect to any insurance ceded, and this would become an actual liability in the event that the assuming insurance company became unable to meet its obligation under the reinsurance treaty.
 
94

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Premiums and annuity considerations include the following reinsurance amounts:
 
                
 
Year Ended December 31
    
2025
    
2024
    
2023
 
                
Direct premiums
 $20,078   $19,907   $16,262 
Reinsurance assumed - non affiliates
  945    886    866 
Reinsurance assumed - affiliates
  (15   68    (10
Reinsurance ceded - non affiliates
  (1,483   (1,503   (2,547
Reinsurance ceded - affiliates
  (4,493   (591   (5,055
Net premiums earned
 $15,032   $18,767   $9,516 
 
The Company received reinsurance recoveries in the amount of $3,349, $3,294 and $3,327 during 2025, 2024 and 2023, respectively. At December 31, 2025 and 2024, estimated amounts recoverable from reinsurers that have been deducted from policy and contract claim reserves totaled $828 and $858, respectively. The aggregate reserves for policies and contracts were reduced for reserve credits for reinsurance ceded at December 31, 2025 and 2024 of $37,863 and $37,420, respectively, of which $17,693 and $16,315 were ceded to affiliates, respectively.
 
During 2025, 2024 and 2023, amortization of deferred gains associated with previously transacted reinsurance agreements was released into income in the amount of ($1,228) (($1,030) after tax), $387 ($255 after tax) and $684 ($429 after tax), respectively.
 
Effective December 9, 2025, the Company entered into a reinsurance agreement with Dawn Re, Inc., an affiliate, to cede universal life with secondary guarantee insurance business. As part of the transaction, the Company paid $3,903 in net reinsurance consideration and ceded $5,884 of reserves. Additionally, a pre-tax IMR asset of $275 was ceded with the transaction. The transaction generated a realized gain of $1,706, which was deferred to equity.
 
Effective June 30, 2025, the Company, through its subsidiary LIICA Re II which subsequently merged into TLIC effective December 9, 2025, entered into an agreement with Ironwood Re Corp. (IRC) to transfer, by novation, rights and obligations under the coinsurance agreement covering certain universal life insurance policies issued by TLB to IRC. As part of this transaction, the Company (through LIICA Re II) paid consideration of $68 to release reserves of $397, resulting in a net pre-tax income impact of $329.
 
Effective December 31, 2023, the Company entered into a reinsurance agreement whereby the Company ceded fixed deferred annuity business to an affiliated entity, Transamerica Bermuda Re, Ltd. (TBRe). The Company paid a ceding commission of $138 in addition to reinsurance premiums of $4,394 in the form of a funds withheld payable and ceded $4,394 of statutory reserves. The transaction resulted in a pre-tax loss of $138, which has been included in the Statements of Operations.
 
95

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Effective July 1, 2023, the Company ceded universal life with secondary guarantee (SGUL) insurance business to an unaffiliated entity. The Company paid considerations of $1,057 in assets and cash, ceded $1,436 of reserves and $555 of policy loans. After a $199 realized loss, the transaction resulted in a pre-tax gain of $179.
 
Effective July 1, 2023, the Company recaptured a specific list of policies from an affiliate, LIICA Re II. As a result, the Company received $5 in cash and $114 in policyholder reserves. The transaction resulted in a pre-tax loss of $109 which has been included in the Statements of Operations.
 
Effective July 1, 2023, the Company recaptured a specific list of policies from an affiliate, TPRe. As a result, the Company received $12 in cash and $33 in policyholder reserves. The transaction resulted in a pre-tax loss of $21 which has been included in the Statements of Operations.
 
The Company is party to an affiliated coinsurance arrangement, effective July 1, 2022, under which it assumes the remaining in force universal life business from TLB, net of third-party reinsurance. Refer to the preceding table for premiums earned from reinsurance assumed from affiliates, including reinsurance assumed under this agreement.
 
In January 2018, Scottish Re Group announced a sale and restructuring plan and commenced Chapter 11 (reorganization) procedures for some of its subsidiaries. In December 2018, the Delaware Department of Insurance began oversight procedures of Scottish Re (U.S.), Inc. (SRUS), with whom the Company is a counterparty for some of its reinsurance activities. SRUS was ordered into receivership for the purposes of rehabilitation on March 6, 2019. On May 16, 2019, the IID suspended the certificate of authority for SRUS but later clarified that reserve credit could be taken on reinsurance agreements entered into prior to the revocation date if a recovery analysis could be illustrated. On July 19, 2023, a Motion for Liquidation of SRUS was granted, resulting in any related treaty coverage ending on September 30, 2023. The Company reported gross receivables on billed and unbilled claims of $164 and $261 as of December 31, 2025, respectively, all of which have been fully non-admitted.
96

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
8.
Income Taxes
 
The net deferred income tax asset at December 31, 2025 and 2024 and the change from the prior year are comprised of the following components:
 
                
 
December 31, 2025
    
Ordinary
    
Capital
    
Total
 
Gross Deferred Tax Assets
 $2,072   $275   $2,347 
Statutory Valuation Allowance Adjustment
           
Adjusted Gross Deferred Tax Assets
  2,072    275    2,347 
Deferred Tax Assets Nonadmitted
  863        863 
Subtotal (Net Deferred Tax Assets)
  1,209    275    1,484 
Deferred Tax Liabilities
  484    311    795 
Net Admitted Deferred Tax Assets (Liabilities)
 $725   $(36  $689 
                
 
December 31, 2024
    
Ordinary
    
Capital
    
Total
 
Gross Deferred Tax Assets
 $2,597   $215   $2,812 
Statutory Valuation Allowance Adjustment
      2    2 
Adjusted Gross Deferred Tax Assets
  2,597    213    2,810 
Deferred Tax Assets Nonadmitted
  1,169        1,169 
Subtotal (Net Deferred Tax Assets)
  1,428    213    1,641 
Deferred Tax Liabilities
  542    297    839 
Net Admitted Deferred Tax Assets (Liabilities)
 $886   $(84  $802 
                
 
Change
    
Ordinary
    
Capital
    
Total
 
Gross Deferred Tax Assets
 $(525  $60   $(465
Statutory Valuation Allowance Adjustment
      (2   (2
Adjusted Gross Deferred Tax Assets
  (525   62    (463
Deferred Tax Assets Nonadmitted
  (306       (306
Subtotal (Net Deferred Tax Assets)
  (219   62    (157
Deferred Tax Liabilities
  (58   14    (44
Net Admitted Deferred Tax Assets (Liabilities)
 $(161  $48   $(113
 
The Company recognized all of its deferred tax liabilities as of December 31, 2025 and 2024.
 
97

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The main components of deferred income tax amounts are as follows:
 
                
 
Year Ended December 31
    
    
2025
    
2024
    
Change
 
Deferred Tax Assets:
              
Ordinary
              
Policyholder reserves
 $492   $701   $(209
Investments
  227    227     
Deferred acquisition costs
  683    721    (38
Policyholder dividends accrual
  6    6     
Compensation and benefits accrual
  45    43    2 
Receivables - nonadmitted
  131    147    (16
Net operating loss carry-forward
  48    331    (283
Tax credit carry-forward
  317    340    (23
Other
  123    81    42 
Subtotal
  2,072    2,597    (525
                
Statutory valuation allowance adjustment
           
Nonadmitted
  863    1,169    (306
Admitted ordinary deferred tax assets
  1,209    1,428    (219
                
Capital
              
Investments
  179    192    (13
Net capital loss carry-forward
  96    23    73 
Other
           
Subtotal
  275    215    60 
                
Statutory valuation allowance adjustment
      2    (2
Nonadmitted
           
Admitted capital deferred tax assets
  275    213    62 
Admitted deferred tax assets
 $1,484   $1,641   $(157
 
                
 
Year Ended December 31
    
    
2025
    
2024
    
Change
 
Deferred Tax Liabilities:
              
Ordinary
              
Investments
 $409   $450   $(41
Policyholder reserves
  6    77    (71
Other
  69    15    54 
Subtotal
  484    542    (58
Capital
              
Investments
  310    297    13 
Other
  1        1 
Subtotal
  311    297    14 
Deferred tax liabilities
  795    839    (44
Net admitted deferred tax assets (liabilities)
 $689   $802   $(113
 
98

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
As a result of the 2017 Tax Cuts and Jobs Act, the Company’s tax reserve deductible temporary difference decreased by ($396). This change results in an offsetting $396 deductible temporary difference that has been fully amortized into taxable income as of December 31, 2025.
 
At December 31, 2025, the Company removed its valuation allowance of $2 related to capital deferred tax assets in excess of deferred tax liabilities on LIICA Re II. Subsequent to the merger of TLIC, LIICA Re II, and TPRe, the Company now has sufficient capital deferred tax liabilities to offset its capital deferred tax assets and a valuation allowance is no longer required.
 
On July 4, 2025, the One Big Beautiful Bill (Bill) was passed into US law. The Company has no material tax impacts related to the Bill in its December 31, 2025 results.

The Inflation Reduction Act was enacted during the third quarter 2022 reporting period on August 16, 2022. The act included a provision which subjects high earning corporate taxpayers to the Corporate Alternative Minimum Tax (CAMT). The Company is part of an affiliated group that has determined it is a nonapplicable reporting entity for CAMT in 2023, 2024, or 2025 and has not included any impacts of the CAMT in the financial statements as of December 31, 2025.
 
As discussed in Note 2, for the years ended December 31, 2025 and 2024, the Company admits deferred income tax assets pursuant to SSAP No. 101. The amount of admitted adjusted gross deferred income tax assets under each component of SSAP No. 101 is as follows:
 
                  
   
December 31, 2025
      
Ordinary
    
Capital
    
Total
 
Admission Calculation Components SSAP No. 101
              
 (2)(a)
Federal Income Taxes Paid in Prior Years
              
 
Recoverable Through Loss Carrybacks
 $   $   $ 
 (2) 
Adjusted Gross Deferred Tax Assets Expected to
              
 
be Realized (Excluding The Amount of Deferred
              
 
Tax Assets From 2(a) above) After Application of
              
 
the Threshold Limitation (the Lesser of 2(b)1 and
              
 
2(b)2 below)
  641    48    689 
 
1.  Adjusted Gross Deferred Tax Assets
              
 
Expected to be Realized Following the
              
 
Balance Sheet Date
  789    59    848 
 
2.  Adjusted Gross Deferred Tax Assets
              
 
Allowed per Limitation Threshold
  
XXX
    
XXX
    689 
 (2)(c)
Adjusted Gross Deferred Tax Assets (Excluding
              
 
The Amount Of Deferred Tax Assets From 2(a)
              
 
and 2(b) above) Offset by Gross Deferred Tax
              
 
Liabilities
  568    227    795 
 (2)(d)
Deferred Tax Assets Admitted as the result of
application of SSAP No. 101, Total (2(a) + 2(b) + 2(c))
 $1,209   $275   $1,484 
99

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                  
   
December 31, 2024
      
Ordinary
    
Capital
    
Total
 
Admission Calculation Components SSAP No. 101
              
  (2) 
Federal Income Taxes Paid in Prior Years
              
 
Recoverable Through Loss Carrybacks
 $   $   $ 
 (2)(b)
Adjusted Gross Deferred Tax Assets Expected to
              
 
be Realized (Excluding The Amount of Deferred
              
 
Tax Assets From 2(a) above) After Application of
              
 
the Threshold Limitation (the Lesser of 2(b)1 and
              
 
2(b)2 below)
  778    24    802 
 
1.  Adjusted Gross Deferred Tax Assets
              
 
Expected to be Realized Following the
              
 
Balance Sheet Date
  1,037    32    1,069 
 
2.  Adjusted Gross Deferred Tax Assets
              
 
Allowed per Limitation Threshold
  
XXX
    
XXX
    768 
 (2)(c)
Adjusted Gross Deferred Tax Assets (Excluding
              
 
The Amount Of Deferred Tax Assets From 2(a)
              
 
and 2(b) above) Offset by Gross Deferred Tax
              
 
Liabilities
  650    189    839 
 (2)(d)
Deferred Tax Assets Admitted as the result of
application of SSAP No. 101, Total (2(a) + 2(b) + 2(c))
 $1,428   $213   $1,641 
100

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                  
   
Change
      
Ordinary
    
Capital
    
Total
 
Admission Calculation Components SSAP No. 101
              
 (2)(a)
Federal Income Taxes Paid in Prior Years
              
 
Recoverable Through Loss Carrybacks
 $   $   $ 
 (2)(b)
Adjusted Gross Deferred Tax Assets Expected to
              
 
be Realized (Excluding The Amount of Deferred
              
 
Tax Assets From 2(a) above) After Application of
              
 
the Threshold Limitation (the Lesser of 2(b)1 and
              
 
2(b)2 below)
  (137   24    (113
 
1.  Adjusted Gross Deferred Tax Assets
              
 
Expected to be Realized Following the
              
 
Balance Sheet Date
  (248   27    (221
 
2.  Adjusted Gross Deferred Tax Assets
              
 
Allowed per Limitation Threshold
  
XXX
    
XXX
    (79
 (2)(c)
Adjusted Gross Deferred Tax Assets (Excluding
              
 
The Amount Of Deferred Tax Assets From 2(a)
              
 
and 2(b) above) Offset by Gross Deferred Tax
              
 
Liabilities
  (82   38    (44
 (2)(d)
Deferred Tax Assets Admitted as the result of
application of SSAP No. 101, Total (2(a) + 2(b) + 2(c))
 $(219  $62   $(157
 
  December 31
    2025    2024 
Ratio Percentage Used To Determine Recovery          
Period and Threshold Limitation Amount   707%   780%
Amount of Adjusted Capital and Surplus Used To          
Determine Recovery Period and Threshold          
Limitation in 2(b)2 Above  $4,592   $5,123 
 
 
The impact of tax planning strategies at December 31, 2025 and 2024 was as follows:
 
                
 
December 31, 2025
    
Ordinary
    
Capital
    
Total
 
    
Percent
    
Percent
    
Percent
 
Impact of Tax Planning Strategies:
              
                
(% of Total Adjusted Gross DTAs)
  0%   0%   0%
                
(% of Total Net Admitted Adjusted Gross DTAs)
  0%   0%   0%
 
101

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                
 
December 31, 2024
    
Ordinary
    
Capital
    
Total
 
    
Percent
    
Percent
    
Percent
 
Impact of Tax Planning Strategies:
              
                
(% of Total Adjusted Gross DTAs)
  0%   0%   0%
                
(% of Total Net Admitted Adjusted Gross DTAs)
  2%   0%   2%
 
The Company's tax planning strategies as of December 31, 2024 include the use of reinsurance-related tax planning strategies.
 
Current income taxes incurred consist of the following major components:
 
                
 
Year Ended December 31
    
    
2025
    
2024
    
Change
 
Current Income Tax
              
                
Federal
 $(61  $(37  $(24
Subtotal
  (61   (37   (24
Federal income tax on net capital gains
  (4       (4
Federal and foreign income taxes incurred
 $(65  $(37  $(28
 
                
 
Year Ended December 31
    
    
2024
    
2023
    
Change
 
Current Income Tax
              
                
Federal
 $(37  $75   $(112
Subtotal
  (37   75    (112
Federal income tax on net capital gains
      (106   106 
Federal and foreign income taxes incurred
 $(37  $(31  $(6
 
102

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company’s current income tax incurred and change in deferred income tax differs from the amount obtained by applying the federal statutory rate to income before tax as follows:
 
  Year Ended December 31
    2025    2024    2023 
                
Current income taxes incurred  $(65  $(37  $(31
                
Change in deferred income taxes   431    (8   (149
(without tax on unrealized gains and losses)               
Total income tax reported  $366   $(45  $(180
                
Income before taxes  $916   $784   $312 
Federal statutory tax rate   21.00%   21.00%   21.00%
Expected income tax expense (benefit) at               
statutory rate  $192   $165   $66 
                
Increase (decrease) in actual tax reported resulting from:               
                
Pre-tax income of disregarded subsidiaries  $(7  $11   $6 
Dividends received deduction   (87   (128   (127
Tax-exempt income   (3   (4   (4
Nondeductible expenses   6    5    3 
Pre-tax items reported net of tax   219    (51   (97
Tax credits   (26   (27   (21
Prior period tax return adjustment   10    24    (18
Change in statutory valuation allowance   (2   1    —  
Change in uncertain tax positions   (18   —     —  
Deferred tax change on other items in surplus   77    (38   13 
Other   5    (3   (1
Total income tax reported  $366   $(45  $(180
 
The Company's federal income tax return is consolidated with other includible affiliated companies. Please see the listing of companies in Appendix A. The method of allocation between the companies is subject to a written tax allocation agreement. Under the terms of the tax allocation agreement, allocations are based on separate income tax return calculations. The Company is entitled to recoup federal income taxes paid in the event the future losses and credits reduce the greater of the Company’s separately computed income tax liability or the consolidated group’s income tax liability in the year generated. The Company is also entitled to recoup federal income taxes paid in the event the losses and credits reduce the greater of the Company’s separately computed income tax liability or the consolidated group’s income tax liability in any carryback or carryforward year when so applied. Intercompany income tax balances are settled within thirty days of payment to or filing with the Internal Revenue Service. A tax return has not been filed for 2025.
 
The amounts, origination dates and expiration dates of operating loss and tax credit carryforwards available for tax purposes:
 
103

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
Description
  
Amount
 
Origination Dates
  
Expiration Dates
 
Operating Loss
 $231 
12/31/2024
   N/A  
Operating Loss Total
 $231        
             
Foreign Tax Credit
 $11 
12/31/2024
  
12/31/2034
 
Foreign Tax Credit Total
 $11        
             
General Business Credit
 $2 
12/31/2009
  
12/31/2029
 
General Business Credit
  26 
12/31/2011
  
12/31/2031
 
General Business Credit
  32 
12/31/2012
  
12/31/2032
 
General Business Credit
  40 
12/31/2013
  
12/31/2033
 
General Business Credit
  25 
12/31/2014
  
12/31/2034
 
General Business Credit
  56 
12/31/2015
  
12/31/2035
 
General Business Credit
  7 
12/31/2016
  
12/31/2036
 
General Business Credit
  10 
12/31/2017
  
12/31/2037
 
General Business Credit
  7 
12/31/2018
  
12/31/2038
 
General Business Credit
  8 
12/31/2019
  
12/31/2039
 
General Business Credit
  14 
12/31/2020
  
12/31/2040
 
General Business Credit
  17 
12/31/2021
  
12/31/2041
 
General Business Credit
  19 
12/31/2022
  
12/31/2042
 
General Business Credit
  16 
12/31/2023
  
12/31/2043
 
General Business Credit
  15 
12/31/2024
  
12/31/2044
 
General Business Credit
  14 
12/31/2025
  
12/31/2045
 
General Business Credit Total
 $308        
 
The Company has net capital loss carryforwards which expire as follows: 2028: $76, 2029: $30 and 2030: $354.
 
The Company did not have any income tax expense available for recoupment in the event of future losses for December 31, 2025, 2024 and 2023.
 
The Company did not have any deposits admitted under Internal Revenue Code Section 6603 for December 31, 2025 and 2024.
 
104

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The total amount of the unrecognized tax benefits that if recognized would affect the effective income tax rate:
 
    
Unrecognized Tax Benefits
 
Balance at January 1, 2024
 $18 
Tax positions taken during prior period
   
Balance at December 31, 2024
 $18 
Tax positions taken during prior period
  (18
Balance at December 31, 2025
 $ 
 
The Company is not subject to the repatriation transition tax.
 
The Company did not have any alternative minimum tax credit carryovers as of December 31, 2025 and 2024.
 
The Company classifies interest and penalties related to income taxes as income tax expense. The amount of interest and penalties accrued on the Balance Sheets as income taxes includes the following:
 
    
Interest
    
Penalties
    
Total payable (receivable)
 
Balance at January 1, 2023
 $2   $   $2 
Interest expense (benefit)
  2        2 
Cash received (paid)
  (1       (1
Balance at December 31, 2023
 $3   $   $3 
Interest expense (benefit)
  1        1 
Cash received (paid)
  (2       (2
Balance at December 31, 2024
 $2   $   $2 
Interest expense (benefit)
  (2       (2
Cash received (paid)
           
Balance at December 31, 2025
 $   $   $ 
 
The IRS has completed its examination of 2014 - 2017 with an expected refund for 2014 pending Joint Committee on Taxation approval. The 2018 amended tax return remains under audit, and the IRS opened exam on the 2019 tax return. Federal income tax returns filed in 2020 through 2024 remain open, subject to potential future examination. The statute of limitations for all other tax years have been closed. The Company believes there are adequate defenses against, or sufficient provisions established related to any open or contested tax positions.
105

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
 
9.
Capital and Surplus
 
The Company has authorized 1,000,000 common stock shares at $10 per share par value, of which 676,190 shares were issued and outstanding at December 31, 2025 and 2024.
 
The Company is subject to limitations, imposed by the State of Iowa, on the payment of dividends and other distributions to its parent companies. Total distributions, within the preceding 12-month period, are generally limited to the greater of (a) 10 percent of surplus as regards to policyholders as of the preceding December 31 (excluding any reported special surplus), or (b) statutory net gain from operations for the preceding year. Dividend payments are further limited by the availability of unassigned funds at the time of the payment. Iowa law grants the Commissioner authority to approve, or in some cases non-disapprove, distributions requested in excess of these limitations.
 
On December 21, 2022, the Company purchased 250,000 shares of TBRe to become its sole shareholder. TBRe received additional capital contributions from the Company of $490 on December 29, 2023.
 
The Company received regulatory approval to recharacterize its gross paid‑in and contributed surplus to unassigned surplus pursuant to the quasi‑reorganization provisions of SSAP No. 72, Surplus and Quasi-Reorganizations, effective December 9, 2025. This restatement does not impact total surplus, net income, dividends to stockholders or the valuation of any assets or liabilities.
 
    
Change in Year Surplus
    
Change in Gross Paid-in and Contributed Surplus
 
2025
 $824   $(824
 
On November 28, 2025, the Company received a capital contribution of $425 from CGC.
 
On June 24, 2025, the Company paid an ordinary common stock dividend of $200 to CGC.
 
On December 19, 2024, the Company paid an ordinary common stock dividend of $150 to CGC.
 
On June 20, 2024, the Company paid an ordinary common stock dividend of $265 to CGC.
 
On December 14, 2023, the Company paid an ordinary common stock dividend of $300 to CGC.
 
On November 9, 2023, the Company received a return of capital of $267 from TLB.
 
106

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
On September 29, 2023, the Company paid an ordinary common stock dividend of $200 to CGC.
 
On June 21, 2023, the Company paid an ordinary common stock dividend of $300 to CGC.
 
On March 30, 2023, the Company paid an ordinary common stock dividend of $58 to CGC.
 
Life and health insurance companies are subject to certain RBC requirements as specified by the NAIC. Under those requirements, the amount of capital and surplus maintained by a life or health insurance company is to be determined based on various risk factors. At December 31, 2025 and 2024, the Company met the minimum RBC requirements.
 
The Company held special surplus funds in the amount of $645 and $883, as of December 31, 2025 and 2024, respectively, for derivatives hedging variable annuity guarantees as required under SSAP No. 108.
 
The Company held special surplus funds in the amount of $382 and $193, as of December 31, 2025 and 2024, respectively, for admitted disallowed IMR as required under INT 23-01.
 
10.
Securities Lending
 
The Company participates in an agent-managed securities lending program in which the Company primarily loans out US Treasuries and other bonds. The Company receives collateral equal to 102% of the fair value of the loaned government or other domestic securities as of the transaction date. If the fair value of the collateral is at any time less than 102% of the fair value of the loaned securities, the counterparty is mandated to deliver additional collateral, the fair value of which, together with the collateral already held in connection with the lending transaction, is at least equal to 102% of the fair value of the loaned government or other domestic securities. In the event the Company loans a foreign security and the denomination of the currency of the collateral is other than the denomination of the currency of the loaned foreign security, the Company receives and maintains collateral equal to 105% of the fair value of the loaned security.
 
At December 31, 2025 and 2024, respectively, securities with a fair value of $1,611 and $1,394 were on loan under securities lending agreements. At December 31, 2025 and 2024, the collateral the Company received from securities lending activities was in the form of cash and on open terms. This cash collateral is reinvested and is not available for general corporate purposes. The reinvested cash collateral has a fair value of $1,657 and $1,667 at December 31, 2025 and 2024, respectively.
 
107

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The contractual maturities of the securities lending collateral positions are as follows:
 
           
 
Fair Value
    
2025
    
2024
 
Open
 $1,657   $1,667 
Total collateral received
 $1,657   $1,667 
 
The Company receives primarily cash collateral in an amount in excess of the fair value of the securities lent. The Company reinvests the cash collateral into higher yielding securities than the securities which the Company has lent to other entities under the arrangement.
 
The maturity dates of the reinvested securities lending collateral are as follows:
 
                     
 
2025
2024
    
Amortized Cost
    
Fair
Value
    
Amortized Cost
    
Fair
Value
 
Open
 $79   $79   $130   $130 
30 days or less
  540    540    658    658 
31 to 60 days
  285    285    263    263 
61 to 90 days
  190    190    318    318 
91 to 120 days
  120    120    105    105 
121 to 180 days
  129    129    150    150 
181 to 365 days
  200    200    43    43 
2 to 3 years
  35    35         
Greater than 3 years
  79    79         
Total
  1,657    1,657    1,667    1,667 
Securities received
               
Total collateral reinvested
 $1,657   $1,657   $1,667   $1,667 
 
For securities lending, the Company’s source of cash used to return the cash collateral is dependent upon the liquidity of the current market conditions. Under current conditions, the Company has securities with a par value of $1,659 (fair value of $1,657) that are currently tradable securities that could be sold and used to pay for the $1,657 in collateral calls that could come due under a worst-case scenario.
 
108

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following table presents collateral associated with securities lending transactions that extend beyond one year for 2025 and 2024:
 
Description of collateral
  
2025
    
2024
 
ABS credit cards
 $26   $ 
ABS autos
  54     
ABS other non-housing
  35     
Total collateral extending beyond one year of the reporting date
 $115   $ 
 
11.
Retirement and Compensation Plans
 
Defined Contribution Plans
 
The Company’s employees participate in a contributory defined contribution plan sponsored by Transamerica Corporation (TA Corp) which is qualified under Section 401(k) of the Internal Revenue Code. Generally, employees of the Company who customarily work at least 20 hours per week and meet the other eligibility requirements are participants of the plan. Participants may elect to contribute up to 100% of eligible earnings, subject to government or other plan restrictions for certain key employees. The Company will contribute an amount up to four percent of the participant's eligible earnings per the plan's matching formula. Participants may direct all of their contributions and plan balances to be invested in a variety of investment options. The plan is subject to the reporting and disclosure requirements of the Employee Retirement Income Security Act of 1974 (ERISA), as amended. Benefits expense of $21, $21 and $18 was allocated to the Company for the years ended December 31, 2025, 2024 and 2023, respectively.
 
Defined Benefit Plans
 
The Company’s employees participate in a qualified defined benefit pension plan sponsored by TA Corp. Generally, employees of the Company who customarily work at least 20 hours per week and complete six months of continuous service and meet the other eligibility requirements are participants of the plan. The Company has no legal obligation for the plan. The benefits are based on the employee’s eligible compensation. The plan provides benefits based on a cash balance formula. The plan is subject to the reporting and disclosure requirements of the ERISA.
 
TA Corp sponsors supplemental retirement plans to provide the Company’s senior management with benefits in excess of normal pension benefits. The Company has no legal obligation for the plan. The plans are noncontributory. The benefits are based on the employee's eligible compensation. The plans provide benefits based on a cash balance formula. The plans are unfunded and nonqualified under the IRS Code.
 
109

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company recognizes pension expense equal to its allocation from TA Corp. The pension expense related to both the qualified defined pension plan and the supplemental retirement plans is allocated among the participating companies based on International Accounting Standards 19 (IAS 19), Accounting for Employee Benefits, and based upon actuarial participant benefit calculations, which is within the guidelines of SSAP No. 102, Pensions. Pension expenses were $13, $13 and $11 for the years ended December 31, 2025, 2024 and 2023, respectively.
 
In addition to pension benefits, TA Corp sponsors unfunded plans that provide health care and life insurance benefits to retired Company employees meeting certain eligibility requirements. The Company has no legal obligation for the plans. Portions of the medical and dental plans are contributory. The expenses of the postretirement plans are allocated among the participating companies based on IAS 19 and based upon actuarial participant benefit calculations, which is within the guidelines of SSAP No. 92, Postretirement Benefits Other Than Pensions. The Company’s allocation of postretirement expenses was $2, $2 and $4 for the years ended December 31, 2025, 2024 and 2023, respectively.
 
Other Plans
 
TA Corp has established deferred compensation plans for certain key employees of the Company. The Company’s allocation of expense for these plans for each of the years ended December 31, 2025, 2024 and 2023 was insignificant.
 
12.
Related Party Transactions
 
The Company shares certain officers, employees and general expenses with affiliated companies.
 
The Company is party to a shared services and cost sharing agreement among and between the Transamerica companies, under which various affiliated companies may perform specified administrative functions in connection with the operation of the Company, in consideration of reimbursement of actual costs of services rendered. The Company and an affiliate, Transamerica Financial Life Insurance Company (TFLIC), are parties to a Shared Services and Cost Sharing Agreement whereby both provide accounting, administrative, and other advisory services in accordance with the agreement. The net amount received by the Company as a result of being a party to these agreements was $1,421, $436 and $2 during 2025, 2024 and 2023, respectively. Fees charged between affiliates approximate their cost.
 
The Company is party to a Management and Administrative and Advisory agreement with AEGON USA Realty Advisors (AURA), LLC whereby AURA serves as the administrator and advisor for the Company’s mortgage loan operations. The Company paid $31, $29 and $30 for these services during 2025, 2024 and 2023, respectively.
 
110

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company is party to an Investment Management Agreement with AEGON USA Investment Management (AUIM), LLC whereby AUIM acts as a discretionary investment manager for the Company. The Company paid $109, $98 and $98 for these services during 2025, 2024 and 2023, respectively.
 
The Company has an administration service agreement with Transamerica Asset Management to provide administrative services to the Transamerica Series Trust. The Company received $109, $119 and $115 for these services during 2025, 2024 and 2023, respectively.
 
Transamerica Capital, LLC provides wholesaling distribution services for the Company under a distribution agreement. The Company incurred expenses under this agreement of $432, $23 and $10 for the years ended December 31, 2025, 2024 and 2023, respectively.
 
During 2025, the Company purchased $43 of other invested assets from a modified separate account of the Company. In addition, the Company sold $150 of other invested assets to TFLIC and a modified separate account of the Company for $130 and $20, respectively.
 
Receivables from (payables to) affiliates and intercompany borrowings bear interest at the thirty-day commercial paper rate. During 2025, 2024 and 2023, the Company received (paid) net interest of $26, $28 and $21 from (to) affiliates, respectively. At December 31, 2025 and 2024, respectively, the Company reported net receivables (payables) from (to) affiliates of $641 and $256. Terms of settlement require that these amounts are settled within 90 days of quarter-end per the requirements of SSAP No. 25, Affiliates and Other Related Parties.
 
At December 31, 2025, the Company has outstanding intercompany notes receivables of $500, as shown below:
 
              
Receivable from
  
Amount
 
Due  By
Interest Rate
TA Corp
 $175 
March 27, 2026
  4.34 %
TA Corp
  25 
April 25, 2026
  4.34  
TA Corp
  75 
June 20, 2026
  4.32  
TA Corp
  75 
June 25, 2026
  4.32  
TA Corp
  150 
June 30, 2026
  4.32  
111

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
At December 31, 2024, the Company had outstanding intercompany notes receivables of $550, as shown below:
 
              
Receivable from
  
Amount
 
Due By
Interest Rate
TA Corp
 $275 
March 27, 2025
  5.33 %
TA Corp
  25 
April 26, 2025
  5.33  
TA Corp
  75 
June 21, 2025
  5.30  
TA Corp
  75 
June 25, 2025
  5.30  
ULI Funding LLC
  100 
December 30, 2025
  4.70  
 
At December 31, 2025 and 2024, the Company had no short-term intercompany notes payable.
 
The Company utilizes the look-through approach in valuing its investment in the following entities.
 
    
Book Adjusted Carrying Value
 
Real Estate Alternatives Portfolio 3, LLC
 $13 
Real Estate Alternatives Portfolio 4 HR, LLC
  147 
Real Estate Alternatives Portfolio 4 MR, LLC
  9 
Aegon Workforce Housing Fund 2, L.P.
  140 
Natural Resources Alternatives Portfolio I, LLC
  308 
Natural Resources Alternatives Portfolio II, LLC
  138 
Natural Resources Alternatives Portfolio 3, LLC
  213 
TA Private Equity Assets LLC
  317 
Zero Beta Fund, LLC
  4 
TA-APOP I, LLC
  263 
TA-APOP I-A, LLC
  109 
 
These entity’s financial statements are not audited and the Company has limited the value of its investment in these entities to the value contained in the audited financial statements of the underlying LP/LLC investments, including adjustments required by SSAP No. 97 entities and/or non-SCA SSAP No. 48, Joint Ventures, Partnerships and Limited Liability Companies, entities owned by these entities. All liabilities, commitments, contingencies, guarantees or obligations of these entities which are required to be recorded as liabilities, commitments, contingencies, guarantees or obligations under applicable accounting guidance, are reflected in the Company’s determination of the carrying value of the investment in these entities.
 
112

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following tables show the disclosures for all SCA investments, except 8bi entities, Balance Sheets value (admitted and nonadmitted) and the NAIC responses for the SCA filings as of December 31, 2025 and 2024:
 
                      
December 31, 2025
SCA Entity
Percentage of SCA Ownership
  
Gross Amount
    
Admitted Amount
    
Nonadmitted Amount
 
SSAP No. 97 8a Entities
                    
  None      %  $   $   $ 
Total SSAP No. 97 8a Entities
  
XXX
   $   $   $ 
SSAP No. 97 8b(ii) Entities
                    
  None      %  $   $   $ 
Total SSAP No. 97 8b(ii) Entities
  
XXX
   $   $   $ 
SSAP No. 97 8b(iii) Entities
                    
AEGON Direct Marketing Services, Inc.
  73 %  $   $   $ 
AEGON Financial Services Group
  100              
Garnet Assurance Corporation
  100              
Garnet Assurance Corporation III
  100              
Life Investors Alliance LLC
  100              
Real Estate Alternatives Portfolio 3A, Inc.
  91              
Transamerica Asset Management, Inc.
  77     155    155     
Transamerica Fund Services, Inc.
  44              
Total SSAP No. 97 8b(iii) Entities
  
XXX
   $155   $155   $ 
SSAP No. 97 8b(iv) Entities
                    
Transamerica Bermuda Re, Ltd.
  100 %  $520   $520   $ 
Total SSAP No. 97 8b(iv) Entities
  
XXX
   $520   $520   $ 
Total SSAP No. 97 8b Entities (except 8bi entities)
  
XXX
   $675   $675   $ 
Aggregate Total
  
XXX
   $675   $675   $ 
113

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
                      
December 31, 2024
SCA Entity
Percentage of SCA Ownership
  
Gross Amount
    
Admitted Amount
    
Nonadmitted Amount
 
SSAP No. 97 8a Entities
                    
  None      %  $   $   $ 
Total SSAP No. 97 8a Entities
  
XXX
   $   $   $ 
SSAP No. 97 8b(ii) Entities
                    
  None      %  $   $   $ 
Total SSAP No. 97 8b(ii) Entities
  
XXX
   $   $   $ 
SSAP No. 97 8b(iii) Entities
                    
AEGON Direct Marketing Services, Inc.
  73 %  $   $   $ 
AEGON Financial Services Group
  100              
Garnet Assurance Corporation
  100              
Garnet Assurance Corporation III
  100              
Life Investors Alliance LLC
  100              
Real Estate Alternatives Portfolio 3A, Inc.
  91              
Transamerica Asset Management, Inc.
  77     149    149     
Transamerica Fund Services, Inc.
  44              
Total SSAP No. 97 8b(iii) Entities
  
XXX
   $149   $149   $ 
SSAP No. 97 8b(iv) Entities
                    
Transamerica Bermuda Re, Ltd.
  100 %  $434   $434   $ 
Total SSAP No. 97 8b(iv) Entities
  
XXX
   $434   $434   $ 
Total SSAP No. 97 8b Entities (except 8bi entities)
  
XXX
   $583   $583   $ 
Aggregate Total
  
XXX
   $583   $583   $ 
 
114

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following table shows the NAIC responses for the SCA filings (except 8bi entities):
 
December 31, 2025
 
SCA Entity
  
Type of NAIC Filing*
    
Date of Filing to the NAIC
    
NAIC Valuation Amount (1)
    
NAIC Response Received Y/N
    
NAIC Disallowed Entities Valuation Method, Submission Required Y/N
    
Code**
 
SSAP No. 97 8a Entities
                             
  None              $                
Total SSAP No. 97 8a Entities
         $             
SSAP No. 97 8b(ii) Entities
                             
  None              $                
Total SSAP No. 97 8b(ii) Entities
         $             
SSAP No. 97 8b(iii) Entities
                             
AEGON Direct Marketing Services, Inc.
   NA         $            
I
 
AEGON Financial Services Group
   NA                      
I
 
Garnet Assurance Corporation
   NA                      
I
 
Garnet Assurance Corporation III
   NA                      
I
 
Life Investors Alliance LLC
   NA                      
I
 
Real Estate Alternatives Portfolio 3A, Inc.
   NA                      
I
 
Transamerica Asset Management, Inc.
  
S2
    
10/14/2025
    123    
Y
    
N
    
I
 
Transamerica Fund Services, Inc.
   NA                       
I
 
Total SSAP No. 97 8b(iii) Entities
         $123             
SSAP No. 97 8b(iv) Entities
                             
Transamerica Bermuda Re, Ltd.
  
S2
    
10/14/2025
   $514    
Y
    
N
    
I
 
Total SSAP No. 97 8b(iv) Entities
         $514             
Total SSAP No. 97 8b Entities (except 8bi entities)
         $637             
Aggregate Total
         $637             
*S1 - Sub1, S2 - Sub2 or RDF - Resubmission of Disallowed Filing
** I - Immaterial or M - Material
(1) NAIC Valuation Amount is as of the Filing Date to the NAIC
 
115

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
December 31, 2024
 
SCA Entity
  
Type of NAIC Filing*
    
Date of Filing to the NAIC
    
NAIC Valuation Amount (1)
    
NAIC Response Received Y/N
    
NAIC Disallowed Entities Valuation Method, Submission Required Y/N
    
Code**
 
SSAP No. 97 8a Entities
                             
  None              $                
Total SSAP No. 97 8a Entities
         $             
SSAP No. 97 8b(ii) Entities
                             
  None              $                
Total SSAP No. 97 8b(ii) Entities
         $             
SSAP No. 97 8b(iii) Entities
                             
AEGON Direct Marketing Services, Inc.
   NA         $            
I
 
AEGON Financial Services Group
   NA                      
I
 
Garnet Assurance Corporation
   NA                      
I
 
Garnet Assurance Corporation III
   NA                      
I
 
Life Investors Alliance LLC
   NA                      
I
 
Real Estate Alternatives Portfolio 3A, Inc.
   NA                      
I
 
Transamerica Asset Management, Inc.
  
S2
    
11/4/2024
    136    
Y
    
N
    
I
 
Transamerica Fund Services, Inc.
   NA                       
I
 
Total SSAP No. 97 8b(iii) Entities
         $136             
SSAP No. 97 8b(iv) Entities
                             
Transamerica Bermuda Re, Ltd.
  
S2
    
11/4/2024
   $502    
Y
    
N
    
I
 
Total SSAP No. 97 8b(iv) Entities
         $502             
Total SSAP No. 97 8b Entities (except 8bi entities)
         $638             
Aggregate Total
         $638             
*S1 - Sub1, S2 - Sub2 or RDF - Resubmission of Disallowed Filing
** I - Immaterial or M - Material
(1) NAIC Valuation Amount is as of the Filing Date to the NAIC
 
116

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company has two Limited Purpose Subsidiaries (LPS) with prescribed practices whereby under Iowa Administrative Code 191-99.11(3), the LPS are entitled to admit the following assets that would not be admissible under the NAIC SAP:
 
TLIC Oakbrook Reinsurance, Inc. (TORI)
Credit linked note
TLIC Watertree Reinsurance, Inc. (TWRI)
Excess of loss reinsurance asset
 
The monetary effect on net income and surplus as a result of using an accounting practice that differed from NAIC SAP, the amount of the investment in the insurance SCA per reported statutory equity, and amount of the investment if the insurance SCA has completed statutory financial statements in accordance with the NAIC SAP. The SCAs are valued in the Company’s financial statements at zero in accordance with SSAP No. 97.
 
                     
 
Monetary Effect on NAIC SAP
Amount of Investment
SCA Entity
(Investments in Insurance SCA Entities)
  
Net
Income Increase (Decrease)
    
Surplus
Increase (Decrease)
    
Per
Reported Statutory Equity
    
If the Insurance SCA Had Completed Statutory Financial Statements*
 
TORI
 $   $(3,053  $841   $ 
TWRI
      (1,384   631     
 
*Per AP&P Manual (without permitted or prescribed practices)
 
Had the above SCA entities not been permitted to recognize the credit linked note or the excess of loss reinsurance asset as admitted assets in the financial statements, the risk-based capital would have been below the control level which would have triggered a regulatory event.
 
Information regarding the Company's affiliated reinsurance transactions is available in Note 7.
 
Information regarding the Company’s affiliated guarantees is available in Note 14.
 
13.
Managing General Agents and Third-Party Administrators
 
The Company utilizes managing general agents (MGA) and third-party administrators (TPA) in its operation. There were no MGA's/TPA's that wrote premiums in excess of 5% of the Company's surplus.
 
117

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
14.
Commitments and Contingencies
 
At December 31, 2025 and 2024, the Company has mortgage loan commitments of $43 and $179, respectively.
 
The Company has contingent commitments of $835 and $812, as of December 31, 2025 and 2024, respectively, to provide additional funding for joint ventures, partnerships and limited liability companies, which includes LIHTC commitments of $3 and $2, respectively.
 
The Company leases office buildings and equipment under various non-cancelable operating lease agreements. Rental expense for the years 2025 and 2024 was $9 and $13, respectively.
 
At December 31, 2025, the minimum aggregate rental commitments are as follows:
 
Year
  
Amount
 
2026
 $10 
2027
  9 
2028
  8 
2029
  4 
2030
  2 
 
Private placement commitments outstanding as of December 31, 2025 and 2024 were $328 and $238, respectively.
 
The Company did not sell any “to-be-announced” (TBA) securities as of December 31, 2025 and 2024.
 
The Company may pledge cash as collateral for derivative transactions. When cash is pledged as collateral, it is derecognized and a receivable is recorded to reflect the eventual return of that cash by the counterparty. The amount of cash collateral pledged by the Company as of December 31, 2025 and 2024, respectively, was $531 and $466.
 
At December 31, 2025 and 2024, securities in the amount of $51 and $114, respectively, were posted to the Company as collateral from derivative counterparties. The securities were not included on the Company's Balance Sheets as the Company does not have the ability to sell or repledge the collateral.
118

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following table provides the nature and circumstances of guarantee as of December 31, 2025 and 2024:
 
Nature and Circumstances of Guarantee
 
Liability Recognition of Guarantee
 
Ultimate Financial Statement Impact if Action Under the Guarantee is Required
 
Maximum Potential Amount of Future Payments (Undiscounted) the Guarantor Could be Required to Make Under the Guarantee
 
Current Status of Payment or Performance Risk of Guarantees
The Company has provided back-stop guarantees for the performance of non-insurance affiliates or subsidiaries that are involved in the guaranteed sale of investments in low-income housing tax credit partnerships. The nature of the obligation is to provide third party investors with a minimum guaranteed annual and cumulative return on their contributed capital which is based on tax credits and tax losses generated from the low income housing tax credit partnerships.  Guarantee payments arise if low income housing tax credit partnerships experience unexpected significant decreases in tax credits and tax losses or there are compliance issues with the partnerships. A significant portion of the remaining term of the guarantees is between 13-18 years.
 
$
 
Payment would impact Investment Expenses, which will ultimately roll up to Net investment income.
 
$
 
No payments required as of December 31, 2025. Current assessment of risk of making payments under guarantees is remote.
                 
The Company has guaranteed to the Hong Kong Insurance Authority that it will provide the financial support to TLB for maintaining TLB’s solvency at all times so as to enable TLB to promptly meet its obligations and liabilities. If at any time the value of TLB’s assets do not exceed its liabilities by the prevailing acceptable level of solvency, the Company will increase the paid up share capital of TLB or provide financial assistance to TLB to maintain the acceptable level of solvency. An acceptable level of solvency is net assets at one hundred and fifty percent of the required margin of solvency as stipulated under the Insurance Companies (Margin of Solvency) Regulation.
 
Exempt. Guarantee is on behalf of a wholly owned subsidiary.
 
None. Capital contributions to wholly owned subsidiaries would not affect the Company's financial position.
 
Unlimited
 
None pending as of December 31, 2025. The current assessment of risk of making payments under these guarantees is remote.
                 
The Company has guaranteed that TLB will (1) maintain tangible net worth of at least equal to the greater of 165% of S&P’s Risk-Based Capital and the minimum required by regulatory authorities in all jurisdictions in which TLB operates, (2) have, at all times, sufficient cash to pay all contractual obligations in a timely manner and (3) have a maximum operating leverage ratio of 20 times. The Company can terminate this agreement upon thirty days written notice, but not until TLB attains a rating from S&P’s the same as without the support from this agreement, or the entire book of TLB business is transferred provided that it is transferred to an entity with a rating from S&P that is the same as or better than the Company’s then current rating or AA, whichever is lower.
 
Exempt. Guarantee is on behalf of a wholly owned subsidiary.
 
None. Capital contributions to wholly owned subsidiaries would not affect the Company's financial position.
 
Unlimited
 
None pending as of December 31, 2025. The current assessment of risk of making payments under these guarantees is remote.
                 
The Company has provided a guarantee to TLB’s Hong Kong and Singapore Branch policyholders. If TLB fails to pay a valid claim solely by reason of it becoming insolvent as defined by Bermuda law, then the Company shall pay directly to the policy owner or named beneficiary the amount of the valid claim.
 
Exempt. Guarantee is on behalf of a wholly owned subsidiary.
 
None. Capital contributions to wholly owned subsidiaries would not affect the Company's financial position.
 
274
 
None pending as of December 31, 2025. The current assessment of risk of making payments under these guarantees is remote.
                 
Total
 
$
     
$
274
   
 
119

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following table provides an aggregate compilation of guarantee obligations as of December 31, 2025 and 2024:
 
           
 
December 31
    
2025
    
2024
 
Aggregate maximum potential of future payments
of all guarantees (undiscounted)
 $274   $268 
Current liability recognized in financial statements:
         
Noncontingent liabilities
       
Contingent liabilities
       
Ultimate financial statement impact if action required:
         
Investments in SCA
  274    268 
Total impact if action required
 $274   $268 
 
During 2019, the Company entered into an agreement with AURA, LLC to commit to purchase certain tax credit investments up to a maximum of $100. Under the terms of the agreement, the Company provides certain commitments to purchase tax credit investments that are part of tax credit funds in the event certain conditions are met. The Company acquired five tax credit investments during 2025 or 2024 under this agreement. As of December 31, 2025 and 2024, there is $46 and $48 committed to these purchases.
 
The Company is a member of the FHLB of Des Moines. Through its membership, the Company establishes the option to access funds through secured borrowing arrangements with the FHLB. It is part of the Company's strategy to utilize these funds for asset and liability management and other strategic initiatives. The Company has determined the actual/estimated long-term maximum borrowing capacity as $5,255 and $5,320 at December 31, 2025 and 2024, respectively. The Company calculated this amount in accordance with the terms and conditions of agreement with FHLB of Des Moines.
 
120

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
At December 31, 2025 and 2024, the Company purchased/owned the following FHLB stock as part of the agreement:
 
           
 
Year Ended December 31
    
2025
    
2024
 
Membership Stock:
         
Class A
 $   $ 
Class B
  10    10 
Activity Stock
  29    68 
Excess Stock
       
Total
 $39   $78 
 
At December 31, 2025 and 2024, membership stock (Class A and B) eligible for redemption and the anticipated timeframe for redemption was as follows:
 
    
Less Than 6 Months
    
6 Months to Less Than 1 Year
    
1 to Less Than 3 Years
    
3 to 5 Years
 
December 31, 2025
                   
Membership Stock
                   
Class A
 $   $   $   $ 
Class B
              10 
Total
 $   $   $   $10 
                     
    
Less Than 6 Months
    
6 Months to Less Than 1 Year
    
1 to Less Than 3 Years
    
3 to 5 Years
 
December 31, 2024
                   
Membership Stock
                   
Class A
 $   $   $   $ 
Class B
              10 
Total
 $   $   $   $10 
 
At December 31, 2025 and 2024, the amount of collateral pledged and the maximum amount pledged to the FHLB was as follows:
 
    
Fair Value
    
Carry Value
 
December 31, 2025
         
Total Collateral Pledged
 $3,524   $3,909 
Maximum Collateral Pledged
  3,526    3,977 
           
    
Fair Value
    
Carry Value
 
December 31, 2024
         
Total Collateral Pledged
 $3,433   $3,956 
Maximum Collateral Pledged
  3,995    4,603 
 
121

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
At December 31, 2025 and 2024, the borrowings from the FHLB were as follows:
 
           
 
December 31,
    
2025
    
2024
 
    
General Account
    
General Account
 
           
Debt 1
 $650   $1,500 
Total
 $650   $1,500 
 
1 The maximum amount of borrowing during 2025 and 2024 was $1,650 and $1,725, respectively.
 
As of December 31, 2025, the weighted average interest rate on FHLB advances was 4.162% with a weighted average term of 3.9 years. As of December 31, 2024, the weighted average interest rate on FHLB advances was 4.415% with a weighted average term of 0.9 years.
 
At December 31, 2025 and 2024, the borrowings from the FHLB were not subject to prepayment penalties.
 
The Company has issued synthetic GIC primarily to tax-qualified institutional entities such as 401(k) plans and other retirement plans and college savings plans with a book value totaling $26,256 and $32,000 as of December 31, 2025 and 2024, respectively. In a synthetic GIC, the Company generally guarantees book value withdrawals by plan participants from plan-owned assets by paying the difference between book value and the fair value of those assets in the event the book value exceeds fair value upon termination. The Company mitigates the related investment risk through certain contractual provisions and approval of the investment guidelines applicable to the plan-owned assets. Funding requirements to date have been minimal and management does not anticipate future funding requirements having a material financial impact. There were no related reserves as of December 31, 2025 and 2024.
 
The Company may be a party to legal proceedings involving a variety of issues incidental to its business, including class action lawsuits. Lawsuits may be brought in any federal or state court in the United States or in an arbitral forum. In addition, there continues to be significant federal and state regulatory activity relating to financial services companies. The Company's legal proceedings are subject to many variables, and given their complexity and scope, outcomes cannot be predicted with certainty. Although legal proceedings sometimes include substantial demands for compensatory and punitive damages, and injunctive relief, damages arising from such demands are typically not material to the Company's financial position.
122

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The Company was named in a class action lawsuit alleging that certain monthly deduction rate increases on universal life insurance products in 2022 and 2023 were improper. The Company has entered into a settlement agreement in the amount of $57, pending approval by the court.
 
The Company was named in a class action lawsuit alleging that policyholders were entitled to persistency bonuses on certain Direct Recognition Life policies. Plaintiffs have issued a best‑and‑final settlement demand of $115, which will be submitted for internal governance approval and is also subject to court approval.
 
The Company is subject to insurance guaranty laws in the states in which it writes business. These laws provide for assessments against insurance companies for the benefit of policyholders and claimants in the event of insolvency of other insurance companies. Assessments are charged to operations when received by the Company, except where right of offset against other taxes paid is allowed by law. Amounts available for future offsets are recorded as an asset on the Company’s Balance Sheets. The future obligation for known insolvencies has been accrued based on the most recent information available from the National Organization of Life and Health Insurance Guaranty Associations. Potential future obligations for unknown insolvencies are not determinable by the Company and are not required to be accrued for financial reporting purposes. The Company has established a reserve of $12 and $14 and an offsetting premium tax benefit $7 and $9 at December 31, 2025 and 2024, respectively, for its estimated share of future guaranty fund assessments related to several major insurer insolvencies. The guaranty fund (benefit) expense was $2, $10 and $0 for the years ended December 31, 2025, 2024 and 2023, respectively.
 
15.
Sales, Transfers, and Servicing of Financial Assets and Extinguishments of Liabilities
 
The Company is party to municipal repurchase agreements which were established via bilateral trades and accounted for as secured borrowings. For municipal repurchase agreements, the Company rigorously manages asset/liability risks via an integrated risk management framework. The Company’s liquidity position is monitored constantly, and factors heavily in the management of the asset portfolio. Projections comparing liquidity needs to available resources in both adverse and routine scenarios are refreshed monthly. The results of these projections on time horizons ranging from 16 months to 24 months are the basis for the near-term liquidity planning. This liquidity model excludes new business (non-applicable for the spread business), renewals and other sources of cash and assumes all liabilities are paid off on the earliest dates required. Interest rate risk is carefully managed, in part through rigorously defined and monitored derivatives programs.
 
123

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following tables provide information on the securities sold under the municipal repurchase agreements for four quarters of 2025 and 2024:
 
December 31, 2025
                   
    
First Quarter
    
Second Quarter
    
Third Quarter
    
Fourth Quarter
 
Maximum Amount
                   
BACV
  
XXX
    
XXX
    
XXX
   $301 
Fair Value
 $460   $245   $327   $310 
                     
Ending Balance
                   
BACV
  
XXX
    
XXX
    
XXX
   $313 
Fair Value
 $460   $245   $327   $321 
 
December 31, 2024
                   
    
First Quarter
    
Second Quarter
    
Third Quarter
    
Fourth Quarter
 
Maximum Amount
                   
BACV
  
XXX
    
XXX
    
XXX
   $315 
Fair Value
 $200   $266   $323   $320 
                     
Ending  Balance
                   
BACV
  
XXX
    
XXX
    
XXX
   $306 
Fair Value
 $200   $266   $323   $308 
 
                               
 
2025
2024
    
NAIC 1
    
NAIC 2
    
Total
    
NAIC 1
    
NAIC 2
    
Total
 
ICO - BACV
 $276   $38   $314   $257   $49   $306 
ICO - FV
  283    38    321    259    50    309 
 
These securities have maturity dates that range from January 15, 2026 to November 15, 2079.
124

 
Transamerica Life Insurance Company
 
Notes to Financial Statements – Statutory Basis
(Dollars in Millions, Except per Share amounts)
 
The following table provides information on the cash collateral received and liability to return collateral under the municipal repurchase agreements for four quarters of 2025 and 2024:
 
December 31, 2025
                   
    
First Quarter
    
Second Quarter
    
Third Quarter
    
Fourth Quarter
 
Maximum Amount
                   
Cash
 $311   $207   $232   $117 
                     
Ending Balance (1)
                   
Cash
 $311   $207   $81   $117 
(1) The remaining collateral held was greater than 90 days from contractual maturity.
 
December 31, 2024
                   
    
First Quarter
    
Second Quarter
    
Third Quarter
    
Fourth Quarter
 
Maximum Amount
                   
Cash
 $154   $197   $221   $113 
                     
Ending Balance(1)
                   
Cash
 $154   $197   $80   $113 
(1) The remaining collateral held was greater than 90 days from contractual maturity.
 
The Company does not maintain or utilize dollar repurchase agreements.
 
In the course of the Company’s asset management, securities are sold and reacquired within 30 days of the sale date to enhance the Company’s yield on its investment portfolio. The Company did not sell or reacquire any securities with an NAIC designation of 3 or below during 2025.
 
16.
Subsequent Events
 
The financial statements are adjusted to reflect events that occurred between the Balance Sheets date and the date when the financial statements are available to be issued, provided they give evidence of conditions that existed at the Balance Sheets date (Type I). Events that are indicative of conditions that arose after the Balance Sheets date are disclosed, but do not result in an adjustment of the financial statements themselves (Type II). The Company has not identified any Type I or Type II subsequent events for the year ended December 31, 2025 through April 9, 2026.
 
125

 
Transamerica Life Insurance Company
 
Appendix A – Listing of Affiliated Companies
 
Transamerica Corporation
 
EIN:  42-1484983
 
AFFILIATIONS SCHEDULE
 
YEAR ENDED DECEMBER 31, 2025
 
   
Entity Name
FEIN
   
Transamerica Corporation
42-1484983
AEGON Direct Marketing Services Inc
42-1470697
AEGON Financial Services Group Inc
41-1479568
AEGON Institutional Markets Inc
61-1085329
AEGON Management Company
35-1113520
AEGON USA Real Estate Services Inc
61-1098396
AEGON USA Realty Advisors of CA
20-5023693
AUSA Properties Inc
27-1275705
Commonwealth General Corporation
51-0108922
Creditor Resources Inc
42-1079584
CRI Solutions Inc
52-1363611
Financial Planning Services Inc
23-2130174
Garnet Assurance Corporation
11-3674132
Garnet Assurance Corporation II
14-1893533
Garnet Assurance Corporation III
01-0947856
Ironwood Re Corp
47-1703149
LIICA RE II
20-5927773
Money Services Inc
42-1079580
Monumental General Administrators Inc
52-1243288
Pearl Holdings Inc I
20-1063558
Pearl Holdings Inc II
20-1063571
Real Estate Alternatives Portfolio 3A Inc
20-1627078
River Ridge Insurance Company
20-0877184
Stonebridge Benefit Services Inc
75-2548428
TLIC Oakbrook Reinsurance Inc.
47-1026613
TLIC Watertree Reinsurance, Inc.
81-3715574
Transamerica Affordable Housing Inc
94-3252196
Transamerica Asset Management
59-3403585
Transamerica Bermuda Re, Ltd
98-1701849
Transamerica Casualty Insurance Company
31-4423946
Transamerica Corporation (OREGON)
98-6021219
Transamerica Finance Corporation
95-1077235
Transamerica Financial Life Insurance Company
36-6071399
 
126

 
Transamerica Life Insurance Company
 
Appendix A – Listing of Affiliated Companies
 
Transamerica Corporation
 
EIN:  42-1484983
 
AFFILIATIONS SCHEDULE
 
YEAR ENDED DECEMBER 31, 2025
 
   
Entity Name
FEIN
   
Transamerica Fund Services Inc
59-3403587
Transamerica Life Insurance Company
39-0989781
Transamerica Pacific Re, Inc.
85-1028131
Transamerica Resources Inc
52-1525601
Transamerica Stable Value Solutions Inc
27-0648897
Transamerica Trust Company
42-0947998
Transamerica United Financial Services LLC
52-1263786
World Fin Group Ins Agency of Massachusetts Inc
04-3182849
World Financial Group Inc
42-1518386
World Financial Group Ins Agency of Hawaii Inc
99-0277127
World Financial Group Insurance Agency of WY Inc
42-1519076
Zahorik Company Inc
95-2775959
Zero Beta Fund LLC
26-1298094
   
 
 
127

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statutory-Basis Financial
Statement Schedules
 
128

 
 
Report of Independent Auditors
 
To the Board of Directors of
Transamerica Life Insurance Company 
 
We have audited the statutory-basis financial statements of Transamerica Life Insurance Company (the Company) as of December 31, 2025 and 2024 and for the years then ended, and have issued our report thereon dated April 9, 2026. Our audit of the statutory-basis financial statements included the financial statement supplementary information, which includes Schedule I Summary of Investments – Other Than Investments in Related Parties, Schedule III – Supplementary Insurance Information, and Schedule IV - Reinsurance (the “supplementary information”). These schedules are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s supplementary information based on our audit.
 
In our opinion, the supplementary information present fairly, in all material respects, the information set forth therein when considered in conjunction with the statutory-basis financial statements.
 
/s/ Ernst & Young LLP
April 9, 2026
Philadelphia, PA
 
129

 
Transamerica Life Insurance Company
 
Summary of Investments – Other Than
Investments in Related Parties
(Dollars in Millions)
 
December 31, 2025
 
SCHEDULE I
Type of Investment
  
Cost (1)
    
Fair
Value
    
Amount at
Which Shown
in the
Balance Sheet (2)
 
Fixed maturities
              
Bonds:
              
United States government and
government agencies and authorities
 $4,098   $3,605   $4,739 
States, municipalities and political
subdivisions
  2,042    1,733    2,042 
Foreign governments
  791    735    791 
Hybrid securities
           
All other corporate bonds
  41,625    39,695    41,624 
Preferred stocks
  42    40    40 
Total fixed maturities
  48,598    45,808    49,236 
                
Equity securities
              
Common stocks:
              
Industrial, miscellaneous and all other
  58    73    73 
Total equity securities
  58    73    73 
                
Mortgage loans on real estate
  8,818         8,818 
Real estate
  37         37 
Policy loans
  2,376         2,376 
Other long-term investments
  1,002         1,002 
Receivable for securities
  10         10 
Receivable for derivative cash collateral
posted to counterparty
  531         531 
Securities lending
  1,657         1,657 
Cash, cash equivalents and short-term
investments
  1,103         1,103 
Total investments
 $64,190        $64,843 
 (1) Equity securities are reported at original cost. Fixed maturities are reported at original cost reduced by repayments and adjusted for amortization of premiums and accrual of discounts.
(2) Bonds of $31 are held at fair value rather than amortized cost. Preferred stock of $40 are held at fair value.
130

 
Transamerica Life Insurance Company
 
Supplementary Insurance Information
(Dollars in Millions)
 
SCHEDULE III
 
    
Future Policy Benefits and Expenses
    
Unearned Premiums
    
Policy and Contract Liabilities
    
Premium Revenue
    
Net Investment Income*
    
Benefits, Claims Losses and Settlement Expenses
    
Other Operating Expenses*
 
Year ended December 31, 2025
                                  
Individual life
 $28,785   $   $478   $(365  $1,914   $(1,718  $1,815 
Individual health
  6,273    98    267    595    397    789    169 
Group life and health
  2,397    17    136    836    130    587    299 
Annuity
  16,839        38    13,966    1,148    20,686    (4,740
   $54,294   $115   $919   $15,032   $3,589   $20,344   $(2,457
                                    
Year ended December 31, 2024
                                  
Individual life
 $34,414   $   $576   $3,467   $1,983   $4,960   $1,418 
Individual health
  6,304    100    306    625    391    943    196 
Group life and health
  2,404    17    130    833    158    517    345 
Annuity
  14,816        36    13,842    1,211    19,311    (5,173
   $57,938   $117   $1,048   $18,767   $3,743   $25,731   $(3,214
                                    
Year ended December 31, 2023
                                  
Individual life
 $29,961   $   $493   $2,410   $1,882   $2,870   $1,808 
Individual health
  6,083    105    317    665    382    807    221 
Group life and health
  2,455    19    124    788    134    520    370 
Annuity
  13,873        49    5,653    1,199    10,215    (4,060
   $52,372   $124   $983   $9,516   $3,597   $14,412   $(1,661
 
*Allocations of net investment income and other operating expenses are based on a number of assumptions and estimates, and the results would change if different methods were applied.
 
131

 
Transamerica Life Insurance Company
 
Reinsurance
(Dollars in Millions)
 
SCHEDULE IV
 
                             
      
Gross Amount
    
Ceded to Other Companies
    
Assumed From Other Companies
    
Net Amount
 
Percentage of Amount Assumed to Net
Year ended December 31, 2025
                         
Life insurance in force
 $820,838   $459,377   $203,762   $565,223    36 %
                             
                             
Premiums:
                         
 
Individual life
 $4,592   $5,879   $922   $(365   (253 )%
 
Individual health
  643    52    4    595    1  
 
Group life and health
  867    32    1    836    0  
 
Annuity
  13,976    13    3    13,966    0  
     $20,078   $5,976   $930   $15,032    6 %
                             
                             
Year ended December 31, 2024
                         
Life insurance in force
 $805,576   $494,708   $234,794   $545,662    43 %
                             
                             
Premiums:
                         
 
Individual life
 $4,495   $1,971   $943   $3,467    27 %
 
Individual health
  673    53    5    625    1  
 
Group life and health
  886    54    1    833    0  
 
Annuity
  13,853    16    5    13,842    0  
     $19,907   $2,094   $954   $18,767    5 %
                             
                             
Year ended December 31, 2023
                         
Life insurance in force
 $798,119   $540,679   $262,185   $519,625    50 %
                             
                             
Premiums:
                         
 
Individual life
 $4,598   $3,029   $841   $2,410    35 %
 
Individual health
  717    58    6    665    1  
 
Group life and health
  898    112    2    788    0  
 
Annuity
  10,049    4,403    7    5,653    0  
     $16,262   $7,602   $856   $9,516    9 %
132

 
 
 
1

 
FINANCIAL STATEMENTS
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Years Ended December 31, 2025 and 2024
 
 
 
 
 
 
 
 
 
 
1

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Financial Statements
Years Ended December 31, 2025 and 2024
 
 
 
 
 
Report of Independent Registered Public Accounting Firm3
Statement of Assets and Liabilities4
Statements of Operations and Changes in Net Assets6
Notes to Financial Statements24
 
 
 
1

 
 
Report of Independent Registered Public Accounting Firm
To the Board of Directors of Transamerica Life Insurance Company and
Contract Owners of WRL Series Life Corporate Account
Opinion on the Financial Statements
We have audited the accompanying statements of assets and liabilities of each of the subaccounts listed in the table below that comprise WRL Series Life Corporate Account (the Separate Account), as of December 31, 2025, the related statements of operations and changes in net assets for each of the periods indicated in the table below, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of each subaccount as of December 31, 2025, the results of its operations and changes in its net assets for each of the periods indicated in the table below, in conformity with U.S. generally accepted accounting principles.
Subaccounts
American Funds - Global Small Cap Class 2 Shares (1)
Morningstar Income and Growth ETF Asset Allocation Class I Shares (1)
American Funds - Growth Class 2 Shares (1)
MS VIF Emerging Markets Debt Class I Shares (1)
American Funds - International Class 2 Shares (1)
MS VIF Emerging Markets Equity Class I Shares (1)
American Funds - New World Class 2 Shares (1)
PIMCO All Asset Administrative Class (1)
Dimensional VA Global Bond (1)
PIMCO All Asset Institutional Class (1)
Dimensional VA International Small (1)
PIMCO High Yield Institutional Class (1)
Dimensional VA International Value (1)
PIMCO Low Duration Institutional Class (1)
Dimensional VA Short-Term Fixed (1)
PIMCO Real Return Institutional Class (1)
Dimensional VA U.S. Large Value (1)
PIMCO Short-Term Institutional Class (1)
Dimensional VA U.S. Targeted Value (1)
PIMCO Total Return Institutional Class (1)
DWS Equity 500 Index Class A Shares (1)
Royce Capital Micro Cap Investment Class (1)
DWS Small Cap Index Class A Shares (1)
Royce Capital Small Cap Investment Class (1)
Fidelity® VIP Balanced Initial Class (1)
Rydex NASDAQ-100® (1)
Fidelity® VIP Contrafund® Initial Class (1)
Rydex VIT Nova (1)
Fidelity® VIP Government Money Market Initial Class (1)
T. Rowe Price All-Cap Opportunities (1)
Fidelity® VIP Growth Initial Class (1)
T. Rowe Price Blue Chip Growth (1)
Fidelity® VIP Growth Opportunities Initial Class (1)
T. Rowe Price Equity Income Service Class (1)
Fidelity® VIP High Income Initial Class (1)
T. Rowe Price International Stock (1)
First Eagle Overseas Variable (1)
T. Rowe Price Limited-Term Bond (1)
Invesco V.I. American Franchise Series I Shares (1)
T. Rowe Price Mid-Cap Growth (1)
Invesco V.I. American Value Series I Shares (1)
Third Avenue FFI Strategies (1)
Invesco V.I. Diversified Dividend Series I Shares (1)
Vanguard® Balanced (1)
Invesco V.I. Health Care Series I Shares (1)
Vanguard® Capital Growth (1)
Invesco V.I. Small Cap Equity Series I Shares (1)
Vanguard® Diversified Value (1)
Invesco V.I. Technology Series I Shares (1)
Vanguard® Equity Income (1)
Janus Henderson - Balanced Institutional Shares (1)
Vanguard® Equity Index (1)
Janus Henderson - Enterprise Institutional Shares (1)
Vanguard® Growth (1)
Janus Henderson - Flexible Bond Institutional Shares (1)
Vanguard® High Yield Bond (1)
Janus Henderson - Forty Institutional Shares (1)
Vanguard® International (1)
Janus Henderson - Global Research Institutional Shares (1)
Vanguard® Mid-Cap Index (1)
Janus Henderson - Overseas Institutional Shares (1)
Vanguard® Money Market (1)
Janus Henderson - Research Institutional Shares (1)
Vanguard® Real Estate Index (1)
Morningstar Aggressive Growth ETF Asset Allocation Class I Shares (1)
Vanguard® Short-Term Investment Grade (1)
Morningstar Balanced ETF Asset Allocation Class I Shares (1)
Vanguard® Small Company Growth (1)
Morningstar Conservative ETF Asset Allocation Class I Shares (1)
Vanguard® Total Bond Market Index (1)
Morningstar Growth ETF Asset Allocation Class I Shares (1)
Vanguard® Total Stock Market Index (1)
(1) Statements of operations and changes in net assets for the years ended December 31, 2025 and 2024
 
Basis for Opinion
These financial statements are the responsibility of the Separate Account’s management. Our responsibility is to express an opinion on each of the subaccounts’ financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Separate Account in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of December 31, 2025, by correspondence with the fund companies or their transfer agents, as applicable. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the auditor of the Separate Account since 2024.
 
Chicago, IL
April 24, 2026
1

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Assets and Liabilities
December 31, 2025
                             
Subaccount Number of Shares Cost Assets at Market Value Due (to)/from General Account Net Assets Units Outstanding Range of Unit Values
American Funds - Global Small Cap Class 2 Shares - $ - $ - $ - $ - - $ 3.713729 $ 4.356535
American Funds - Growth Class 2 Shares 3,824.715   395,784   530,870   2   530,872 43,384   7.732250   12.236460
American Funds - International Class 2 Shares 22,035.051   424,712   489,619   -   489,619 137,550   2.722005   3.559558
American Funds - New World Class 2 Shares 33,328.651   914,951   1,067,517   (56)   1,067,461 201,467   3.875786   5.298443
Dimensional VA Global Bond -   -   -   -   - -   1.426139   1.806090
Dimensional VA International Small 258,173.562   3,056,775   3,815,805   26   3,815,831 1,252,737   2.141808   3.045996
Dimensional VA International Value -   -   -   -   - -   1.521457   2.362550
Dimensional VA Short-Term Fixed -   -   -   -   - -   1.194697   1.314789
Dimensional VA U.S. Large Value 29,612.013   968,080   1,033,755   18   1,033,773 231,596   3.398854   4.463686
Dimensional VA U.S. Targeted Value 3,651.970   70,021   81,366   -   81,366 16,385   4.215115   4.965867
DWS Equity 500 Index Class A Shares -   -   -   -   - -   4.901931   7.186194
DWS Small Cap Index Class A Shares 235,426.195   3,081,848   3,536,101   (47)   3,536,054 539,858   5.231748   6.549973
Fidelity® VIP Balanced Initial Class 259,841.630   5,819,522   6,888,402   14   6,888,416 1,074,774   4.799235   6.409175
Fidelity® VIP Contrafund® Initial Class 165,152.912   8,399,040   9,891,008   148   9,891,156 857,169   7.099805   14.960879
Fidelity® VIP Government Money Market Initial Class 32,870,262.050   32,870,262   32,870,262   (5,674)   32,864,588 19,698,054   1.524366   1.668418
Fidelity® VIP Growth Initial Class 29,559.017   2,804,033   2,888,507   (142)   2,888,365 357,982   5.385597   8.068472
Fidelity® VIP Growth Opportunities Initial Class -   -   -   -   - -   6.559032   11.109187
Fidelity® VIP High Income Initial Class 48,775.388   231,314   238,024   (3)   238,021 78,059   2.535474   3.049241
First Eagle Overseas Variable 6,752.124   166,567   188,519   1   188,520 30,429   4.247922   9.377781
Invesco V.I. American Franchise Series I Shares -   -   -   -   - -   4.130602   6.221565
Invesco V.I. American Value Series I Shares -   -   -   -   - -   5.273895   8.322217
Invesco V.I. Diversified Dividend Series I Shares -   -   -   -   - -   3.042468   3.986715
Invesco V.I. Health Care Series I Shares 8,912.964   238,546   266,408   9   266,417 46,146   4.805758   5.773304
Invesco V.I. Small Cap Equity Series I Shares 51,301.476   910,640   1,029,108   (24)   1,029,084 257,343   3.998879   3.998879
Invesco V.I. Technology Series I Shares -   -   -   -   - -   3.056171   3.056171
Janus Henderson - Balanced Institutional Shares -   -   -   -   - -   7.330658   7.330658
Janus Henderson - Enterprise Institutional Shares -   -   -   -   - -   6.457999   14.974297
Janus Henderson - Flexible Bond Institutional Shares 19,106.930   193,816   189,732   -   189,732 62,372   2.643831   3.041956
Janus Henderson - Forty Institutional Shares -   -   -   -   - -   9.831276   16.835764
Janus Henderson - Global Research Institutional Shares -   -   -   -   - -   3.735286   6.855190
Janus Henderson - Overseas Institutional Shares 0.057   2   3   (3)   - -   4.085914   6.735462
Janus Henderson - Research Institutional Shares -   -   -   -   - -   6.383012   6.383012
Morningstar Aggressive Growth ETF Asset Allocation Class I Shares -   -   -   -   - -   3.497454   3.497454
Morningstar Balanced ETF Asset Allocation Class I Shares -   -   -   -   - -   2.696940   2.696940
Morningstar Conservative ETF Asset Allocation Class I Shares -   -   -   -   - -   1.787873   1.787873
Morningstar Growth ETF Asset Allocation Class I Shares -   -   -   -   - -   3.173064   3.173064
Morningstar Income and Growth ETF Asset Allocation Class I Shares -   -   -   -   - -   2.216701   2.216701
MS VIF Emerging Markets Debt Class I Shares -   -   -   -   - -   5.049703   5.049703
MS VIF Emerging Markets Equity Class I Shares -   -   -   -   - -   5.409508   5.409508
PIMCO All Asset Administrative Class 58,929.685   537,513   564,546   12   564,558 179,956   3.137204   3.137204
 
See accompanying notes.
2

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Assets and Liabilities
December 31, 2025
                             
Subaccount Number of Shares Cost Assets at Market Value Due (to)/from General Account Net Assets Units Outstanding Range of Unit Values
PIMCO All Asset Institutional Class - $ - $ - $ - $ - - $ 2.571778 $ 2.571778
PIMCO High Yield Institutional Class -   -   -   -   - -   4.631061   4.631061
PIMCO Low Duration Institutional Class -   -   -   -   - -   1.763747   1.763747
PIMCO Real Return Institutional Class 194,781.159   2,356,585   2,339,322   (5)   2,339,317 1,033,955   2.262493   2.262493
PIMCO Short-Term Institutional Class 88,048.790   904,484   909,544   (99)   909,445 433,869   1.779047   2.096126
PIMCO Total Return Institutional Class 1,395,576.631   12,735,052   13,188,199   23   13,188,222 4,056,661   2.638125   3.251004
Royce Capital Micro Cap Investment Class 33,561.844   328,880   319,173   (36)   319,137 57,445   5.555565   6.426690
Royce Capital Small Cap Investment Class 0.328   3   3   (3)   - -   5.560909   5.560909
Rydex NASDAQ-100® -   -   -   -   - -   20.642166   20.642166
Rydex VIT Nova -   -   -   -   - -   14.690814   14.690814
T. Rowe Price All-Cap Opportunities -   -   -   -   - -   10.799358   10.799358
T. Rowe Price Blue Chip Growth 11,175.977   509,487   730,127   26   730,153 72,884   10.018025   10.018025
T. Rowe Price Equity Income Service Class 6,723.731   198,056   194,383   152   194,535 27,695   6.838052   7.024151
T. Rowe Price International Stock 2,178,227.681   33,383,068   34,633,820   12   34,633,832 13,631,095   2.540796   2.540796
T. Rowe Price Limited-Term Bond 18,691.673   91,670   88,785   (90)   88,695 51,912   1.708397   1.708558
T. Rowe Price Mid-Cap Growth 431,424.088   13,373,931   11,303,311   (11)   11,303,300 1,062,132   10.642083   12.008460
Third Avenue FFI Strategies -   -   -   -   - -   4.034703   5.382321
Vanguard® Balanced 2,024,271.139   48,611,910   51,436,730   39   51,436,769 6,961,741   7.294878   7.419591
Vanguard® Capital Growth 383,931.312   16,160,527   23,734,634   (149)   23,734,485 1,397,184   16.987366   16.987366
Vanguard® Diversified Value 0.541   14   9   (9)   - -   8.296172   9.077946
Vanguard® Equity Income 1,200,743.548   28,145,398   31,483,496   39   31,483,535 3,860,982   8.154281   8.154281
Vanguard® Equity Index 1,559,813.047   85,014,004   127,842,277   46   127,842,323 12,496,939   9.848927   11.361805
Vanguard® Growth -   -   -   -   - -   9.623713   9.623713
Vanguard® High Yield Bond 570,118.333   4,236,878   4,304,393   5   4,304,398 1,051,781   4.091979   4.194181
Vanguard® International 536,049.525   13,703,699   15,325,656   (73)   15,325,583 2,041,835   7.485801   7.521269
Vanguard® Mid-Cap Index 725,522.891   17,014,478   20,285,620   (34)   20,285,586 1,912,463   10.605718   10.608202
Vanguard® Money Market 65,357,053.910   65,357,054   65,357,054   6,597   65,363,651 42,143,235   1.525543   1.550988
Vanguard® Real Estate Index 414,728.624   4,827,023   4,798,410   67   4,798,477 719,688   6.571993   7.213415
Vanguard® Short-Term Investment Grade 1,559,959.561   16,439,802   16,644,769   109   16,644,878 7,882,344   2.102915   2.152933
Vanguard® Small Company Growth 416,722.843   7,417,519   7,946,905   (16)   7,946,889 894,745   8.496062   8.992737
Vanguard® Total Bond Market Index 1,857,837.867   19,992,086   20,064,649   (22)   20,064,627 9,281,898   2.159425   2.217613
Vanguard® Total Stock Market Index 204,002.858   12,051,121   12,429,894   (36)   12,429,858 1,077,726   11.533415   11.533415
 
See accompanying notes.
 
 
3

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        American Funds - Global Small Cap Class 2 Shares American Funds - Growth Class 2 Shares American Funds - International Class 2 Shares American Funds - New World Class 2 Shares
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                 301,915 $                                                 371,754 $                                                 693,119
               
Investment Income:        
  Reinvested Dividends - 1,257 4,907 10,027
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 1,257 4,907 10,027
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 7,685 - 3,407
  Realized Gain (Loss) on Investments - 2,124 (2,338) (27,913)
    Net Realized Capital Gains (Losses) on Investments - 9,809 (2,338) (24,506)
    Net Change in Unrealized Appreciation (Depreciation) - 97,621 7,660 59,142
      Net Gain (Loss) on Investment - 107,430 5,322 34,636
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 108,687 10,229 44,663
               
Increase (Decrease) in Net Assets from Contract Transactions - 40,733 18,298 (39,541)
               
Total Increase (Decrease) in Net Assets - 149,420 28,527 5,122
               
Net Assets as of December 31, 2024: $                                                                   - $                                                 451,335 $                                                 400,281 $                                                 698,241
               
Investment Income:        
  Reinvested Dividends - 732 5,985 8,241
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 732 5,985 8,241
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 37,388 - 31,199
  Realized Gain (Loss) on Investments - 28,809 6,589 9,414
    Net Realized Capital Gains (Losses) on Investments - 66,197 6,589 40,613
    Net Change in Unrealized Appreciation (Depreciation) - 30,852 99,371 146,020
      Net Gain (Loss) on Investment - 97,049 105,960 186,633
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 97,781 111,945 194,874
               
Increase (Decrease) in Net Assets from Contract Transactions - (18,244) (22,607) 174,346
               
Total Increase (Decrease) in Net Assets - 79,537 89,338 369,220
               
Net Assets as of December 31, 2025: $                                                                   - $                                                 530,872 $                                                 489,619 $                                            1,067,461
 See Accompanying Notes.
(1)See Footnote 1
4

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Dimensional VA Global Bond Dimensional VA International Small Dimensional VA International Value Dimensional VA Short-Term Fixed
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                            3,284,341 $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - 123,555 - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 123,555 - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 96,628 - -
  Realized Gain (Loss) on Investments - (56,754) - -
    Net Realized Capital Gains (Losses) on Investments - 39,874 - -
    Net Change in Unrealized Appreciation (Depreciation) - (44,846) - -
      Net Gain (Loss) on Investment - (4,972) - -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 118,583 - -
               
Increase (Decrease) in Net Assets from Contract Transactions - 138,578 - -
               
Total Increase (Decrease) in Net Assets - 257,161 - -
               
Net Assets as of December 31, 2024: $                                                                   - $                                            3,541,502 $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - 118,649 - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 118,649 - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 143,554 - -
  Realized Gain (Loss) on Investments - 15,098 - -
    Net Realized Capital Gains (Losses) on Investments - 158,652 - -
    Net Change in Unrealized Appreciation (Depreciation) - 849,342 - -
      Net Gain (Loss) on Investment - 1,007,994 - -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 1,126,643 - -
               
Increase (Decrease) in Net Assets from Contract Transactions - (852,314) - -
               
Total Increase (Decrease) in Net Assets - 274,329 - -
               
Net Assets as of December 31, 2025: $                                                                   - $                                            3,815,831 $                                                                   - $                                                                   -
 See Accompanying Notes.
(1)See Footnote 1
5

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Dimensional VA U.S. Large Value Dimensional VA U.S. Targeted Value DWS Equity 500 Index Class A Shares DWS Small Cap Index Class A Shares
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                 836,413 $                                                    71,839 $                                                                   - $                                            3,051,842
               
Investment Income:        
  Reinvested Dividends 17,025 1,050 - 32,370
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 17,025 1,050 - 32,370
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 85,778 5,114 - 75,867
  Realized Gain (Loss) on Investments 57,480 362 - 79,212
    Net Realized Capital Gains (Losses) on Investments 143,258 5,476 - 155,079
    Net Change in Unrealized Appreciation (Depreciation) (51,374) (770) - 137,721
      Net Gain (Loss) on Investment 91,884 4,706 - 292,800
               
Net Increase (Decrease) in Net Assets Resulting from Operations 108,909 5,756 - 325,170
               
Increase (Decrease) in Net Assets from Contract Transactions (109,127) (1,458) - 274,713
               
Total Increase (Decrease) in Net Assets (218) 4,298 - 599,883
               
Net Assets as of December 31, 2024: $                                                 836,195 $                                                    76,137 $                                                                   - $                                            3,651,725
               
Investment Income:        
  Reinvested Dividends 18,951 1,410 - 46,608
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 18,951 1,410 - 46,608
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 59,194 6,381 - 199,041
  Realized Gain (Loss) on Investments 29,772 319 - 13,860
    Net Realized Capital Gains (Losses) on Investments 88,966 6,700 - 212,901
    Net Change in Unrealized Appreciation (Depreciation) 38,213 (1,450) - 175,965
      Net Gain (Loss) on Investment 127,179 5,250 - 388,866
               
Net Increase (Decrease) in Net Assets Resulting from Operations 146,130 6,660 - 435,474
               
Increase (Decrease) in Net Assets from Contract Transactions 51,448 (1,431) - (551,145)
               
Total Increase (Decrease) in Net Assets 197,578 5,229 - (115,671)
               
Net Assets as of December 31, 2025: $                                            1,033,773 $                                                    81,366 $                                                                   - $                                            3,536,054
 See Accompanying Notes.
(1)See Footnote 1
6

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Fidelity® VIP Balanced Initial Class Fidelity® VIP Contrafund® Initial Class Fidelity® VIP Government Money Market Initial Class Fidelity® VIP Growth Initial Class
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                            4,379,804 $                                            8,956,346 $                                         29,879,092 $                                            2,115,999
               
Investment Income:        
  Reinvested Dividends 104,209 17,653 1,500,357 20
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 104,209 17,653 1,500,357 20
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 149,815 1,132,282 - 504,369
  Realized Gain (Loss) on Investments (11,558) 876,944 - 5,189
    Net Realized Capital Gains (Losses) on Investments 138,257 2,009,226 - 509,558
    Net Change in Unrealized Appreciation (Depreciation) 544,270 596,729 - 32,881
      Net Gain (Loss) on Investment 682,527 2,605,955 - 542,439
               
Net Increase (Decrease) in Net Assets Resulting from Operations 786,736 2,623,608 1,500,357 542,459
               
Increase (Decrease) in Net Assets from Contract Transactions 974,473 (1,528,619) (6,338,308) (233,896)
               
Total Increase (Decrease) in Net Assets 1,761,209 1,094,989 (4,837,951) 308,563
               
Net Assets as of December 31, 2024: $                                            6,141,013 $                                         10,051,335 $                                         25,041,141 $                                            2,424,562
               
Investment Income:        
  Reinvested Dividends 112,597 12,830 1,412,732 7,880
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 112,597 12,830 1,412,732 7,880
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 309,599 1,475,385 - 347,846
  Realized Gain (Loss) on Investments (1,662) 1,306,239 - (26,637)
    Net Realized Capital Gains (Losses) on Investments 307,937 2,781,624 - 321,209
    Net Change in Unrealized Appreciation (Depreciation) 504,127 (824,417) - 26,089
      Net Gain (Loss) on Investment 812,064 1,957,207 - 347,298
               
Net Increase (Decrease) in Net Assets Resulting from Operations 924,661 1,970,037 1,412,732 355,178
               
Increase (Decrease) in Net Assets from Contract Transactions (177,258) (2,130,216) 6,410,715 108,625
               
Total Increase (Decrease) in Net Assets 747,403 (160,179) 7,823,447 463,803
               
Net Assets as of December 31, 2025: $                                            6,888,416 $                                            9,891,156 $                                         32,864,588 $                                            2,888,365
 See Accompanying Notes.
(1)See Footnote 1
7

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Fidelity® VIP Growth Opportunities Initial Class Fidelity® VIP High Income Initial Class First Eagle Overseas Variable Invesco V.I. American Franchise Series I Shares
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                                   - $                                                 134,452 $                                                                   -
               
Investment Income:        
  Reinvested Dividends - 8,299 2,482 -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 8,299 2,482 -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - 981 -
  Realized Gain (Loss) on Investments - 10,898 (82) -
    Net Realized Capital Gains (Losses) on Investments - 10,898 899 -
    Net Change in Unrealized Appreciation (Depreciation) - 2,107 4,804 -
      Net Gain (Loss) on Investment - 13,005 5,703 -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 21,304 8,185 -
               
Increase (Decrease) in Net Assets from Contract Transactions - 118,864 (2,831) -
               
Total Increase (Decrease) in Net Assets - 140,168 5,354 -
               
Net Assets as of December 31, 2024: $                                                                   - $                                                 140,168 $                                                 139,806 $                                                                   -
               
Investment Income:        
  Reinvested Dividends - 15,067 2,998 -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 15,067 2,998 -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - 21,579 -
  Realized Gain (Loss) on Investments - 5,073 299 -
    Net Realized Capital Gains (Losses) on Investments - 5,073 21,878 -
    Net Change in Unrealized Appreciation (Depreciation) - 4,603 26,965 -
      Net Gain (Loss) on Investment - 9,676 48,843 -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 24,743 51,841 -
               
Increase (Decrease) in Net Assets from Contract Transactions - 73,110 (3,127) -
               
Total Increase (Decrease) in Net Assets - 97,853 48,714 -
               
Net Assets as of December 31, 2025: $                                                                   - $                                                 238,021 $                                                 188,520 $                                                                   -
 See Accompanying Notes.
(1)See Footnote 1
8

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Invesco V.I. American Value Series I Shares Invesco V.I. Diversified Dividend Series I Shares Invesco V.I. Health Care Series I Shares Invesco V.I. Small Cap Equity Series I Shares
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                 357,977 $                                                 243,002 $                                                 928,366
               
Investment Income:        
  Reinvested Dividends - 7,398 - 1,268
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 7,398 - 1,268
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 15,746 - 44,840
  Realized Gain (Loss) on Investments - (118) (189) 48,942
    Net Realized Capital Gains (Losses) on Investments - 15,628 (189) 93,782
    Net Change in Unrealized Appreciation (Depreciation) - 24,069 9,773 73,028
      Net Gain (Loss) on Investment - 39,697 9,584 166,810
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 47,095 9,584 168,078
               
Increase (Decrease) in Net Assets from Contract Transactions - (4,069) (13,746) (125,778)
               
Total Increase (Decrease) in Net Assets - 43,026 (4,162) 42,300
               
Net Assets as of December 31, 2024: $                                                                   - $                                                 401,003 $                                                 238,840 $                                                 970,666
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - 10,251 44,430
  Realized Gain (Loss) on Investments - 48,368 498 29,783
    Net Realized Capital Gains (Losses) on Investments - 48,368 10,749 74,213
    Net Change in Unrealized Appreciation (Depreciation) - (4,769) 24,835 17,719
      Net Gain (Loss) on Investment - 43,599 35,584 91,932
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 43,599 35,584 91,932
               
Increase (Decrease) in Net Assets from Contract Transactions - (444,602) (8,007) (33,514)
               
Total Increase (Decrease) in Net Assets - (401,003) 27,577 58,418
               
Net Assets as of December 31, 2025: $                                                                   - $                                                                   - $                                                 266,417 $                                            1,029,084
 See Accompanying Notes.
(1)See Footnote 1
9

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Invesco V.I. Technology Series I Shares Janus Henderson - Balanced Institutional Shares Janus Henderson - Enterprise Institutional Shares Janus Henderson - Flexible Bond Institutional Shares
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - (332)
    Net Realized Capital Gains (Losses) on Investments - - - (332)
    Net Change in Unrealized Appreciation (Depreciation) - - - -
      Net Gain (Loss) on Investment - - - (332)
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - (332)
               
Increase (Decrease) in Net Assets from Contract Transactions - - - 332
               
Total Increase (Decrease) in Net Assets - - - -
               
Net Assets as of December 31, 2024: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - 4,937
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - 4,937
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - -
    Net Realized Capital Gains (Losses) on Investments - - - -
    Net Change in Unrealized Appreciation (Depreciation) - - - (4,084)
      Net Gain (Loss) on Investment - - - (4,084)
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - 853
               
Increase (Decrease) in Net Assets from Contract Transactions - - - 188,879
               
Total Increase (Decrease) in Net Assets - - - 189,732
               
Net Assets as of December 31, 2025: $                                                                   - $                                                                   - $                                                                   - $                                                 189,732
 See Accompanying Notes.
(1)See Footnote 1
10

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Janus Henderson - Forty Institutional Shares Janus Henderson - Global Research Institutional Shares Janus Henderson - Overseas Institutional Shares Janus Henderson - Research Institutional Shares
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - -
    Net Realized Capital Gains (Losses) on Investments - - - -
    Net Change in Unrealized Appreciation (Depreciation) - - - -
      Net Gain (Loss) on Investment - - - -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - -
               
Increase (Decrease) in Net Assets from Contract Transactions - - - -
               
Total Increase (Decrease) in Net Assets - - - -
               
Net Assets as of December 31, 2024: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - -
    Net Realized Capital Gains (Losses) on Investments - - - -
    Net Change in Unrealized Appreciation (Depreciation) - - 1 -
      Net Gain (Loss) on Investment - - 1 -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - 1 -
               
Increase (Decrease) in Net Assets from Contract Transactions - - (1) -
               
Total Increase (Decrease) in Net Assets - - - -
               
Net Assets as of December 31, 2025: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
 See Accompanying Notes.
(1)See Footnote 1
11

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Morningstar Aggressive Growth ETF Asset Allocation Class I Shares Morningstar Balanced ETF Asset Allocation Class I Shares Morningstar Conservative ETF Asset Allocation Class I Shares Morningstar Growth ETF Asset Allocation Class I Shares
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - -
    Net Realized Capital Gains (Losses) on Investments - - - -
    Net Change in Unrealized Appreciation (Depreciation) - - - -
      Net Gain (Loss) on Investment - - - -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - -
               
Increase (Decrease) in Net Assets from Contract Transactions - - - -
               
Total Increase (Decrease) in Net Assets - - - -
               
Net Assets as of December 31, 2024: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - -
    Net Realized Capital Gains (Losses) on Investments - - - -
    Net Change in Unrealized Appreciation (Depreciation) - - - -
      Net Gain (Loss) on Investment - - - -
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - -
               
Increase (Decrease) in Net Assets from Contract Transactions - - - -
               
Total Increase (Decrease) in Net Assets - - - -
               
Net Assets as of December 31, 2025: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
 See Accompanying Notes.
(1)See Footnote 1
12

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Morningstar Income and Growth ETF Asset Allocation Class I Shares MS VIF Emerging Markets Debt Class I Shares MS VIF Emerging Markets Equity Class I Shares PIMCO All Asset Administrative Class
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                                   - $                                                                   - $                                                 682,626
               
Investment Income:        
  Reinvested Dividends - - - 34,237
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - 34,237
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - (62,732)
    Net Realized Capital Gains (Losses) on Investments - - - (62,732)
    Net Change in Unrealized Appreciation (Depreciation) - - - 46,367
      Net Gain (Loss) on Investment - - - (16,365)
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - 17,872
               
Increase (Decrease) in Net Assets from Contract Transactions - - - (176,283)
               
Total Increase (Decrease) in Net Assets - - - (158,411)
               
Net Assets as of December 31, 2024: $                                                                   - $                                                                   - $                                                                   - $                                                 524,215
               
Investment Income:        
  Reinvested Dividends - - - 23,827
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - 23,827
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - (34,668)
    Net Realized Capital Gains (Losses) on Investments - - - (34,668)
    Net Change in Unrealized Appreciation (Depreciation) - - - 81,345
      Net Gain (Loss) on Investment - - - 46,677
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - 70,504
               
Increase (Decrease) in Net Assets from Contract Transactions - - - (30,161)
               
Total Increase (Decrease) in Net Assets - - - 40,343
               
Net Assets as of December 31, 2025: $                                                                   - $                                                                   - $                                                                   - $                                                 564,558
 See Accompanying Notes.
(1)See Footnote 1
13

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        PIMCO All Asset Institutional Class PIMCO High Yield Institutional Class PIMCO Low Duration Institutional Class PIMCO Real Return Institutional Class
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - 3
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - 3
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - (19)
    Net Realized Capital Gains (Losses) on Investments - - - (19)
    Net Change in Unrealized Appreciation (Depreciation) - - - -
      Net Gain (Loss) on Investment - - - (19)
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - (16)
               
Increase (Decrease) in Net Assets from Contract Transactions - - - 16
               
Total Increase (Decrease) in Net Assets - - - -
               
Net Assets as of December 31, 2024: $                                                                   - $                                                                   - $                                                                   - $                                                                   -
               
Investment Income:        
  Reinvested Dividends - - - 18,527
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - 18,527
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - -
  Realized Gain (Loss) on Investments - - - (141)
    Net Realized Capital Gains (Losses) on Investments - - - (141)
    Net Change in Unrealized Appreciation (Depreciation) - - - (17,263)
      Net Gain (Loss) on Investment - - - (17,404)
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - 1,123
               
Increase (Decrease) in Net Assets from Contract Transactions - - - 2,338,194
               
Total Increase (Decrease) in Net Assets - - - 2,339,317
               
Net Assets as of December 31, 2025: $                                                                   - $                                                                   - $                                                                   - $                                            2,339,317
 See Accompanying Notes.
(1)See Footnote 1
14

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        PIMCO Short-Term Institutional Class PIMCO Total Return Institutional Class Royce Capital Micro Cap Investment Class Royce Capital Small Cap Investment Class
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                            1,014,262 $                                         12,387,963 $                                                 179,302 $                                                                   -
               
Investment Income:        
  Reinvested Dividends 54,004 523,400 - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 54,004 523,400 - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - 13,361 -
  Realized Gain (Loss) on Investments 3,079 (637,846) (3,907) -
    Net Realized Capital Gains (Losses) on Investments 3,079 (637,846) 9,454 -
    Net Change in Unrealized Appreciation (Depreciation) 6,770 419,267 13,392 -
      Net Gain (Loss) on Investment 9,849 (218,579) 22,846 -
               
Net Increase (Decrease) in Net Assets Resulting from Operations 63,853 304,821 22,846 -
               
Increase (Decrease) in Net Assets from Contract Transactions 465,905 575,071 (2,770) -
               
Total Increase (Decrease) in Net Assets 529,758 879,892 20,076 -
               
Net Assets as of December 31, 2024: $                                            1,544,020 $                                         13,267,855 $                                                 199,378 $                                                                   -
               
Investment Income:        
  Reinvested Dividends 41,658 529,045 - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 41,658 529,045 - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - 47,371 -
  Realized Gain (Loss) on Investments 14,715 (244,344) (1,544) -
    Net Realized Capital Gains (Losses) on Investments 14,715 (244,344) 45,827 -
    Net Change in Unrealized Appreciation (Depreciation) (13,861) 792,311 (8,050) -
      Net Gain (Loss) on Investment 854 547,967 37,777 -
               
Net Increase (Decrease) in Net Assets Resulting from Operations 42,512 1,077,012 37,777 -
               
Increase (Decrease) in Net Assets from Contract Transactions (677,087) (1,156,645) 81,982 -
               
Total Increase (Decrease) in Net Assets (634,575) (79,633) 119,759 -
               
Net Assets as of December 31, 2025: $                                                 909,445 $                                         13,188,222 $                                                 319,137 $                                                                   -
 See Accompanying Notes.
(1)See Footnote 1
15

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Rydex NASDAQ-100® Rydex VIT Nova T. Rowe Price All-Cap Opportunities T. Rowe Price Blue Chip Growth
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                                                   - $                                                                   - $                                                 570,327
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - 28,549
  Realized Gain (Loss) on Investments - - - 11,234
    Net Realized Capital Gains (Losses) on Investments - - - 39,783
    Net Change in Unrealized Appreciation (Depreciation) - - - 153,354
      Net Gain (Loss) on Investment - - - 193,137
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - 193,137
               
Increase (Decrease) in Net Assets from Contract Transactions - - - (54,221)
               
Total Increase (Decrease) in Net Assets - - - 138,916
               
Net Assets as of December 31, 2024: $                                                                   - $                                                                   - $                                                                   - $                                                 709,243
               
Investment Income:        
  Reinvested Dividends - - - -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - - - -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - 60,880
  Realized Gain (Loss) on Investments - - - 31,342
    Net Realized Capital Gains (Losses) on Investments - - - 92,222
    Net Change in Unrealized Appreciation (Depreciation) - - - 26,410
      Net Gain (Loss) on Investment - - - 118,632
               
Net Increase (Decrease) in Net Assets Resulting from Operations - - - 118,632
               
Increase (Decrease) in Net Assets from Contract Transactions - - - (97,722)
               
Total Increase (Decrease) in Net Assets - - - 20,910
               
Net Assets as of December 31, 2025: $                                                                   - $                                                                   - $                                                                   - $                                                 730,153
 See Accompanying Notes.
(1)See Footnote 1
16

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        T. Rowe Price Equity Income Service Class T. Rowe Price International Stock T. Rowe Price Limited-Term Bond T. Rowe Price Mid-Cap Growth
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                 148,389 $                                         33,970,115 $                                                 172,998 $                                         10,233,564
               
Investment Income:        
  Reinvested Dividends 3,225 300,975 5,115 -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 3,225 300,975 5,115 -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 12,807 778,854 - 1,033,218
  Realized Gain (Loss) on Investments 2,481 366,513 (3,134) 56,313
    Net Realized Capital Gains (Losses) on Investments 15,288 1,145,367 (3,134) 1,089,531
    Net Change in Unrealized Appreciation (Depreciation) (3,063) (304,677) 3,672 (137,859)
      Net Gain (Loss) on Investment 12,225 840,690 538 951,672
               
Net Increase (Decrease) in Net Assets Resulting from Operations 15,450 1,141,665 5,653 951,672
               
Increase (Decrease) in Net Assets from Contract Transactions 33,338 (4,097,469) (88,118) 261,434
               
Total Increase (Decrease) in Net Assets 48,788 (2,955,804) (82,465) 1,213,106
               
Net Assets as of December 31, 2024: $                                                 197,177 $                                         31,014,311 $                                                    90,533 $                                         11,446,670
               
Investment Income:        
  Reinvested Dividends 3,108 646,750 3,748 -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 3,108 646,750 3,748 -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 18,454 2,840,579 - 1,426,696
  Realized Gain (Loss) on Investments (272) 296,878 (385) (203,465)
    Net Realized Capital Gains (Losses) on Investments 18,182 3,137,457 (385) 1,223,231
    Net Change in Unrealized Appreciation (Depreciation) 4,361 1,813,053 1,490 (902,465)
      Net Gain (Loss) on Investment 22,543 4,950,510 1,105 320,766
               
Net Increase (Decrease) in Net Assets Resulting from Operations 25,651 5,597,260 4,853 320,766
               
Increase (Decrease) in Net Assets from Contract Transactions (28,293) (1,977,739) (6,691) (464,136)
               
Total Increase (Decrease) in Net Assets (2,642) 3,619,521 (1,838) (143,370)
               
Net Assets as of December 31, 2025: $                                                 194,535 $                                         34,633,832 $                                                    88,695 $                                         11,303,300
 See Accompanying Notes.
(1)See Footnote 1
17

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Third Avenue FFI Strategies Vanguard® Balanced Vanguard® Capital Growth Vanguard® Diversified Value
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                                                   - $                                         16,271,047 $                                         36,929,314 $                                                                   -
               
Investment Income:        
  Reinvested Dividends - 481,549 442,146 -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 481,549 442,146 -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 1,041,499 808,178 -
  Realized Gain (Loss) on Investments - 380,466 494,304 -
    Net Realized Capital Gains (Losses) on Investments - 1,421,965 1,302,482 -
    Net Change in Unrealized Appreciation (Depreciation) - 1,164,090 3,171,238 1
      Net Gain (Loss) on Investment - 2,586,055 4,473,720 1
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 3,067,604 4,915,866 1
               
Increase (Decrease) in Net Assets from Contract Transactions - 4,873,698 (1,837,365) (1)
               
Total Increase (Decrease) in Net Assets - 7,941,302 3,078,501 -
               
Net Assets as of December 31, 2024: $                                                                   - $                                         24,212,349 $                                         40,007,815 $                                                                   -
               
Investment Income:        
  Reinvested Dividends - 759,997 434,650 -
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) - 759,997 434,650 -
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 3,255,289 1,867,602 1
  Realized Gain (Loss) on Investments - 862,380 17,160,886 -
    Net Realized Capital Gains (Losses) on Investments - 4,117,669 19,028,488 1
    Net Change in Unrealized Appreciation (Depreciation) - 949,611 (9,898,546) 1
      Net Gain (Loss) on Investment - 5,067,280 9,129,942 2
               
Net Increase (Decrease) in Net Assets Resulting from Operations - 5,827,277 9,564,592 2
               
Increase (Decrease) in Net Assets from Contract Transactions - 21,397,143 (25,837,922) (2)
               
Total Increase (Decrease) in Net Assets - 27,224,420 (16,273,330) -
               
Net Assets as of December 31, 2025: $                                                                   - $                                         51,436,769 $                                         23,734,485 $                                                                   -
 
 See Accompanying Notes.
(1)See Footnote 1
18

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Vanguard® Equity Income Vanguard® Equity Index Vanguard® Growth Vanguard® High Yield Bond
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                         33,260,560 $                                      122,850,765 $                                                                   - $                                                    40,588
               
Investment Income:        
  Reinvested Dividends 990,711 1,760,332 - 1,516
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 990,711 1,760,332 - 1,516
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 2,088,475 5,032,676 - -
  Realized Gain (Loss) on Investments 117,820 5,673,237 - 1,353
    Net Realized Capital Gains (Losses) on Investments 2,206,295 10,705,913 - 1,353
    Net Change in Unrealized Appreciation (Depreciation) 1,713,062 16,791,269 - (1,159)
      Net Gain (Loss) on Investment 3,919,357 27,497,182 - 194
               
Net Increase (Decrease) in Net Assets Resulting from Operations 4,910,068 29,257,514 - 1,710
               
Increase (Decrease) in Net Assets from Contract Transactions 266,967 (11,477,735) - (20,757)
               
Total Increase (Decrease) in Net Assets 5,177,035 17,779,779 - (19,047)
               
Net Assets as of December 31, 2024: $                                         38,437,595 $                                      140,630,544 $                                                                   - $                                                    21,541
               
Investment Income:        
  Reinvested Dividends 971,471 1,490,442 - 1,349
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 971,471 1,490,442 - 1,349
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 2,953,063 2,871,816 - -
  Realized Gain (Loss) on Investments 1,197,718 22,188,964 - 4,070
    Net Realized Capital Gains (Losses) on Investments 4,150,781 25,060,780 - 4,070
    Net Change in Unrealized Appreciation (Depreciation) 759,014 (3,619,616) - 67,625
      Net Gain (Loss) on Investment 4,909,795 21,441,164 - 71,695
               
Net Increase (Decrease) in Net Assets Resulting from Operations 5,881,266 22,931,606 - 73,044
               
Increase (Decrease) in Net Assets from Contract Transactions (12,835,326) (35,719,827) - 4,209,813
               
Total Increase (Decrease) in Net Assets (6,954,060) (12,788,221) - 4,282,857
               
Net Assets as of December 31, 2025: $                                         31,483,535 $                                      127,842,323 $                                                                   - $                                            4,304,398
 
 See Accompanying Notes.
(1)See Footnote 1
 
 
19

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Vanguard® International Vanguard® Mid-Cap Index Vanguard® Money Market Vanguard® Real Estate Index
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                         33,014,126 $                                         33,394,496 $                                                                   - $                                         11,484,513
               
Investment Income:        
  Reinvested Dividends 414,292 478,987 - 363,809
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 414,292 478,987 - 363,809
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 1,096,690 399,194 - 306,914
  Realized Gain (Loss) on Investments (242,256) 796,197 - (92,917)
    Net Realized Capital Gains (Losses) on Investments 854,434 1,195,391 - 213,997
    Net Change in Unrealized Appreciation (Depreciation) 1,643,043 3,149,544 - (51,708)
      Net Gain (Loss) on Investment 2,497,477 4,344,935 - 162,289
               
Net Increase (Decrease) in Net Assets Resulting from Operations 2,911,769 4,823,922 - 526,098
               
Increase (Decrease) in Net Assets from Contract Transactions (280,664) (1,631,156) - (40,912)
               
Total Increase (Decrease) in Net Assets 2,631,105 3,192,766 - 485,186
               
Net Assets as of December 31, 2024: $                                         35,645,231 $                                         36,587,262 $                                                                   - $                                         11,969,699
               
Investment Income:        
  Reinvested Dividends 321,032 459,085 400,452 320,415
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 321,032 459,085 400,452 320,415
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions 2,163,683 1,828,937 - 205,163
  Realized Gain (Loss) on Investments 6,885,282 7,439,216 - (172,893)
    Net Realized Capital Gains (Losses) on Investments 9,048,965 9,268,153 - 32,270
    Net Change in Unrealized Appreciation (Depreciation) (1,690,637) (5,478,014) - 86,901
      Net Gain (Loss) on Investment 7,358,328 3,790,139 - 119,171
               
Net Increase (Decrease) in Net Assets Resulting from Operations 7,679,360 4,249,224 400,452 439,586
               
Increase (Decrease) in Net Assets from Contract Transactions (27,999,008) (20,550,900) 64,963,199 (7,610,808)
               
Total Increase (Decrease) in Net Assets (20,319,648) (16,301,676) 65,363,651 (7,171,222)
               
Net Assets as of December 31, 2025: $                                         15,325,583 $                                         20,285,586 $                                         65,363,651 $                                            4,798,477
 
 See Accompanying Notes.
(1)See Footnote 1
20

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Statements of Operations and Changes in Net Assets
Years Ended December 31, 2025 and 2024
 
        Vanguard® Short-Term Investment Grade Vanguard® Small Company Growth Vanguard® Total Bond Market Index Vanguard® Total Stock Market Index
        Subaccount Subaccount Subaccount Subaccount
               
Net Assets as of December 31, 2023: $                                            4,239,291 $                                         21,287,939 $                                            1,162,251 $                                                 693,264
               
Investment Income:        
  Reinvested Dividends 130,270 118,871 29,264 9,602
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 130,270 118,871 29,264 9,602
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - - - 52,642
  Realized Gain (Loss) on Investments (123,071) (306,892) (52,103) (85)
    Net Realized Capital Gains (Losses) on Investments (123,071) (306,892) (52,103) 52,557
    Net Change in Unrealized Appreciation (Depreciation) 157,273 2,553,010 32,973 101,152
      Net Gain (Loss) on Investment 34,202 2,246,118 (19,130) 153,709
               
Net Increase (Decrease) in Net Assets Resulting from Operations 164,472 2,364,989 10,134 163,311
               
Increase (Decrease) in Net Assets from Contract Transactions (868,561) (436,819) (285,581) (9,702)
               
Total Increase (Decrease) in Net Assets (704,089) 1,928,170 (275,447) 153,609
               
Net Assets as of December 31, 2024: $                                            3,535,202 $                                         23,216,109 $                                                 886,804 $                                                 846,873
               
Investment Income:        
  Reinvested Dividends 134,146 108,639 27,122 10,181
Investment Expense:        
  Mortality and Expense Risk and Administrative Charges - - - -
    Net Investment Income (Loss) 134,146 108,639 27,122 10,181
               
Increase (Decrease) in Net Assets from Operations:        
  Capital Gain Distributions - 1,544,426 - 47,526
  Realized Gain (Loss) on Investments 30,661 (793,710) (52,474) 8,467
    Net Realized Capital Gains (Losses) on Investments 30,661 750,716 (52,474) 55,993
    Net Change in Unrealized Appreciation (Depreciation) 153,196 228,379 196,714 298,147
      Net Gain (Loss) on Investment 183,857 979,095 144,240 354,140
               
Net Increase (Decrease) in Net Assets Resulting from Operations 318,003 1,087,734 171,362 364,321
               
Increase (Decrease) in Net Assets from Contract Transactions 12,791,673 (16,356,954) 19,006,461 11,218,664
               
Total Increase (Decrease) in Net Assets 13,109,676 (15,269,220) 19,177,823 11,582,985
               
Net Assets as of December 31, 2025: $                                         16,644,878 $                                            7,946,889 $                                         20,064,627 $                                         12,429,858
 
 See Accompanying Notes.
(1)See Footnote 1
 
 
21

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
1.  Organization
                               
WRL Series Life Corporate Account (the Separate Account) is a segregated investment account of Transamerica Life Insurance Company (TLIC), an indirect wholly owned subsidiary of Aegon Ltd., a holding company organized under the laws of Bermuda.
The Separate Account is registered with the Securities and Exchange Commission as a Unit Investment Trust pursuant to provisions of the Investment Company Act of 1940.  TLIC and the Separate Account are regulated by the Securities and Exchange Commission.  The assets and liabilities of the Separate Account are clearly identified and distinguished from TLIC's other assets and liabilities.  The Separate Account consists of multiple investment subaccounts.  Each subaccount invests exclusively in the corresponding portfolio of a Mutual Fund.  Each Mutual Fund is registered as an open-end management investment company under the Investment Company Act of 1940, as amended.  Activity in these specified investment subaccounts is available to contract owners of Variable Adjustable Life.
                               
Subaccount Investment by Mutual Fund:    
Subaccount         Mutual Fund        
  American Funds Insurance Series®     American Funds Insurance Series®  
    American Funds - Global Small Cap Class 2 Shares     American Funds - Global Small Cap Fund Class 2 Shares
    American Funds - Growth Class 2 Shares       American Funds - Growth Fund Class 2 Shares
    American Funds - International Class 2 Shares     American Funds - International Fund Class 2 Shares
    American Funds - New World Class 2 Shares       American Funds - New World Fund Class 2 Shares
  DFA Investment Dimensions Group, Inc.     DFA Investment Dimensions Group, Inc.  
    Dimensional VA Global Bond         Dimensional VA Global Bond Portfolio  
    Dimensional VA International Small       Dimensional VA International Small Portfolio
    Dimensional VA International Value       Dimensional VA International Value Portfolio
    Dimensional VA Short-Term Fixed       Dimensional VA Short-Term Fixed Portfolio
    Dimensional VA U.S. Large Value         Dimensional VA U.S. Large Value Portfolio  
    Dimensional VA U.S. Targeted Value       Dimensional VA U.S. Targeted Value Portfolio
  DWS Investments VIT Funds       DWS Investments VIT Funds    
    DWS Equity 500 Index Class A Shares       DWS Equity 500 Index Class A Shares  
    DWS Small Cap Index Class A Shares       DWS Small Cap Index Class A Shares  
  Fidelity® Variable Insurance Products Funds     Fidelity® Variable Insurance Products Funds  
    Fidelity® VIP Balanced Initial Class       Fidelity® VIP Balanced Portfolio Initial Class
    Fidelity® VIP Contrafund® Initial Class       Fidelity® VIP Contrafund® Portfolio Initial Class
    Fidelity® VIP Government Money Market Initial Class     Fidelity® VIP Government Money Market Portfolio Initial Class
    Fidelity® VIP Growth Initial Class         Fidelity® VIP Growth Portfolio Initial Class  
    Fidelity® VIP Growth Opportunities Initial Class     Fidelity® VIP Growth Opportunities Portfolio Initial Class
    Fidelity® VIP High Income Initial Class       Fidelity® VIP High Income Portfolio Initial Class
  First Eagle Variable Funds       First Eagle Variable Funds    
    First Eagle Overseas Variable         First Eagle Overseas Variable Fund  
  AIM Variable Insurance Funds (Invesco Variable Insurance Funds)     AIM Variable Insurance Funds (Invesco Variable Insurance Funds)  
    Invesco V.I. American Franchise Series I Shares     Invesco V.I. American Franchise Fund Series I Shares
    Invesco V.I. American Value Series I Shares       Invesco V.I. American Value Fund Series I Shares
    Invesco V.I. Diversified Dividend Series I Shares     Invesco V.I. Diversified Dividend Fund Series I Shares
    Invesco V.I. Health Care Series I Shares       Invesco V.I. Health Care Fund Series I Shares
    Invesco V.I. Small Cap Equity Series I Shares       Invesco V.I. Small Cap Equity Fund Series I Shares
22

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
1.  Organization (continued)
                               
Subaccount Investment by Mutual Fund:    
Subaccount         Mutual Fund        
  AIM Variable Insurance Funds (Invesco Variable Insurance Funds)     AIM Variable Insurance Funds (Invesco Variable Insurance Funds)  
    Invesco V.I. Technology Series I Shares       Invesco V.I. Technology Fund Series I Shares
  Janus Aspen Series         Janus Aspen Series      
    Janus Henderson - Balanced Institutional Shares     Janus Henderson - Balanced Portfolio Institutional Shares
    Janus Henderson - Enterprise Institutional Shares     Janus Henderson - Enterprise Portfolio Institutional Shares
    Janus Henderson - Flexible Bond Institutional Shares     Janus Henderson - Flexible Bond Portfolio Institutional Shares
    Janus Henderson - Forty Institutional Shares     Janus Henderson - Forty Portfolio Institutional Shares
    Janus Henderson - Global Research Institutional Shares   Janus Henderson - Global Research Portfolio Institutional Shares
    Janus Henderson - Overseas Institutional Shares     Janus Henderson - Overseas Portfolio Institutional Shares
    Janus Henderson - Research Institutional Shares     Janus Henderson - Research Portfolio Institutional Shares
  ALPS Variable Investment Trust       ALPS Variable Investment Trust    
    Morningstar Aggressive Growth ETF Asset Allocation Class I Shares     Morningstar Aggressive Growth ETF AAP Class I Shares
    Morningstar Balanced ETF Asset Allocation Class I Shares   Morningstar Balanced ETF AAP Class I Shares
    Morningstar Conservative ETF Asset Allocation Class I Shares Morningstar Conservative ETF AAP Class I Shares
    Morningstar Growth ETF Asset Allocation Class I Shares   Morningstar Growth ETF AAP Class I Shares  
    Morningstar Income and Growth ETF Asset Allocation Class I Shares     Morningstar Income and Growth ETF AAP Class I Shares
  Morgan Stanley Variable Insurance Fund, Inc.     Morgan Stanley Variable Insurance Fund, Inc.  
    MS VIF Emerging Markets Debt Class I Shares     MS VIF Emerging Markets Debt Portfolio Class I Shares
    MS VIF Emerging Markets Equity Class I Shares     MS VIF Emerging Markets Equity Portfolio Class I Shares
  PIMCO Variable Insurance Trust       PIMCO Variable Insurance Trust    
    PIMCO All Asset Administrative Class       PIMCO All Asset Portfolio Administrative Class
    PIMCO All Asset Institutional Class       PIMCO All Asset Portfolio Institutional Class
    PIMCO High Yield Institutional Class       PIMCO High Yield Portfolio Institutional Class
    PIMCO Low Duration Institutional Class       PIMCO Low Duration Portfolio Institutional Class
    PIMCO Real Return Institutional Class       PIMCO Real Return Portfolio Institutional Class
    PIMCO Short-Term Institutional Class       PIMCO Short-Term Portfolio Institutional Class
    PIMCO Total Return Institutional Class       PIMCO Total Return Portfolio Institutional Class
  Royce Capital Fund         Royce Capital Fund      
    Royce Capital Micro Cap Investment Class       Royce Capital Micro Cap Portfolio Investment Class
    Royce Capital Small Cap Investment Class       Royce Capital Small Cap Portfolio Investment Class
  Rydex Variable Trust         Rydex Variable Trust      
    Rydex NASDAQ-100®           Rydex NASDAQ-100®      
    Rydex VIT Nova           Rydex VIT Nova      
  T. Rowe Price Equity Series, Inc.       T. Rowe Price Equity Series, Inc.    
    T. Rowe Price All-Cap Opportunities       T. Rowe Price All-Cap Opportunities Portfolio
    T. Rowe Price Blue Chip Growth         T. Rowe Price Blue Chip Growth Portfolio  
    T. Rowe Price Equity Income Service Class       T. Rowe Price Equity Income Portfolio Service Class
    T. Rowe Price International Stock       T. Rowe Price International Stock Portfolio  
    T. Rowe Price Limited-Term Bond       T. Rowe Price Limited-Term Bond Portfolio  
    T. Rowe Price Mid-Cap Growth         T. Rowe Price Mid-Cap Growth Portfolio  
 
 
23

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
1.  Organization (continued)
                               
Subaccount Investment by Mutual Fund:    
Subaccount         Mutual Fund        
  Third Avenue           Third Avenue        
    Third Avenue FFI Strategies         Third Avenue FFI Strategies Portfolio  
  Vanguard® Variable Insurance Fund       Vanguard® Variable Insurance Fund  
    Vanguard® Balanced           Vanguard® Balanced Portfolio    
    Vanguard® Capital Growth         Vanguard® Capital Growth Portfolio  
    Vanguard® Diversified Value         Vanguard® Diversified Value Portfolio  
    Vanguard® Equity Income         Vanguard® Equity Income Portfolio  
    Vanguard® Equity Index         Vanguard® Equity Index Portfolio  
    Vanguard® Growth           Vanguard® Growth Portfolio    
    Vanguard® High Yield Bond         Vanguard® High Yield Bond Portfolio  
    Vanguard® International         Vanguard® International Portfolio  
    Vanguard® Mid-Cap Index         Vanguard® Mid-Cap Index Portfolio  
    Vanguard® Money Market         Vanguard® Money Market Portfolio  
    Vanguard® Real Estate Index         Vanguard® Real Estate Index Portfolio  
    Vanguard® Short-Term Investment Grade       Vanguard® Short-Term Portfolio Investment Grade
    Vanguard® Small Company Growth       Vanguard® Small Company Growth Portfolio
    Vanguard® Total Bond Market Index       Vanguard® Total Bond Market Index Portfolio
    Vanguard® Total Stock Market Index       Vanguard® Total Stock Market Index Portfolio
                               
24

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
                         
                         
2.  Summary of Significant Accounting Policies      
                         
The financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for variable life separate accounts registered as unit investment trusts.  The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions regarding matters that affect the reported amount of assets and liabilities.  Actual results could differ from those estimates.
                         
                         
Investments                      
Net purchase payments received by the Separate Account are invested in the portfolios of the Mutual Funds as selected by the contract owner. Investments are stated at the closing net asset values per share on December 31, 2025.
Realized capital gains and losses from sales of shares in the Separate Account are determined on the first-in, first-out basis. Investment transactions are accounted for on the trade date (date the order to buy or sell is executed) and dividend income is recorded on the ex-dividend date. Unrealized gains or losses from investments in the Mutual Funds are included in the Statements of Operations and Changes in Net Assets.
                         
Dividend Income                    
Dividends received from the Mutual Fund investments are reinvested to purchase additional mutual fund shares.
                         
                         
Fair Value Measurements and Fair Value Hierarchy              
The Accounting Standards Codification™ (ASC) 820 defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the nature of inputs used to measure fair value and enhances disclosure requirements for fair value measurements.
The Separate Account has categorized its financial instruments into a three level hierarchy which is based on the priority of the inputs to the valuation technique.    The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument.
Financial assets and liabilities recorded at fair value on the Statements of Assets and Liabilities are categorized as follows:
Level 1. Unadjusted quoted prices for identical assets or liabilities in an active market.
Level 2. Quoted prices in markets that are not active or inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:
  a)  Quoted prices for similar assets or liabilities in active markets          
  b)  Quoted prices for identical or similar assets or liabilities in non-active markets        
  c)  Inputs other than quoted market prices that are observable          
  d)  Inputs that are derived principally from or corroborated by observable market data through correlation or other means.
                         
Level 3. Prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. They reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset or liability.
All investments in the Mutual Funds included in the Statements of Assets and Liabilities are stated at fair value and are based upon published closing NAV per share and therefore are considered Level 1.
There were no transfers between Level 1, Level 2 and Level 3 during the year ended December 31, 2025.
25

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
         
         
         
         
         
3. Investments         
         
The aggregate cost of purchases and proceeds from sales of investments for the period ended December 31, 2025 were as follows:         
         
Subaccount Purchases Sales
American Funds - Global Small Cap Class 2 Shares $ - $ -
American Funds - Growth Class 2 Shares   110,714   90,838
American Funds - International Class 2 Shares   55,929   72,552
American Funds - New World Class 2 Shares   432,428   218,631
Dimensional VA Global Bond   -   -
Dimensional VA International Small   399,957   990,082
Dimensional VA International Value   -   -
Dimensional VA Short-Term Fixed   -   -
Dimensional VA U.S. Large Value   258,717   129,126
Dimensional VA U.S. Targeted Value   7,791   1,432
DWS Equity 500 Index Class A Shares   -   -
DWS Small Cap Index Class A Shares   639,055   944,544
Fidelity® VIP Balanced Initial Class   528,185   283,243
Fidelity® VIP Contrafund® Initial Class   2,161,637   2,803,664
Fidelity® VIP Government Money Market Initial Class   76,082,985   68,259,061
Fidelity® VIP Growth Initial Class   957,160   492,791
Fidelity® VIP Growth Opportunities Initial Class   -   -
Fidelity® VIP High Income Initial Class   171,247   83,070
First Eagle Overseas Variable   24,578   3,128
Invesco V.I. American Franchise Series I Shares   -   -
Invesco V.I. American Value Series I Shares   -   -
Invesco V.I. Diversified Dividend Series I Shares   -   444,601
Invesco V.I. Health Care Series I Shares   21,790   19,547
Invesco V.I. Small Cap Equity Series I Shares   223,557   212,638
Invesco V.I. Technology Series I Shares   -   -
Janus Henderson - Balanced Institutional Shares   -   -
Janus Henderson - Enterprise Institutional Shares   -   -
Janus Henderson - Flexible Bond Institutional Shares   194,144   328
Janus Henderson - Forty Institutional Shares   -   -
Janus Henderson - Global Research Institutional Shares   -   -
Janus Henderson - Overseas Institutional Shares   -   -
Janus Henderson - Research Institutional Shares   -   -
Morningstar Aggressive Growth ETF Asset Allocation Class I Shares   -   -
Morningstar Balanced ETF Asset Allocation Class I Shares   -   -
Morningstar Conservative ETF Asset Allocation Class I Shares   -   -
Morningstar Growth ETF Asset Allocation Class I Shares   -   -
 
26

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
         
         
         
         
         
         
3. Investments (continued)         
         
         
Subaccount Purchases Sales
Morningstar Income and Growth ETF Asset Allocation Class I Shares   -   -
MS VIF Emerging Markets Debt Class I Shares $ - $ -
MS VIF Emerging Markets Equity Class I Shares   -   -
PIMCO All Asset Administrative Class   193,132   199,467
PIMCO All Asset Institutional Class   -   -
PIMCO High Yield Institutional Class   -   -
PIMCO Low Duration Institutional Class   -   -
PIMCO Real Return Institutional Class   2,384,106   27,380
PIMCO Short-Term Institutional Class   71,317   706,745
PIMCO Total Return Institutional Class   2,538,603   3,166,200
Royce Capital Micro Cap Investment Class   149,767   20,409
Royce Capital Small Cap Investment Class   -   -
Rydex NASDAQ-100®   -   -
Rydex VIT Nova   -   -
T. Rowe Price All-Cap Opportunities   -   -
T. Rowe Price Blue Chip Growth   60,880   97,726
T. Rowe Price Equity Income Service Class   25,089   31,839
T. Rowe Price International Stock   3,487,330   1,977,837
T. Rowe Price Limited-Term Bond   3,749   6,686
T. Rowe Price Mid-Cap Growth   2,060,867   1,098,312
Third Avenue FFI Strategies   -   -
Vanguard® Balanced   32,578,540   7,166,141
Vanguard® Capital Growth   2,762,104   26,297,735
Vanguard® Diversified Value   1   -
Vanguard® Equity Income   5,545,413   14,456,208
Vanguard® Equity Index   7,836,258   39,193,748
Vanguard® Growth   -   -
Vanguard® High Yield Bond   4,498,397   287,237
Vanguard® International   3,101,507   28,615,773
Vanguard® Mid-Cap Index   3,119,105   21,381,966
Vanguard® Money Market   66,133,904   776,850
Vanguard® Real Estate Index   632,443   7,717,678
Vanguard® Short-Term Investment Grade   15,250,337   2,324,543
Vanguard® Small Company Growth   2,971,488   17,675,372
Vanguard® Total Bond Market Index   19,501,259   467,665
Vanguard® Total Stock Market Index   11,606,832   330,452
 
27

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
               
4. Change in Units                
               
The change in units outstanding were as follows:               
  Year Ended December 31, 2025   Year Ended December 31, 2024
Subaccount Units Purchased Units Redeemed and Transferred to/from Net Increase (Decrease)   Units Purchased Units Redeemed and Transferred to/from Net Increase (Decrease)
American Funds - Global Small Cap Class 2 Shares - - -   - - -
American Funds - Growth Class 2 Shares 6,553 (7,515) (962)   18,589 (13,289) 5,300
American Funds - International Class 2 Shares 15,925 (20,925) (5,000)   19,903 (13,927) 5,976
American Funds - New World Class 2 Shares 77,699 (45,302) 32,397   38,326 (48,089) (9,763)
Dimensional VA Global Bond - - -   - - -
Dimensional VA International Small 54,078 (394,056) (339,978)   253,858 (194,586) 59,272
Dimensional VA International Value - - -   - - -
Dimensional VA Short-Term Fixed - - -   - - -
Dimensional VA U.S. Large Value 45,497 (30,883) 14,614   17,016 (46,121) (29,105)
Dimensional VA U.S. Targeted Value - (319) (319)   - (339) (339)
DWS Equity 500 Index Class A Shares - - -   - - -
DWS Small Cap Index Class A Shares 72,196 (160,300) (88,104)   156,272 (111,641) 44,631
Fidelity® VIP Balanced Initial Class 19,471 (48,541) (29,070)   234,781 (43,542) 191,239
Fidelity® VIP Contrafund® Initial Class 73,246 (274,233) (200,987)   117,570 (320,906) (203,336)
Fidelity® VIP Government Money Market Initial Class 45,272,244 (41,203,608) 4,068,636   5,643,576 (9,615,154) (3,971,578)
Fidelity® VIP Growth Initial Class 82,870 (70,156) 12,714   41,547 (89,179) (47,632)
Fidelity® VIP Growth Opportunities Initial Class - - -   - - -
Fidelity® VIP High Income Initial Class 56,288 (28,960) 27,328   121,702 (70,971) 50,731
First Eagle Overseas Variable - (592) (592)   - (630) (630)
Invesco V.I. American Franchise Series I Shares - - -   - - -
Invesco V.I. American Value Series I Shares - - -   - - -
Invesco V.I. Diversified Dividend Series I Shares - (116,416) (116,416)   - (1,244) (1,244)
Invesco V.I. Health Care Series I Shares 2,255 (3,819) (1,564)   942 (3,797) (2,855)
Invesco V.I. Small Cap Equity Series I Shares 51,531 (56,454) (4,923)   22,278 (56,228) (33,950)
Invesco V.I. Technology Series I Shares - - -   - - -
Janus Henderson - Balanced Institutional Shares - - -   - - -
Janus Henderson - Enterprise Institutional Shares - - -   - - -
 
28

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
               
               
               
4. Change in Units (continued)               
               
  Year Ended December 31, 2025   Year Ended December 31, 2024
Subaccount Units Purchased Units Redeemed and Transferred to/from Net Increase (Decrease)   Units Purchased Units Redeemed and Transferred to/from Net Increase (Decrease)
Janus Henderson - Flexible Bond Institutional Shares 62,480 (108) 62,372   19,563 (19,563) -
Janus Henderson - Forty Institutional Shares - - -   - - -
Janus Henderson - Global Research Institutional Shares - - -   - - -
Janus Henderson - Overseas Institutional Shares - - -   - - -
Janus Henderson - Research Institutional Shares - - -   - - -
Morningstar Aggressive Growth ETF Asset Allocation Class I Shares - - -   - - -
Morningstar Balanced ETF Asset Allocation Class I Shares - - -   - - -
Morningstar Conservative ETF Asset Allocation Class I Shares - - -   - - -
Morningstar Growth ETF Asset Allocation Class I Shares - - -   - - -
Morningstar Income and Growth ETF Asset Allocation Class I Shares - - -   - - -
MS VIF Emerging Markets Debt Class I Shares - - -   - - -
MS VIF Emerging Markets Equity Class I Shares - - -   - - -
PIMCO All Asset Administrative Class 55,810 (66,684) (10,874)   32,761 (99,732) (66,971)
PIMCO All Asset Institutional Class - - -   - - -
PIMCO High Yield Institutional Class - - -   - - -
PIMCO Low Duration Institutional Class - - -   - - -
PIMCO Real Return Institutional Class 1,046,037 (12,082) 1,033,955   2,157 (2,157) -
PIMCO Short-Term Institutional Class 14,640 (352,938) (338,298)   338,668 (105,239) 233,429
PIMCO Total Return Institutional Class 650,460 (1,044,352) (393,892)   1,081,596 (898,103) 183,493
Royce Capital Micro Cap Investment Class 20,763 (4,191) 16,572   2,691 (3,601) (910)
Royce Capital Small Cap Investment Class - - -   - - -
Rydex NASDAQ-100® - - -   - - -
Rydex VIT Nova - - -   - - -
T. Rowe Price All-Cap Opportunities - - -   - - -
T. Rowe Price Blue Chip Growth - (11,177) (11,177)   - (7,540) (7,540)
T. Rowe Price Equity Income Service Class 563 (4,971) (4,408)   9,190 (4,073) 5,117
T. Rowe Price International Stock - (823,014) (823,014)   - (1,892,381) (1,892,381)
 
29

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
               
               
               
4. Change in Units (continued)               
               
  Year Ended December 31, 2025   Year Ended December 31, 2024
Subaccount Units Purchased Units Redeemed and Transferred to/from Net Increase (Decrease)   Units Purchased Units Redeemed and Transferred to/from Net Increase (Decrease)
T. Rowe Price Limited-Term Bond - (4,103) (4,103)   - (56,335) (56,335)
T. Rowe Price Mid-Cap Growth 59,425 (111,032) (51,607)   156,054 (130,799) 25,255
Third Avenue FFI Strategies - - -   - - -
Vanguard® Balanced 4,238,163 (1,076,966) 3,161,197   2,386,750 (1,518,291) 868,459
Vanguard® Capital Growth 30,472 (1,670,908) (1,640,436)   48,699 (190,996) (142,297)
Vanguard® Diversified Value - - -   - - -
Vanguard® Equity Income 212,906 (1,857,519) (1,644,613)   425,658 (404,506) 21,152
Vanguard® Equity Index 403,258 (3,882,088) (3,478,830)   1,192,418 (2,706,833) (1,514,415)
Vanguard® Growth - - -   - - -
Vanguard® High Yield Bond 1,116,487 (70,314) 1,046,173   - (5,639) (5,639)
Vanguard® International 88,593 (3,737,275) (3,648,682)   204,314 (259,251) (54,937)
Vanguard® Mid-Cap Index 86,273 (2,021,046) (1,934,773)   100,916 (294,596) (193,680)
Vanguard® Money Market 42,645,649 (502,414) 42,143,235   - - -
Vanguard® Real Estate Index 14,891 (1,155,542) (1,140,651)   51,622 (61,544) (9,922)
Vanguard® Short-Term Investment Grade 7,240,808 (1,113,044) 6,127,764   329,955 (782,360) (452,405)
Vanguard® Small Company Growth 157,216 (2,015,621) (1,858,405)   47,836 (108,218) (60,382)
Vanguard® Total Bond Market Index 9,071,502 (217,238) 8,854,264   - (139,795) (139,795)
Vanguard® Total Stock Market Index 1,020,454 (28,589) 991,865   - (1,094) (1,094)
30

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
                           
                           
                           
4. Change in Unit Dollars (continued)                           
                           
    Year Ended December 31, 2025     Year Ended December 31, 2024
Subaccount   Units Purchased in Dollars   Units Redeemed and Transferred to/from in Dollars   Dollar Net Increase (Decrease)     Units Purchased  in Dollars   Units Redeemed and Transferred to/from in Dollars   Dollar Net Increase (Decrease)
American Funds - Global Small Cap Class 2 Shares $ - $ - $ -   $ - $ - $ -
American Funds - Growth Class 2 Shares   72,594   (90,838)   (18,244)     167,306   (126,573)   40,733
American Funds - International Class 2 Shares   49,944   (72,551)   (22,607)     58,766   (40,468)   18,298
American Funds - New World Class 2 Shares   392,988   (218,642)   174,346     159,005   (198,546)   (39,541)
Dimensional VA Global Bond   -   -   -     -   -   -
Dimensional VA International Small   137,753   (990,067)   (852,314)     568,862   (430,284)   138,578
Dimensional VA International Value   -   -   -     -   -   -
Dimensional VA Short-Term Fixed   -   -   -     -   -   -
Dimensional VA U.S. Large Value   180,572   (129,124)   51,448     61,472   (170,599)   (109,127)
Dimensional VA U.S. Targeted Value   -   (1,431)   (1,431)     -   (1,458)   (1,458)
DWS Equity 500 Index Class A Shares   -   -   -     -   -   -
DWS Small Cap Index Class A Shares   393,406   (944,551)   (551,145)     862,368   (587,655)   274,713
Fidelity® VIP Balanced Initial Class   105,989   (283,247)   (177,258)     1,201,189   (226,716)   974,473
Fidelity® VIP Contrafund® Initial Class   673,422   (2,803,638)   (2,130,216)     995,820   (2,524,439)   (1,528,619)
Fidelity® VIP Government Money Market Initial Class 74,670,252   (68,259,537)   6,410,715     8,694,827   (15,033,135)   (6,338,308)
Fidelity® VIP Growth Initial Class   601,433   (492,808)   108,625     275,469   (509,365)   (233,896)
Fidelity® VIP Growth Opportunities Initial Class   -   -   -     -   -   -
Fidelity® VIP High Income Initial Class   156,180   (83,070)   73,110     307,997   (189,133)   118,864
First Eagle Overseas Variable   -   (3,127)   (3,127)     -   (2,831)   (2,831)
Invesco V.I. American Franchise Series I Shares   -   -   -     -   -   -
Invesco V.I. American Value Series I Shares   -   -   -     -   -   -
Invesco V.I. Diversified Dividend Series I Shares   -   (444,602)   (444,602)     -   (4,069)   (4,069)
Invesco V.I. Health Care Series I Shares   11,539   (19,546)   (8,007)     4,968   (18,714)   (13,746)
Invesco V.I. Small Cap Equity Series I Shares   179,126   (212,640)   (33,514)     74,647   (200,425)   (125,778)
Invesco V.I. Technology Series I Shares   -   -   -     -   -   -
Janus Henderson - Balanced Institutional Shares   -   -   -     -   -   -
Janus Henderson - Enterprise Institutional Shares -   -   -     -   -   -
 
31

 
 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
                           
                           
                           
4. Change in Unit Dollars (continued)                           
                           
    Year Ended December 31, 2025     Year Ended December 31, 2024
Subaccount   Units Purchased in Dollars   Units Redeemed and Transferred to/from in Dollars   Dollar Net Increase (Decrease)     Units Purchased  in Dollars   Units Redeemed and Transferred to/from in Dollars   Dollar Net Increase (Decrease)
Janus Henderson - Flexible Bond Institutional Shares   189,206   (327)   188,879     54,526   (54,194)   332
Janus Henderson - Forty Institutional Shares $ - $ - $ -   $ - $ - $ -
Janus Henderson - Global Research Institutional Shares   -   -   -     -   -   -
Janus Henderson - Overseas Institutional Shares -   (1)   (1)     -   -   -
Janus Henderson - Research Institutional Shares   -   -   -     -   -   -
Morningstar Aggressive Growth ETF Asset Allocation Class I Shares   -   -   -     -   -   -
Morningstar Balanced ETF Asset Allocation Class I Shares   -   -   -     -   -   -
Morningstar Conservative ETF Asset Allocation Class I Shares   -   -   -     -   -   -
Morningstar Growth ETF Asset Allocation Class I Shares   -   -   -     -   -   -
Morningstar Income and Growth ETF Asset Allocation Class I Shares   -   -   -     -   -   -
MS VIF Emerging Markets Debt Class I Shares   -   -   -     -   -   -
MS VIF Emerging Markets Equity Class I Shares   -   -   -     -   -   -
PIMCO All Asset Administrative Class   169,305   (199,466)   (30,161)     90,215   (266,498)   (176,283)
PIMCO All Asset Institutional Class   -   -   -     -   -   -
PIMCO High Yield Institutional Class   -   -   -     -   -   -
PIMCO Low Duration Institutional Class   -   -   -     -   -   -
PIMCO Real Return Institutional Class   2,365,578   (27,384)   2,338,194     4,481   (4,465)   16
PIMCO Short-Term Institutional Class   29,660   (706,747)   (677,087)     665,957   (200,052)   465,905
PIMCO Total Return Institutional Class   2,009,558   (3,166,203)   (1,156,645)     3,205,014   (2,629,943)   575,071
Royce Capital Micro Cap Investment Class   102,396   (20,414)   81,982     12,305   (15,075)   (2,770)
Royce Capital Small Cap Investment Class   -   -   -     -   -   -
Rydex NASDAQ-100®   -   -   -     -   -   -
Rydex VIT Nova   -   -   -     -   -   -
T. Rowe Price All-Cap Opportunities   -   -   -     -   -   -
T. Rowe Price Blue Chip Growth   -   (97,722)   (97,722)     -   (54,221)   (54,221)
 
32

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
                           
                           
                           
4. Change in Unit Dollars (continued)                           
                           
    Year Ended December 31, 2025     Year Ended December 31, 2024
Subaccount   Units Purchased in Dollars   Units Redeemed and Transferred to/from in Dollars   Dollar Net Increase (Decrease)     Units Purchased  in Dollars   Units Redeemed and Transferred to/from in Dollars   Dollar Net Increase (Decrease)
T. Rowe Price Equity Income Service Class   3,526   (31,819)   (28,293)     57,134   (23,796)   33,338
T. Rowe Price International Stock   -   (1,977,739)   (1,977,739)     -   (4,097,469)   (4,097,469)
T. Rowe Price Limited-Term Bond $ - $ (6,691) $ (6,691)   $ - $ (88,118) $ (88,118)
T. Rowe Price Mid-Cap Growth   634,171   (1,098,307)   (464,136)     1,545,291   (1,283,857)   261,434
Third Avenue FFI Strategies   -   -   -     -   -   -
Vanguard® Balanced   28,563,254   (7,166,111)   21,397,143     14,083,229   (9,209,531)   4,873,698
Vanguard® Capital Growth   459,852   (26,297,774)   (25,837,922)     634,873   (2,472,238)   (1,837,365)
Vanguard® Diversified Value   -   (2)   (2)     -   (1)   (1)
Vanguard® Equity Income   1,620,879   (14,456,205)   (12,835,326)     2,836,977   (2,570,010)   266,967
Vanguard® Equity Index   3,474,000   (39,193,827)   (35,719,827)     9,186,001   (20,663,736)   (11,477,735)
Vanguard® Growth   -   -   -     -   -   -
Vanguard® High Yield Bond   4,497,048   (287,235)   4,209,813     -   (20,757)   (20,757)
Vanguard® International   616,793   (28,615,801)   (27,999,008)     1,260,602   (1,541,266)   (280,664)
Vanguard® Mid-Cap Index   831,083   (21,381,983)   (20,550,900)     897,504   (2,528,660)   (1,631,156)
Vanguard® Money Market   65,740,036   (776,837)   64,963,199     -   -   -
Vanguard® Real Estate Index   106,865   (7,717,673)   (7,610,808)     360,948   (401,860)   (40,912)
Vanguard® Short-Term Investment Grade   15,116,191   (2,324,518)   12,791,673     653,430   (1,521,991)   (868,561)
Vanguard® Small Company Growth   1,318,423   (17,675,377)   (16,356,954)     381,888   (818,707)   (436,819)
Vanguard® Total Bond Market Index   19,474,138   (467,677)   19,006,461     -   (285,581)   (285,581)
Vanguard® Total Stock Market Index   11,549,125   (330,461)   11,218,664     -   (9,702)   (9,702)
33

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights                                    
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
American Funds - Global Small Cap Class 2 Shares                                
    12/31/2025 - $4.36 to $4.36 $                         -   - % - % to - % 14.64 % to 14.64 %
    12/31/2024 - 3.80 to 3.80 -   -   -   to -   2.33   to 2.33  
    12/31/2023 - 3.71 to 3.71 -   -   -   to -   16.17   to 16.17  
    12/31/2022 - 3.20 to 3.20 -   -   -   to -   (29.55)   to (29.55)  
    12/31/2021 - 4.54 to 4.54 -   -   -   to -   6.74   to 6.74  
American Funds - Growth Class 2 Shares                                  
    12/31/2025 43,384 12.24 to 12.24 530,872   0.14   -   to -   20.23   to 20.23  
    12/31/2024 44,346 10.18 to 10.18 451,335   0.31   -   to -   31.63   to 31.63  
    12/31/2023 39,046 7.73 to 7.73 301,915   0.37   -   to -   38.48   to 38.48  
    12/31/2022 35,515 5.58 to 5.58 198,302   0.29   -   to -   (29.94)   to (29.94)  
    12/31/2021 41,936 7.97 to 7.97 334,205   0.27   -   to -   21.99   to 21.99  
American Funds - International Class 2 Shares                                
    12/31/2025 137,550 3.56 to 3.56 489,619   1.31   -   to -   26.77   to 26.77  
    12/31/2024 142,550 2.81 to 2.81 400,281   1.25   -   to -   3.16   to 3.16  
    12/31/2023 136,574 2.72 to 2.72 371,754   1.25   -   to -   15.84   to 15.84  
    12/31/2022 161,876 2.35 to 2.35 380,362   1.75   -   to -   (20.79)   to (20.79)  
    12/31/2021 149,402 2.97 to 2.97 443,165   2.30   -   to -   (1.50)   to (1.50)  
American Funds - New World Class 2 Shares                                
    12/31/2025 201,467 5.30 to 5.30 1,067,461   1.08   -   to -   28.30   to 28.30  
    12/31/2024 169,070 4.13 to 4.13 698,241   1.47   -   to -   6.56   to 6.56  
    12/31/2023 178,833 3.88 to 3.88 693,119   1.25   -   to -   16.00   to 16.00  
    12/31/2022 236,866 3.34 to 3.34 791,447   1.37   -   to -   (22.10)   to (22.10)  
    12/31/2021 226,310 4.29 to 4.29 970,647   0.70   -   to -   4.92   to 4.92  
Dimensional VA Global Bond                                  
    12/31/2025 - 1.81 to 1.57 -   -   -   to -   4.35   to 4.35  
    12/31/2024 - 1.73 to 1.50 -   -   -   to -   5.39   to 5.38  
    12/31/2023 - 1.64 to 1.43 -   -   -   to -   5.05   to 5.05  
    12/31/2022 - 1.56 to 1.36 -   -   -   to -   (6.33)   to (6.33)  
    12/31/2021 - 1.67 to 1.45 -   -   -   to -   (1.04)   to (1.04)  
Dimensional VA International Small                                  
    12/31/2025 1,252,737 3.05 to 3.05 3,815,831   3.32   -   to -   36.99   to 36.99  
    12/31/2024 1,592,715 2.22 to 2.22 3,541,502   3.68   -   to -   3.82   to 3.82  
    12/31/2023 1,533,443 2.14 to 2.14 3,284,341   3.01   -   to -   14.11   to 14.11  
    12/31/2022 1,553,938 1.88 to 1.88 2,916,669   2.41   -   to -   (17.64)   to (17.64)  
    12/31/2021 1,718,174 2.28 to 2.28 3,915,809   2.45   -   to -   14.56   to 14.56  
Dimensional VA International Value                                  
    12/31/2025 - 2.36 to 2.36 -   -   -   to -   45.64   to 45.64  
    12/31/2024 - 1.62 to 1.62 -   -   -   to -   6.62   to 6.62  
    12/31/2023 - 1.52 to 1.52 -   -   -   to -   17.86   to 17.86  
    12/31/2022 - 1.29 to 1.29 -   -   -   to -   (3.46)   to (3.46)  
    12/31/2021 - 1.34 to 1.34 -   -   -   to -   18.11   to 18.11  
Dimensional VA Short-Term Fixed                                  
    12/31/2025 - 1.31 to 1.31 -   -   -   to -   4.33   to 4.33  
    12/31/2024 - 1.26 to 1.26 -   -   -   to -   5.48   to 5.48  
    12/31/2023 - 1.19 to 1.19 -   -   -   to -   4.98   to 4.98  
    12/31/2022 - 1.14 to 1.14 -   -   -   to -   (1.16)   to (1.16)  
    12/31/2021 - 1.15 to 1.15 -   -   -   to -   (0.19)   to (0.19)  
34

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
Dimensional VA U.S. Large Value                                  
    12/31/2025 231,596 $4.46 to $4.46 $       1,033,773   1.96 % - % to - % 15.83 % to 15.83 %
    12/31/2024 216,982 3.85 to 3.85 836,195   1.93   -   to -   13.38   to 13.38  
    12/31/2023 246,087 3.40 to 3.40 836,413   1.98   -   to -   10.92   to 10.92  
    12/31/2022 299,742 3.06 to 3.06 918,466   2.28   -   to -   (4.88)   to (4.88)  
    12/31/2021 256,906 3.22 to 3.22 827,581   1.62   -   to -   27.04   to 27.04  
Dimensional VA U.S. Targeted Value                                  
    12/31/2025 16,385 4.97 to 4.97 81,366   1.87   -   to -   8.94   to 8.94  
    12/31/2024 16,704 4.56 to 4.56 76,137   1.43   -   to -   8.14   to 8.14  
    12/31/2023 17,043 4.22 to 4.22 71,839   1.61   -   to -   20.03   to 20.03  
    12/31/2022 17,472 3.51 to 3.51 61,356   1.32   -   to -   (4.21)   to (4.21)  
    12/31/2021 17,882 3.67 to 3.67 65,558   1.44   -   to -   39.68   to 39.68  
DWS Equity 500 Index Class A Shares                                  
    12/31/2025 - 7.19 to 7.19 -   -   -   to -   17.63   to 17.63  
    12/31/2024 - 6.11 to 6.11 -   -   -   to -   24.63   to 24.63  
    12/31/2023 - 4.90 to 4.90 -   -   -   to -   26.00   to 26.00  
    12/31/2022 - 3.89 to 3.89 -   -   -   to -   (18.34)   to (18.34)  
    12/31/2021 - 4.76 to 4.76 -   -   -   to -   28.40   to 28.40  
DWS Small Cap Index Class A Shares                                  
    12/31/2025 539,858 6.55 to 6.55 3,536,054   1.41   -   to -   12.64   to 12.64  
    12/31/2024 627,962 5.82 to 5.82 3,651,725   1.06   -   to -   11.15   to 11.15  
    12/31/2023 583,331 5.23 to 5.23 3,051,842   1.02   -   to -   16.76   to 16.76  
    12/31/2022 533,162 4.48 to 4.48 2,389,023   0.92   -   to -   (20.64)   to (20.64)  
    12/31/2021 672,869 5.65 to 5.65 3,798,985   0.82   -   to -   14.50   to 14.50  
Fidelity® VIP Balanced Initial Class                                  
    12/31/2025 1,074,774 6.41 to 6.41 6,888,416   1.76   -   to -   15.20   to 15.20  
    12/31/2024 1,103,844 5.56 to 5.56 6,141,013   1.89   -   to -   15.92   to 15.92  
    12/31/2023 912,605 4.80 to 4.80 4,379,804   1.83   -   to -   21.53   to 21.53  
    12/31/2022 688,338 3.95 to 3.95 2,718,279   1.27   -   to -   (17.94)   to (17.94)  
    12/31/2021 734,590 4.81 to 4.81 3,535,167   1.30   -   to -   18.26   to 18.26  
Fidelity® VIP Contrafund® Initial Class                                  
    12/31/2025 857,169 14.96 to 11.54 9,891,156   0.13   -   to -   21.48   to 21.48  
    12/31/2024 1,058,156 12.32 to 9.50 10,051,335   0.19   -   to -   33.79   to 33.79  
    12/31/2023 1,261,492 9.20 to 7.10 8,956,346   0.50   -   to -   33.45   to 33.45  
    12/31/2022 1,288,490 6.90 to 5.32 6,854,975   0.51   -   to -   (26.31)   to (26.31)  
    12/31/2021 1,232,105 9.36 to 7.22 8,895,680   0.06   -   to -   27.83   to 27.83  
Fidelity® VIP Government Money Market Initial Class                              
    12/31/2025 19,698,054 1.67 to 1.67 32,864,588   3.99   -   to -   4.13   to 4.13  
    12/31/2024 15,629,418 1.60 to 1.60 25,041,141   5.01   -   to -   5.10   to 5.10  
    12/31/2023 19,600,996 1.52 to 1.52 29,879,092   4.79   -   to -   4.89   to 4.89  
    12/31/2022 16,866,365 1.45 to 1.45 24,512,866   1.33   -   to -   1.44   to 1.44  
    12/31/2021 21,181,394 1.43 to 1.43 30,348,236   0.01   -   to -   -   to -  
Fidelity® VIP Growth Initial Class                                  
    12/31/2025 357,982 8.07 to 8.07 2,888,365   0.31   -   to -   14.90   to 14.90  
    12/31/2024 345,268 7.02 to 7.02 2,424,562   0.00   -   to -   30.39   to 30.39  
    12/31/2023 392,900 5.39 to 5.39 2,115,999   0.15   -   to -   36.24   to 36.24  
    12/31/2022 347,284 3.95 to 3.95 1,372,860   0.63   -   to -   (24.46)   to (24.46)  
    12/31/2021 319,792 5.23 to 5.23 1,673,441   -   -   to -   23.21   to 23.21  
35

 
 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
Fidelity® VIP Growth Opportunities Initial Class                                
    12/31/2025 - $11.11 to $11.11 $                         -   - % - % to - % 21.95 % to 21.95 %
    12/31/2024 - 9.11 to 9.11 -   -   -   to -   38.89   to 38.89  
    12/31/2023 - 6.56 to 6.56 -   -   -   to -   45.65   to 45.65  
    12/31/2022 - 4.50 to 4.50 -   -   -   to -   (38.15)   to (38.15)  
    12/31/2021 - 7.28 to 7.28 -   -   -   to -   11.94   to 11.94  
Fidelity® VIP High Income Initial Class                                  
    12/31/2025 78,059 3.05 to 3.05 238,021   5.90   -   to -   10.36   to 10.36  
    12/31/2024 50,731 2.76 to 2.76 140,168   4.16   -   to -   8.97   to 8.97  
    12/31/2023 - 2.54 to 2.54 -   0.11   -   to -   10.48   to 10.48  
    12/31/2022 31,219 2.30 to 2.30 71,649   3.26   -   to -   (11.37)   to (11.37)  
    12/31/2021 122,745 2.59 to 2.59 317,859   5.44   -   to -   4.41   to 4.41  
First Eagle Overseas Variable                                  
    12/31/2025 30,429 9.38 to 6.20 188,520   1.81   -   to -   37.47   to 37.47  
    12/31/2024 31,021 6.82 to 4.51 139,806   1.76   -   to -   6.10   to 6.10  
    12/31/2023 31,651 6.43 to 4.25 134,452   -   -   to -   10.08   to 10.08  
    12/31/2022 32,448 5.84 to 3.86 125,220   2.13   -   to -   (8.17)   to (8.17)  
    12/31/2021 33,210 6.36 to 4.20 139,554   0.93   -   to -   4.44   to 4.44  
Invesco V.I. American Franchise Series I Shares                                
    12/31/2025 - 6.22 to 6.22 -   -   -   to -   11.66   to 11.66  
    12/31/2024 - 5.57 to 5.57 -   -   -   to -   34.89   to 34.89  
    12/31/2023 - 4.13 to 4.13 -   -   -   to -   40.93   to 40.93  
    12/31/2022 - 2.93 to 2.93 -   -   -   to -   (31.11)   to (31.11)  
    12/31/2021 - 4.25 to 4.25 -   -   -   to -   11.93   to 11.93  
Invesco V.I. American Value Series I Shares                                
    12/31/2025 - 8.32 to 8.32 -   -   -   to -   21.00   to 21.00  
    12/31/2024 - 6.88 to 6.88 -   -   -   to -   30.41   to 30.41  
    12/31/2023 - 5.27 to 5.27 -   -   -   to -   15.60   to 15.60  
    12/31/2022 - 4.56 to 4.56 -   -   -   to -   (2.61)   to (2.61)  
    12/31/2021 - 4.68 to 4.68 -   -   -   to -   27.95   to 27.95  
Invesco V.I. Diversified Dividend Series I Shares                                
    12/31/2025 - 3.99 to 3.99 -   -   -   to -   15.74   to 15.74  
    12/31/2024 116,416 3.44 to 3.44 401,003   1.92   -   to -   13.22   to 13.22  
    12/31/2023 117,660 3.04 to 3.04 357,977   2.04   -   to -   9.04   to 9.04  
    12/31/2022 119,001 2.79 to 2.79 332,025   1.90   -   to -   (1.68)   to (1.68)  
    12/31/2021 120,333 2.84 to 2.84 341,478   2.19   -   to -   18.89   to 18.89  
Invesco V.I. Health Care Series I Shares                                  
    12/31/2025 46,146 5.77 to 5.77 266,417   -   -   to -   15.33   to 15.33  
    12/31/2024 47,710 5.01 to 5.01 238,840   -   -   to -   4.17   to 4.17  
    12/31/2023 50,565 4.81 to 4.81 243,002   -   -   to -   3.02   to 3.02  
    12/31/2022 37,104 4.66 to 4.66 173,083   -   -   to -   (13.32)   to (13.32)  
    12/31/2021 27,602 5.38 to 5.38 148,537   0.21   -   to -   12.30   to 12.30  
Invesco V.I. Small Cap Equity Series I Shares                                
    12/31/2025 257,343 4.00 to 4.00 1,029,084   -   -   to -   8.05   to 8.05  
    12/31/2024 262,266 3.70 to 3.70 970,666   0.13   -   to -   18.09   to 18.09  
    12/31/2023 296,216 3.13 to 3.13 928,366   -   -   to -   16.57   to 16.57  
    12/31/2022 271,745 2.69 to 2.69 730,582   -   -   to -   (20.51)   to (20.51)  
    12/31/2021 270,775 3.38 to 3.38 915,766   0.17   -   to -   20.40   to 20.40  
36

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
Invesco V.I. Technology Series I Shares                                  
    12/31/2025 - $3.06 to $3.06 $                         -   - % - % to - % 20.47 % to 20.47 %
    12/31/2024 - 2.54 to 2.54 -   -   -   to -   34.27   to 34.27  
    12/31/2023 - 1.89 to 1.89 -   -   -   to -   46.94   to 46.94  
    12/31/2022 - 1.29 to 1.29 -   -   -   to -   (39.95)   to (39.95)  
    12/31/2021 - 2.14 to 2.14 -   -   -   to -   14.41   to 14.41  
Janus Henderson - Balanced Institutional Shares                                
    12/31/2025 - 7.33 to 7.33 -   -   -   to -   15.11   to 15.11  
    12/31/2024 - 6.37 to 6.37 -   -   -   to -   15.43   to 15.43  
    12/31/2023 - 5.52 to 5.52 -   -   -   to -   15.41   to 15.41  
    12/31/2022 - 4.78 to 4.78 -   -   -   to -   (16.40)   to (16.40)  
    12/31/2021 - 5.72 to 5.72 -   -   -   to -   17.20   to 17.20  
Janus Henderson - Enterprise Institutional Shares                                
    12/31/2025 - 14.97 to 6.46 -   -   -   to -   7.67   to 7.67  
    12/31/2024 - 13.91 to 6.00 -   -   -   to -   15.61   to 15.61  
    12/31/2023 - 12.03 to 5.19 -   -   -   to -   18.07   to 18.07  
    12/31/2022 - 10.19 to 4.39 -   -   -   to -   (15.94)   to (15.94)  
    12/31/2021 - 12.12 to 5.23 -   -   -   to -   16.83   to 16.83  
Janus Henderson - Flexible Bond Institutional Shares                              
    12/31/2025 62,372 3.04 to 2.64 189,732   15.52   -   to -   7.40   to 7.40  
    12/31/2024 - 2.83 to 2.46 -   -   -   to -   1.96   to 1.96  
    12/31/2023 - 2.78 to 2.41 -   -   -   to -   5.50   to 5.50  
    12/31/2022 35,192 2.63 to 2.29 92,663   2.25   -   to -   (13.66)   to (13.66)  
    12/31/2021 31,671 3.05 to 2.65 96,583   1.78   -   to -   (0.90)   to (0.90)  
Janus Henderson - Forty Institutional Shares                                
    12/31/2025 - 16.84 to 9.83 -   -   -   to -   18.14   to 18.14  
    12/31/2024 - 14.25 to 8.32 -   -   -   to -   28.47   to 28.47  
    12/31/2023 - 11.09 to 6.48 -   -   -   to -   39.96   to 39.96  
    12/31/2022 - 7.93 to 4.63 -   -   -   to -   (33.55)   to (33.55)  
    12/31/2021 - 11.93 to 6.96 -   -   -   to -   22.90   to 22.90  
Janus Henderson - Global Research Institutional Shares                            
    12/31/2025 - 6.86 to 3.74 -   -   -   to -   20.92   to 20.92  
    12/31/2024 - 5.67 to 3.09 -   -   -   to -   23.58   to 23.58  
    12/31/2023 - 4.59 to 2.50 -   -   -   to -   26.78   to 26.78  
    12/31/2022 - 3.62 to 1.97 -   -   -   to -   (19.41)   to (19.41)  
    12/31/2021 - 4.49 to 2.45 -   -   -   to -   18.09   to 18.09  
Janus Henderson - Overseas Institutional Shares                                
    12/31/2025 - 6.74 to 4.09 -   -   -   to -   28.87   to 28.87  
    12/31/2024 - 5.23 to 3.17 -   -   -   to -   5.84   to 5.84  
    12/31/2023 - 4.94 to 3.00 -   -   -   to -   10.87   to 10.87  
    12/31/2022 - 4.45 to 2.70 -   -   -   to -   (8.60)   to (8.60)  
    12/31/2021 - 4.87 to 2.96 -   -   -   to -   13.58   to 13.58  
Janus Henderson - Research Institutional Shares                                
    12/31/2025 - 6.38 to 6.38 -   -   -   to -   18.39   to 18.39  
    12/31/2024 - 5.39 to 5.39 -   -   -   to -   35.31   to 35.31  
    12/31/2023 - 3.98 to 3.98 -   -   -   to -   43.17   to 43.17  
    12/31/2022 - 2.78 to 2.78 -   -   -   to -   (29.89)   to (29.89)  
    12/31/2021 - 3.97 to 3.97 -   -   -   to -   20.33   to 20.33  
37

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
Morningstar Aggressive Growth ETF Asset Allocation Class I Shares                          
    12/31/2025 - $3.50 to $3.50 $                         -   - % - % to - % 20.33 % to 20.33 %
    12/31/2024 - 2.91 to 2.91 -   -   -   to -   14.85   to 14.85  
    12/31/2023 - 2.53 to 2.53 -   -   -   to -   17.10   to 17.10  
    12/31/2022 - 2.16 to 2.16 -   -   -   to -   (12.92)   to (12.92)  
    12/31/2021 - 2.48 to 2.48 -   -   -   to -   18.60   to 18.60  
Morningstar Balanced ETF Asset Allocation Class I Shares                            
    12/31/2025 - 2.70 to 2.70 -   -   -   to -   15.07   to 15.07  
    12/31/2024 - 2.34 to 2.34 -   -   -   to -   10.50   to 10.50  
    12/31/2023 - 2.12 to 2.12 -   -   -   to -   13.11   to 13.11  
    12/31/2022 - 1.88 to 1.88 -   -   -   to -   (12.60)   to (12.60)  
    12/31/2021 - 2.15 to 2.15 -   -   -   to -   11.00   to 11.00  
                                         
Morningstar Conservative ETF Asset Allocation Class I Shares                            
    12/31/2025 - 1.79 to 1.79 -   -   -   to -   9.11   to 9.11  
    12/31/2024 - 1.64 to 1.64 -   -   -   to -   5.51   to 5.51  
    12/31/2023 - 1.55 to 1.55 -   -   -   to -   8.19   to 8.19  
    12/31/2022 - 1.44 to 1.44 -   -   -   to -   (11.61)   to (11.61)  
    12/31/2021 - 1.62 to 1.62 -   -   -   to -   2.51   to 2.51  
Morningstar Growth ETF Asset Allocation Class I Shares                            
    12/31/2025 - 3.17 to 3.17 -   -   -   to -   18.15   to 18.15  
    12/31/2024 - 2.69 to 2.69 -   -   -   to -   12.88   to 12.88  
    12/31/2023 - 2.38 to 2.38 -   -   -   to -   15.61   to 15.61  
    12/31/2022 - 2.06 to 2.06 -   -   -   to -   (12.96)   to (12.96)  
    12/31/2021 - 2.36 to 2.36 -   -   -   to -   15.09   to 15.09  
Morningstar Income and Growth ETF Asset Allocation Class I Shares                          
    12/31/2025 - 2.22 to 2.22 -   -   -   to -   11.93   to 11.93  
    12/31/2024 - 1.98 to 1.98 -   -   -   to -   8.20   to 8.20  
    12/31/2023 - 1.83 to 1.83 -   -   -   to -   10.99   to 10.99  
    12/31/2022 - 1.65 to 1.65 -   -   -   to -   (12.31)   to (12.31)  
    12/31/2021 - 1.88 to 1.88 -   -   -   to -   6.66   to 6.66  
MS VIF Emerging Markets Debt Class I Shares                                
    12/31/2025 - 5.05 to 5.05 -   -   -   to -   15.33   to 15.33  
    12/31/2024 - 4.38 to 4.38 -   -   -   to -   11.23   to 11.23  
    12/31/2023 - 3.94 to 3.94 -   -   -   to -   11.84   to 11.84  
    12/31/2022 - 3.52 to 3.52 -   -   -   to -   (18.74)   to (18.74)  
    12/31/2021 - 4.33 to 4.33 -   -   -   to -   (2.02)   to (2.02)  
MS VIF Emerging Markets Equity Class I Shares                                
    12/31/2025 - 5.41 to 5.41 -   -   -   to -   32.96   to 32.96  
    12/31/2024 - 4.07 to 4.07 -   -   -   to -   7.82   to 7.82  
    12/31/2023 - 3.77 to 3.77 -   -   -   to -   11.97   to 11.97  
    12/31/2022 - 3.37 to 3.37 -   -   -   to -   (25.08)   to (25.08)  
    12/31/2021 - 4.50 to 4.50 -   -   -   to -   2.99   to 2.99  
PIMCO All Asset Administrative Class                                  
    12/31/2025 179,956 3.14 to 3.14 564,558   4.44   -   to -   14.20   to 14.20  
    12/31/2024 190,830 2.75 to 2.75 524,215   6.38   -   to -   3.74   to 3.74  
    12/31/2023 257,801 2.65 to 2.65 682,626   3.05   -   to -   8.14   to 8.14  
    12/31/2022 261,487 2.45 to 2.45 640,259   7.80   -   to -   (11.84)   to (11.84)  
    12/31/2021 306,308 2.78 to 2.78 850,772   10.80   -   to -   16.23   to 16.23  
38

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
PIMCO All Asset Institutional Class                                  
    12/31/2025 - $2.57 to $2.57 $                         -   - % - % to - % 14.34 % to 14.34 %
    12/31/2024 - 2.25 to 2.25 -   -   -   to -   3.95   to 3.95  
    12/31/2023 - 2.16 to 2.16 -   -   -   to -   8.28   to 8.28  
    12/31/2022 - 2.00 to 2.00 -   -   -   to -   (11.66)   to (11.66)  
    12/31/2021 - 2.26 to 2.26 -   -   -   to -   16.41   to 16.41  
PIMCO High Yield Institutional Class                                  
    12/31/2025 - 4.63 to 4.63 -   -   -   to -   9.12   to 9.12  
    12/31/2024 - 4.24 to 4.24 -   -   -   to -   7.05   to 7.05  
    12/31/2023 - 3.96 to 3.96 -   -   -   to -   12.38   to 12.38  
    12/31/2022 - 3.53 to 3.53 -   -   -   to -   (10.15)   to (10.15)  
    12/31/2021 - 3.93 to 3.93 -   -   -   to -   3.79   to 3.79  
PIMCO Low Duration Institutional Class                                  
    12/31/2025 - 1.76 to 1.76 -   -   -   to -   5.68   to 5.68  
    12/31/2024 - 1.67 to 1.67 -   -   -   to -   4.65   to 4.65  
    12/31/2023 - 1.59 to 1.59 -   -   -   to -   5.13   to 5.13  
    12/31/2022 - 1.52 to 1.52 -   -   -   to -   (5.60)   to (5.60)  
    12/31/2021 - 1.61 to 1.61 -   -   -   to -   (0.78)   to (0.78)  
PIMCO Real Return Institutional Class                                  
    12/31/2025 1,033,955 2.26 to 2.26 2,339,317   3.42   -   to -   8.01   to 8.01  
    12/31/2024 - 2.09 to 2.09 -   5.63   -   to -   2.28   to 2.28  
    12/31/2023 - 2.05 to 2.05 -   -   -   to -   3.83   to 3.83  
    12/31/2022 - 1.97 to 1.97 -   -   -   to -   (11.77)   to (11.77)  
    12/31/2021 - 2.24 to 2.24 -   -   -   to -   5.74   to 5.74  
PIMCO Short-Term Institutional Class                                  
    12/31/2025 433,869 2.10 to 1.78 909,445   4.64   -   to -   4.83   to 4.83  
    12/31/2024 772,167 2.00 to 1.70 1,544,020   5.12   -   to -   6.21   to 6.21  
    12/31/2023 538,738 1.88 to 1.60 1,014,262   4.66   -   to -   6.06   to 6.06  
    12/31/2022 498,408 1.78 to 1.51 884,692   3.96   -   to -   (0.00)   to (0.00)  
    12/31/2021 - 1.78 to 1.51 -   -   -   to -   0.09   to 0.09  
PIMCO Total Return Institutional Class                                  
    12/31/2025 4,056,661 3.25 to 2.64 13,188,222   4.25   -   to -   9.05   to 9.05  
    12/31/2024 4,450,553 2.98 to 2.42 13,267,855   4.19   -   to -   2.69   to 2.69  
    12/31/2023 4,267,060 2.90 to 2.36 12,387,963   3.71   -   to -   6.09   to 6.09  
    12/31/2022 4,398,730 2.74 to 2.22 12,037,116   2.78   -   to -   (14.17)   to (14.17)  
    12/31/2021 4,113,788 3.19 to 2.59 13,115,951   1.97   -   to -   (1.12)   to (1.12)  
Royce Capital Micro Cap Investment Class                                
    12/31/2025 57,445 6.43 to 5.56 319,137   -   -   to -   13.89   to 13.89  
    12/31/2024 40,873 5.64 to 4.88 199,378   -   -   to -   13.67   to 13.67  
    12/31/2023 41,783 4.96 to 4.29 179,302   -   -   to -   18.78   to 18.78  
    12/31/2022 41,852 4.18 to 3.61 151,200   -   -   to -   (22.43)   to (22.43)  
    12/31/2021 37,538 5.39 to 4.66 174,840   -   -   to -   29.98   to 29.98  
Royce Capital Small Cap Investment Class                                
    12/31/2025 - 5.56 to 5.56 -   -   -   to -   8.93   to 8.93  
    12/31/2024 - 5.10 to 5.10 -   -   -   to -   3.40   to 3.40  
    12/31/2023 - 4.94 to 4.94 -   -   -   to -   25.93   to 25.93  
    12/31/2022 - 3.92 to 3.92 -   -   -   to -   (9.20)   to (9.20)  
    12/31/2021 - 4.32 to 4.32 -   -   -   to -   28.82   to 28.82  
39

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
Rydex NASDAQ-100®                                    
    12/31/2025 - $20.64 to $20.64 $                         -   - % - % to - % 19.04 % to 19.04 %
    12/31/2024 - 17.34 to 17.34 -   -   -   to -   23.91   to 23.91  
    12/31/2023 - 14.00 to 14.00 -   -   -   to -   53.22   to 53.22  
    12/31/2022 - 9.13 to 9.13 -   -   -   to -   (34.14)   to (34.14)  
    12/31/2021 - 13.87 to 13.87 -   -   -   to -   25.54   to 25.54  
Rydex VIT Nova                                    
    12/31/2025 - 14.69 to 14.69 -   -   -   to -   20.86   to 20.86  
    12/31/2024 - 12.15 to 12.15 -   -   -   to -   32.76   to 32.76  
    12/31/2023 - 9.16 to 9.16 -   -   -   to -   35.07   to 35.07  
    12/31/2022 - 6.78 to 6.78 -   -   -   to -   (30.26)   to (30.26)  
    12/31/2021 - 9.72 to 9.72 -   -   -   to -   42.18   to 42.18  
T. Rowe Price All-Cap Opportunities                                  
    12/31/2025 - 10.80 to 10.80 -   -   -   to -   16.30   to 16.30  
    12/31/2024 - 9.29 to 9.29 -   -   -   to -   25.16   to 25.16  
    12/31/2023 - 7.42 to 7.42 -   -   -   to -   28.96   to 28.96  
    12/31/2022 - 5.75 to 5.75 -   -   -   to -   (21.51)   to (21.51)  
    12/31/2021 - 7.33 to 7.33 -   -   -   to -   20.80   to 20.80  
T. Rowe Price Blue Chip Growth                                  
    12/31/2025 72,884 10.02 to 10.02 730,153   -   -   to -   18.74   to 18.74  
    12/31/2024 84,061 8.44 to 8.44 709,243   -   -   to -   35.51   to 35.51  
    12/31/2023 91,601 6.23 to 6.23 570,327   -   -   to -   49.29   to 49.29  
    12/31/2022 114,228 4.17 to 4.17 476,396   -   -   to -   (38.50)   to (38.50)  
    12/31/2021 161,461 6.78 to 6.78 1,094,965   -   -   to -   17.62   to 17.62  
T. Rowe Price Equity Income Service Class                                
    12/31/2025 27,695 7.02 to 6.84 194,535   1.62   -   to -   14.36   to 14.36  
    12/31/2024 32,103 6.14 to 5.98 197,177   1.96   -   to -   11.70   to 11.70  
    12/31/2023 26,986 5.50 to 5.35 148,389   2.02   -   to -   9.54   to 9.54  
    12/31/2022 38,806 5.02 to 4.89 194,798   1.95   -   to -   (3.34)   to (3.34)  
    12/31/2021 34,570 5.19 to 5.06 179,535   1.53   -   to -   25.55   to 25.55  
T. Rowe Price International Stock                                  
    12/31/2025 13,631,095 2.54 to 2.54 34,633,832   1.93   -   to -   18.41   to 18.41  
    12/31/2024 14,454,109 2.15 to 2.15 31,014,311   0.90   -   to -   3.25   to 3.25  
    12/31/2023 16,346,490 2.08 to 2.08 33,970,115   0.97   -   to -   16.24   to 16.24  
    12/31/2022 17,047,384 1.79 to 1.79 30,477,553   0.75   -   to -   (15.81)   to (15.81)  
    12/31/2021 19,452,629 2.12 to 2.12 41,310,595   0.60   -   to -   1.32   to 1.32  
T. Rowe Price Limited-Term Bond                                  
    12/31/2025 51,912 1.71 to 1.71 88,695   4.30   -   to -   5.71   to 5.71  
    12/31/2024 56,015 1.62 to 1.62 90,533   4.19   -   to -   4.96   to 4.96  
    12/31/2023 112,350 1.54 to 1.54 172,998   3.32   -   to -   4.94   to 4.94  
    12/31/2022 113,982 1.47 to 1.47 167,249   1.56   -   to -   (4.52)   to (4.52)  
    12/31/2021 643,869 1.54 to 1.54 989,456   1.41   -   to -   0.13   to 0.13  
T. Rowe Price Mid-Cap Growth                                  
    12/31/2025 1,062,132 12.01 to 10.64 11,303,300   -   -   to -   3.55   to 3.55  
    12/31/2024 1,113,739 11.60 to 10.28 11,446,670   -   -   to -   9.32   to 9.32  
    12/31/2023 1,088,484 10.61 to 9.40 10,233,564   -   -   to -   19.96   to 19.96  
    12/31/2022 1,101,070 8.84 to 7.84 8,629,526   -   -   to -   (22.58)   to (22.58)  
    12/31/2021 980,406 11.42 to 10.12 9,924,858   -   -   to -   14.85   to 14.85  
40

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
Third Avenue FFI Strategies                                  
    12/31/2025 - $5.38 to $4.03 $                         -   - % - % to - % 34.85 % to 34.85 %
    12/31/2024 - 3.99 to 2.99 -   -   -   to -   (2.27)   to (2.27)  
    12/31/2023 - 4.08 to 3.06 -   -   -   to -   20.81   to 20.81  
    12/31/2022 - 3.38 to 2.53 -   -   -   to -   16.11   to 16.11  
    12/31/2021 - 2.91 to 2.18 -   -   -   to -   22.07   to 22.07  
Vanguard® Balanced                                    
    12/31/2025 6,961,741 7.42 to 7.29 51,436,769   1.91   -   to -   16.46   to 16.46  
    12/31/2024 3,800,544 6.37 to 6.26 24,212,349   2.21   -   to -   14.80   to 14.80  
    12/31/2023 2,932,085 5.55 to 5.46 16,271,047   2.53   -   to -   14.33   to 14.33  
    12/31/2022 2,356,383 4.85 to 4.77 11,437,788   1.95   -   to -   (14.30)   to (14.30)  
    12/31/2021 2,454,432 5.66 to 5.57 13,901,955   2.07   -   to -   19.02   to 19.02  
Vanguard® Capital Growth                                  
    12/31/2025 1,397,184 16.99 to 16.99 23,734,485   1.17   -   to -   28.98   to 28.98  
    12/31/2024 3,037,620 13.17 to 13.17 40,007,815   1.11   -   to -   13.41   to 13.41  
    12/31/2023 3,179,917 11.61 to 11.61 36,929,314   1.05   -   to -   27.98   to 27.98  
    12/31/2022 3,271,756 9.07 to 9.07 29,688,556   0.88   -   to -   (15.48)   to (15.48)  
    12/31/2021 3,444,036 10.74 to 10.74 36,977,837   0.97   -   to -   21.54   to 21.54  
Vanguard® Diversified Value                                  
    12/31/2025 - 9.08 to 8.30 -   -   -   to -   16.83   to 16.83  
    12/31/2024 - 7.77 to 7.10 -   -   -   to -   14.89   to 14.89  
    12/31/2023 - 6.76 to 6.18 -   -   -   to -   20.13   to 20.13  
    12/31/2022 - 5.63 to 5.15 -   -   -   to -   (11.49)   to (11.49)  
    12/31/2021 - 6.36 to 5.81 -   -   -   to -   30.47   to 30.47  
Vanguard® Equity Income                                  
    12/31/2025 3,860,982 8.15 to 8.15 31,483,535   2.64   -   to -   16.80   to 16.80  
    12/31/2024 5,505,595 6.98 to 6.98 38,437,595   2.78   -   to -   15.12   to 15.12  
    12/31/2023 5,484,443 6.06 to 6.06 33,260,560   2.63   -   to -   8.10   to 8.10  
    12/31/2022 5,899,850 5.61 to 5.61 33,099,369   2.50   -   to -   (0.66)   to (0.66)  
    12/31/2021 6,959,127 5.65 to 5.65 39,302,149   2.06   -   to -   25.33   to 25.33  
Vanguard® Equity Index                                  
    12/31/2025 12,496,939 11.36 to 9.85 127,842,323   1.11   -   to -   17.70   to 17.70  
    12/31/2024 15,975,769 9.65 to 8.37 140,630,544   1.30   -   to -   24.84   to 24.84  
    12/31/2023 17,490,184 7.73 to 6.70 122,850,765   1.41   -   to -   26.11   to 26.11  
    12/31/2022 18,702,827 6.13 to 5.31 103,898,681   1.33   -   to -   (18.23)   to (18.23)  
    12/31/2021 18,433,607 7.50 to 6.50 125,360,961   1.21   -   to -   28.55   to 28.55  
Vanguard® Growth                                    
    12/31/2025 - 9.62 to 9.62 -   -   -   to -   16.89   to 16.89  
    12/31/2024 - 8.23 to 8.23 -   -   -   to -   33.14   to 33.14  
    12/31/2023 - 6.18 to 6.18 -   -   -   to -   40.13   to 40.13  
    12/31/2022 - 4.41 to 4.41 -   -   -   to -   (33.37)   to (33.37)  
    12/31/2021 - 6.62 to 6.62 -   -   -   to -   17.86   to 17.86  
Vanguard® High Yield Bond                                  
    12/31/2025 1,051,781 4.19 to 4.09 4,304,398   0.12   -   to -   9.18   to 9.18  
    12/31/2024 5,608 3.84 to 3.75 21,541   5.26   -   to -   6.45   to 6.45  
    12/31/2023 11,247 3.61 to 3.52 40,588   4.92   -   to -   11.67   to 11.67  
    12/31/2022 11,411 3.23 to 3.15 36,876   9.70   -   to -   (9.36)   to (9.36)  
    12/31/2021 36,864 3.57 to 3.48 131,441   7.47   -   to -   3.68   to 3.68  
 
 
41

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
      At December 31   For the Year Ended December 31  
          Unit Fair Value           Expense Total Return***  
          Corresponding to       Investment Ratio**     Corresponding to    
          Lowest to Highest   Net   Income Lowest to     Lowest to Highest    
Subaccount Units   Expense Ratio   Assets   Ratio* Highest     Expense Ratio    
                                         
Vanguard® International                                  
    12/31/2025 2,041,835 $7.52 to $7.49 $     15,325,583   0.97 % - % to - % 19.97 % to 19.97 %
    12/31/2024 5,690,517 6.27 to 6.24 35,645,231   1.18   -   to -   9.01   to 9.01  
    12/31/2023 5,745,454 5.75 to 5.72 33,014,126   1.49   -   to -   14.65   to 14.65  
    12/31/2022 5,744,716 5.02 to 4.99 28,792,024   1.35   -   to -   (30.12)   to (30.12)  
    12/31/2021 6,043,052 7.18 to 7.14 43,335,412   0.28   -   to -   (1.54)   to (1.54)  
Vanguard® Mid-Cap Index                                  
    12/31/2025 1,912,463 10.61 to 10.61 20,285,586   1.40   -   to -   11.54   to 11.54  
    12/31/2024 3,847,236 9.51 to 9.51 36,587,262   1.38   -   to -   15.08   to 15.08  
    12/31/2023 4,040,916 8.26 to 8.26 33,394,496   1.39   -   to -   15.83   to 15.83  
    12/31/2022 4,016,044 7.14 to 7.13 28,653,191   1.16   -   to -   (18.82)   to (18.82)  
    12/31/2021 4,377,641 8.79 to 8.79 38,473,672   1.11   -   to -   24.36   to 24.36  
Vanguard® Money Market                                  
    12/31/2025 42,143,235 1.55 to 1.53 65,363,651   3.70   -   to -   4.18   to 4.18  
    12/31/2024 - 1.49 to 1.46 -   -   -   to -   5.19   to 5.19  
    12/31/2023 - 1.42 to 1.39 -   -   -   to -   5.04   to 5.04  
    12/31/2022 - 1.35 to 1.33 -   -   -   to -   1.53   to 1.53  
    12/31/2021 - 1.33 to 1.31 -   -   -   to -   0.01   to 0.01  
Vanguard® Real Estate Index                                  
    12/31/2025 719,688 7.21 to 6.57 4,798,477   3.12   -   to -   3.11   to 3.11  
    12/31/2024 1,860,339 7.00 to 6.37 11,969,699   3.13   -   to -   4.74   to 4.74  
    12/31/2023 1,870,261 6.68 to 6.09 11,484,513   2.48   -   to -   11.70   to 11.70  
    12/31/2022 1,932,106 5.98 to 5.45 10,643,165   1.91   -   to -   (26.30)   to (26.30)  
    12/31/2021 1,985,637 8.11 to 7.39 14,863,566   2.01   -   to -   40.21   to 40.21  
Vanguard® Short-Term Investment Grade                                
    12/31/2025 7,882,344 2.15 to 2.10 16,644,878   2.34   -   to -   6.85   to 6.85  
    12/31/2024 1,754,580 2.01 to 1.97 3,535,202   3.73   -   to -   4.89   to 4.89  
    12/31/2023 2,206,985 1.92 to 1.88 4,239,291   2.11   -   to -   6.16   to 6.16  
    12/31/2022 2,462,901 1.81 to 1.77 4,456,461   1.76   -   to -   (5.72)   to (5.72)  
    12/31/2021 2,940,604 1.92 to 1.87 5,643,802   2.49   -   to -   (0.45)   to (0.45)  
Vanguard® Small Company Growth                                  
    12/31/2025 894,745 8.99 to 8.50 7,946,889   0.57   -   to -   6.11   to 6.11  
    12/31/2024 2,753,150 8.48 to 8.01 23,216,109   0.54   -   to -   11.38   to 11.38  
    12/31/2023 2,813,532 7.61 to 7.19 21,287,939   0.40   -   to -   19.65   to 19.65  
    12/31/2022 2,843,171 6.36 to 6.01 17,978,760   0.27   -   to -   (25.35)   to (25.35)  
    12/31/2021 3,082,428 8.52 to 8.05 26,021,405   0.36   -   to -   14.22   to 14.22  
Vanguard® Total Bond Market Index                                  
    12/31/2025 9,281,898 2.22 to 2.16 20,064,627   0.52   -   to -   6.94   to 6.94  
    12/31/2024 427,634 2.07 to 2.02 886,804   2.94   -   to -   1.24   to 1.24  
    12/31/2023 567,429 2.05 to 1.99 1,162,251   2.62   -   to -   5.58   to 5.58  
    12/31/2022 726,487 1.94 to 1.89 1,409,434   2.87   -   to -   (13.21)   to (13.21)  
    12/31/2021 1,299,299 2.24 to 2.18 2,904,516   3.05   -   to -   (1.72)   to (1.72)  
Vanguard® Total Stock Market Index                                  
    12/31/2025 1,077,726 11.53 to 11.53 12,429,858   0.28   -   to -   16.93   to 16.93  
    12/31/2024 85,861 9.86 to 9.86 846,873   1.23   -   to -   23.71   to 23.71  
    12/31/2023 86,955 7.97 to 7.97 693,264   1.14   -   to -   25.95   to 25.95  
    12/31/2022 88,263 6.33 to 6.33 558,705   1.34   -   to -   (19.59)   to (19.59)  
    12/31/2021 89,493 7.87 to 7.87 704,516   1.43   -   to -   25.64   to 25.64  
                                         
42

 
Transamerica Life Insurance Company
WRL Series Life Corporate Account
Notes to Financial Statements
December 31, 2025
 
5. Financial Highlights (continued)                                  
                                         
  (1) See Footnote 1                                  
                                         
                                         
  * These amounts represent the dividends, excluding distributions of capital gains, received by the subaccount from the Mutual Fund, net of management fees assessed by the fund manager, divided by the average net assets.  These ratios exclude those expenses, such as mortality and expense charges, that are assessed against contract owner accounts either through reductions in the unit values or the redemption of units.  The recognition of investment income by the subaccount is affected by the timing of the declaration of dividends by the Mutual Fund in which the subaccounts invest.  
                                         
  ** These amounts represent the annualized contract expenses of the subaccount, consisting primarily of mortality and expense charges, for each period indicated.  These ratios include only those expenses that result in a direct reduction to unit values.  Charges made directly to contract owner accounts through the redemption of units and expenses of the Mutual Fund have been excluded.  
                                         
                                         
  *** These amounts represent the total return for the periods indicated, including changes in the value of the Mutual Fund, and expenses assessed through the reduction of unit values.  These ratios do not include any expenses assessed through the redemption of units.  Investment options with a date notation indicate the effective date of that investment option in the variable account.  The total return is calculated for each period indicated or from the effective date through the end of the reporting period.  Total returns reflect a full twelve month period and total returns for subaccounts opened during the year have not been disclosed as they may not be indicative of a full year return.  Expense ratios not in effect for the full twelve months are not reflected in the total return as they may not be indicative of a full year return.  
 
43

 
  Transamerica Life Insurance Company
  WRL Series Life Corporate Account
  Notes to Financial Statements
  December 31, 2025
                   
                   
                   
6.  Administrative and Mortality and Expense Risk Charges
                   
TLIC deducts a monthly contract charge from the cash value, not to exceed $16.50, for administrative expenses.  An effective annual rate from 0.20% to 0.90% is also deducted monthly from the policy's cash value in each subaccount of the Separate Account for TLIC's assumption of certain mortality and expense risks incurred in connection with the contract.  Monthly deductions are charged in the same proportion that the value in each subaccount bears to the total cash value on the monthly deduction day.  Charges reflected above are those currently assessed and may be subject to change.  Contract owners should see their actual policy and any related attachments to determine their specific charges.
7.  Income Tax
                   
Operations of the Separate Account form a part of TLIC, which is taxed as a life insurance company under Subchapter L of the Internal Revenue Code of 1986, as amended (the Code).   The operations of the Separate Account are accounted for separately from other operations of TLIC for purposes of federal income taxation.  The Separate Account is not separately taxable as a regulated investment company under Subchapter M of the Code and is not otherwise taxable as an entity separate from TLIC.  Under existing federal income tax laws, the income of the Separate Account is not taxable to TLIC, as long as earnings are credited under the variable life contracts.
44

 
  Transamerica Life Insurance Company
  WRL Series Life Corporate Account
  Notes to Financial Statements
  December 31, 2025
                   
                   
8.  Subsequent Events
                   
The Separate Account has evaluated the financial statements for subsequent events through the date which the financial statements were issued.  During this period, there were no subsequent events requiring recognition in the financial statements.
9.  Related Parties
                   
Transamerica Capital, Inc. (TCI), a wholesaling broker-dealer, is an affiliated entity of TLIC and an indirect wholly owned subsidiary of Aegon Ltd.  TCI distributes TLIC's products through broker-dealers and other financial intermediaries.
No charges other than those disclosed in Footnote 6 are deducted for the service rendered by related parties.
Contract owners may transfer funds between available subaccount options within the Separate Account.  These transfers are performed at unit value at the time of the transfer.
45

 
  Transamerica Life Insurance Company
  WRL Series Life Corporate Account
  Notes to Financial Statements
  December 31, 2025
                   
                   
10.  Segment Reporting
                   
Each fund of the Separate Account constitutes a single operating segment and therefore, a single reportable segment because the Chief Operating Decision Maker (CODM) manages the activities of the Separate Account using information of each fund.  The Separate Account is engaged in a single line of business as a registered unit investment trust.  The Separate Account is a funding vehicle for individual variable annuity contracts with the assets owned by TLIC to support the liabilities of the applicable insurance contracts.  The subaccounts have identified the President and Chief Operating Officer as the CODM as the Separate Account does not have employees and is not a separate legal entity.
The CODM uses increase (decrease) in net assets from operations as their performance measure in order to make operational decisions while monitoring the net assets of each of the funds within the Separate Account.  The Accounting policies used to measure profit and loss of the segments are the same as those described in the Summary of Significant Accounting Policies (see note 2).  The measure of segment assets is reported on the balance sheet as total consolidated assets.  Refer to the Statements of Operations and Changes in Net Assets for each fund’s operating segment and related footnotes for significant expenses principle and the existing segment requirements as of December 31, 2025 and for the year ended December 31, 2025 and December 31, 2024.